

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2018247794 B2**

(54) Title
Bispecific antibodies specifically binding to PD1 and LAG3

(51) International Patent Classification(s)
C07K 16/28 (2006.01)

(21) Application No: **2018247794** (22) Date of Filing: **2018.04.03**

(87) WIPO No: **WO18/185043**

(30) Priority Data

(31) Number	(32) Date	(33) Country
17165125.0	2017.04.05	EP

(43) Publication Date: **2018.10.11**

(44) Accepted Journal Date: **2025.04.17**

(71) Applicant(s)
F. Hoffmann-La Roche AG

(72) Inventor(s)
Codarri Deak, Laura;Fischer, Jens;Imhof-Jung, Sabine;Klein, Christian;Seeber, Stefan;Weber, Patrick Alexander Aaron;Perro, Mario

(74) Agent / Attorney
Griffith Hack, Level 15 376-390 Collins St, MELBOURNE, VIC, 3000, AU

(56) Related Art
RINSE KLOOSTER ET AL: "Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity (B088)", 23 September 2016 (2016-09-23), XP055442867, Retrieved from the Internet [retrieved on 20180122]
BERNETT MJ ET AL: 6 November 2016 Retrieved from the Internet [retrieved on 20180122]



(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2018/058382

(22) International Filing Date:
03 April 2018 (03.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17165125.0 05 April 2017 (05.04.2017) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **CODARRI DEAK, Laura**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FISCHER, Jens**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **IMHOF-JUNG, Sabine**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **SEEBER, Stefan**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **WEBER, Patrick Alexander Aaron**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **KLOSTERMEYER RAUBER, Doerte**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3

(57) Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.



Bispecific Antibodies specifically binding to PD1 and LAG3

FIELD OF THE INVENTION

The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, in particular to bispecific antibodies further comprising a Fc domain that comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fc γ receptor. The invention further relates to methods of producing these molecules and to methods of using the same.

BACKGROUND

The importance of the immune system in the protection against cancer is based on its capacity to detect and destroy abnormal cells. However, some tumor cells are able to escape the immune system by engendering a state of immunosuppression (Zitvogel et al., Nature Reviews Immunology 6 (2006), 715–727). T cells have an important role in antiviral and anti-tumour immune responses. Appropriate activation of antigen-specific T cells leads to their clonal expansion and their acquisition of effector function, and, in the case of cytotoxic T lymphocytes (CTLs) it enables them to specifically lyse target cells. T cells have been the major focus of efforts to therapeutically manipulate endogenous antitumour immunity owing to their capacity for the selective recognition of peptides derived from proteins in all cellular compartments; their capacity to directly recognize and kill antigen-expressing cells (by CD8⁺ effector T cells; also known as cytotoxic T lymphocytes (CTLs)) and their ability to orchestrate diverse immune responses (by CD4⁺ helper T cells), which integrates adaptive and innate effector mechanisms. T cell dysfunction occurs as a result of prolonged antigen exposure: the T cell loses the ability to proliferate in the presence of the antigen and progressively fails to produce cytokines and to lyse target cells¹. The dysfunctional T cells have been termed exhausted T cells and fail to proliferate and exert effector functions such as cytotoxicity and cytokine secretion in response to antigen stimulation. Further studies identified that exhausted T cells are characterized by sustained expression of the inhibitory molecule PD-1 (programmed cell death protein 1) and that blockade of PD-1 and PD-L1 (PD-1 ligand) interactions can reverse T cell exhaustion and restore antigen-specific T cell responses in LCMV-infected mice (Barber et al., Nature 439 (2006), 682–687). However, targeting the PD-1–PD-L1 pathway alone does not always result in reversal of T cell exhaustion (Gehring et al., Gastroenterology 137 (2009), 682–690), indicating that other

molecules are likely involved in T cell exhaustion (Sakuishi, J. Experimental Med. 207 (2010), 2187-2194).

Lymphocyte activation gene-3 (LAG3 or CD223) was initially discovered in an experiment designed to selectively isolate molecules expressed in an IL-2-dependent NK cell
5 line (Triebel F et al., Cancer Lett. 235 (2006), 147–153). LAG3 is a unique transmembrane protein with structural homology to CD4 with four extracellular immunoglobulin superfamily-like domains (D1-D4). The membrane-distal IgG domain contains a short amino acid sequence, the so-called extra loop that is not found in other IgG superfamily proteins. The intracellular domain contains a unique amino acid sequence (KIEELE, SEQ ID NO:75) that is required for
10 LAG3 to exert a negative effect on T cell function. LAG3 can be cleaved at the connecting peptide (CP) by metalloproteases to generate a soluble form, which is detectable in serum. Like CD4, the LAG3 protein binds to MHC class II molecules, however with a higher affinity and at a distinct site from CD4 (Huard et al. Proc. Natl. Acad. Sci. USA 94 (1997), 5744-5749). LAG3 is expressed by T cells, B cells, NK cells and plasmacytoid dendritic cells (pDCs) and is
15 upregulated following T cell activation. It modulates T cell function as well as T cell homeostasis. Subsets of conventional T cells that are anergic or display impaired functions express LAG3. LAG3⁺ T cells are enriched at tumor sites and during chronic viral infections (Sierro et al Expert Opin. Ther. Targets 15 (2011), 91-101). It has been shown that LAG3 plays a role in CD8 T cell exhaustion (Blackburn et al. Nature Immunol. 10 (2009), 29-37). Thus, there
20 is a need for antibodies that antagonize the activity of LAG3 and can be used to generate and restore immune response to tumors.

Monoclonal antibodies to LAG3 have been described, for example, in WO 2004/078928 wherein a composition comprising antibodies specifically binding to CD223 and an anti-cancer vaccine is claimed. WO 2010/019570 discloses human antibodies that bind LAG3, for example
25 the antibodies 25F7 and 26H10. US 2011/070238 relates to a cytotoxic anti-LAG3 antibody useful in the treatment or prevention of organ transplant rejection and autoimmune disease. WO 2014/008218 describes LAG3 antibodies with optimized functional properties (i.e. reduced deamidation sites) compared to antibody 25F7. Furthermore, LAG3 antibodies are disclosed in WO 2015/138920 (for example BAP050), WO 2014/140180, WO 2015/116539, WO
30 2016/028672, WO 2016/126858, WO 2016/200782 and WO 2017/015560.

Programmed cell death protein 1 (PD-1 or CD279) is an inhibitory member of the CD28 family of receptors, that also includes CD28, CTLA-4, ICOS and BTLA. PD-1 is a cell surface receptor and is expressed on activated B cells, T cells, and myeloid cells (Okazaki et al (2002) Curr. Opin. Immunol. 14: 391779-82; Bennett et al. (2003) J Immunol 170:711-8). The structure
35 of PD-1 is a monomeric type 1 transmembrane protein, consisting of one immunoglobulin variable-like extracellular domain and a cytoplasmic domain containing an immunoreceptor

tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). Activated T cells transiently express PD1, but sustained hyperexpression of PD1 and its ligand PDL1 promote immune exhaustion, leading to persistence of viral infections, tumor evasion, increased infections and mortality. PD1 expression is induced by antigen recognition via the T-cell receptor and its expression is maintained primarily through continuous T-cell receptor signaling. After prolonged antigen exposure, the PD1 locus fails to be remethylated, which promotes continuous hyperexpression. Blocking the PD1 pathway can restore the exhausted T-cell functionality in cancer and chronic viral infections (Sheridan, Nature Biotechnology 30 (2012), 729-730). Monoclonal antibodies to PD-1 have been described, for example, in WO 2003/042402, WO 2004/004771, WO 2004/056875, WO 2004/072286, WO 2004/087196, WO 2006/121168, WO 2006/133396, WO 2007/005874, WO 2008/083174, WO 2008/156712, WO 2009/024531, WO 2009/014708, WO 2009/101611, WO 2009/114335, WO 2009/154335, WO 2010/027828, WO 2010/027423, WO 2010/029434, WO 2010/029435, WO 2010/036959, WO 2010/063011, WO 2010/089411, WO 2011/066342, WO 2011/110604, WO 2011/110621, WO 2012/145493, WO 2013/014668, WO 2014/179664, and WO 2015/112900.

Bispecific Fc diabodies having immunoreactivity with PD1 and LAG3 for use in the treatment of cancer or a disease associated with a pathogen such as a bacterium, a fungus or a virus are described in WO 2015/200119. However, there is a need of providing new bispecific antibodies that not only simultaneously bind to PD1 and LAG3 and thus selectively target cells expressing both PD1 and LAG3, but that also avoid blocking of LAG3 on other cells given the broad expression pattern of LAG3. The bispecific antibodies of the present invention do not only effectively block PD1 and LAG3 on T cells overexpressing both PD1 and LAG3, they are very selective for these cells and thereby side effects by administering highly active LAG3 antibodies may be avoided.

It is to be understood that if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art in Australia or any other country.

SUMMARY OF THE INVENTION

The present invention relates to bispecific antibodies comprising at least one antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and at least one second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3). These bispecific antibodies are advantageous as they provide better selectivity and, potentially, efficacy than anti-PD1 and anti-LAG3 combination strategies. They are further characterized in that show a reduced sink effect (as shown by reduced internalization by T cells), they preferentially bind to conventional T cells as to Tregs and are able to rescue T cell effector

-3a-

functions from Treg suppression, they show increased tumor-specific T cell effector functions and increased tumor eradication *in vivo*.

In one aspect, the invention provides a bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein

- 5 said first antigen binding domain specifically binding to PD1 comprises
 a VH domain comprising
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1,
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and
10 a VL domain comprising
 (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;
 (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
 (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.

- 15 In particular, provided is a bispecific antibody comprising a first antigen binding domain
 that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding
 domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein the bispecific
 antibody comprises a Fc domain that is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc
 domain and wherein the Fc domain comprises one or more amino acid substitution that reduces
 binding to an Fc receptor, in particular towards Fc γ receptor.

- 20 In one aspect, provided is a bispecific antibody comprising a first antigen binding domain
 that specifically binds to PD1 and a second antigen binding domain that specifically binds to
 LAG3, wherein the second antigen binding domain that specifically binds to LAG3 comprises

- (a) a VH domain comprising
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14,
25 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:16; and
 a VL domain comprising
 (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17,
 (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and
30 (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19; or
 (b) a VH domain comprising
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22,
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:23, and
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:24; and
35 a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:25,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:26, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27; or

(c) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:30,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:31, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:32; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:33,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:34, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:35; or

(d) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:40; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:41,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:43; or

(e) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:46,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:48; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:49,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:50, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:51.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the first antigen-binding domain specifically binding to PD1 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 11, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 12, or

5 (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 13.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the first antigen-binding domain specifically binding to PD1 comprises
10 a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the second antigen-binding domain
15 specifically binding to LAG3 comprises

(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 28 and a VL domain comprising the amino acid sequence of SEQ ID NO: 29, or

20 (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 36 and a VL domain comprising the amino acid sequence of SEQ ID NO: 37, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 44 and a VL domain comprising the amino acid sequence of SEQ ID NO: 45, or

25 (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

In an additional aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the second antigen-binding domain specifically binding to LAG3 comprises

30 (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 54 and a VL domain comprising the amino acid sequence of SEQ ID NO: 55, or

(b) a VH domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63, or

(c) a VH domain comprising the amino acid sequence of SEQ ID NO: 64 and a VL domain comprising the amino acid sequence of SEQ ID NO: 65, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 66 and a VL domain comprising the amino acid sequence of SEQ ID NO: 67.

5 Furthermore, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

10 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21 or a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

15 In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

20 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21.

25 In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

30 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 56 and a VL domain comprising the amino acid sequence of SEQ ID NO: 57.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody is a humanized or chimeric antibody. In particular, the bispecific antibody is a humanized antibody.

5 In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody comprises an Fc domain of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

10 Furthermore, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody comprises an Fc domain comprising a modification promoting the association of the first and second subunit of the Fc domain. In one aspect, provided is a bispecific antibody, wherein the first subunit of the Fc domain comprises knobs and the second subunit of the Fc domain comprises holes according to the knobs into holes method. In particular, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

20 In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1 and a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3.

25 In one aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein in one of the Fab fragments the the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain. Particularly, provided is bispecific antibody, wherein in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

35 In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises a Fab fragment wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K),

arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index). Particularly, provided is bispecific antibody, wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising

- (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 97, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 102, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 104, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105, or
- (d) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 106, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 107, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

More particularly, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody comprises a Fab fragment comprising the antigen binding domain that specifically binds to LAG3 which is fused to the C-terminus of the Fc domain.

In particular, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 144, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody comprises a third Fab fragment comprising an antigen binding domain that specifically binds to LAG3. In one aspect, provided is a bispecific antibody, wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 are identical.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the Fab fragment comprising the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of one of the heavy chains.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising

- (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 118, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115,
a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
5 to the sequence of SEQ ID NO: 119, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 120, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115,
10 a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 122, a first light chain comprising an amino acid sequence with
15 at least 95% sequence identity to the sequence of SEQ ID NO: 115,
a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

In another aspect, provided is a bispecific antibody comprising a first antigen binding
20 domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein one of the Fab fragments comprising the antigen binding domain that specifically binds to LAG3 is fused via a peptide linker to the C-terminus of one of the heavy chains.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding
25 domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 145,
30 and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the bispecific antibody comprises a fourth
35 Fab fragment comprising an antigen binding domain that specifically binds to PD1. In one aspect,

provided is a bispecific antibody, wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are identical.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before, wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are each fused via a peptide linker to the C-terminus to one of the heavy chains, respectively.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising

- (a) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 114, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or
- (b) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 116, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 99, or
- (c) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 117, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 105.

In yet another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a single chain Fab (scFab) comprising the antigen binding domain that specifically binds to PD1. In particular, the scFab comprising an antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus to one of the heavy chains.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, comprising

- 5 (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 123, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or
- 10 (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 124, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 99, or
- 15 (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 125, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 105.

20 In yet another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a VH and VL domain comprising the antigen binding domain that specifically binds to PD1. In one aspect, the VH domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide

25 linker to the C-terminus of one of the heavy chains and the VL domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of the other one of the heavy chains. In a particular aspect, provided is a bispecific antibody, comprising a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 126, a second heavy chain comprising an amino acid sequence with at

30 least 95% sequence identity to the sequence of SEQ ID NO: 127, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 109.

According to another aspect of the invention, there is provided a polynucleotide encoding the bispecific antibody as described herein before. The invention further provides a vector,

35 particularly an expression vector, comprising a polynucleotide of the invention and a prokaryotic

or eukaryotic host cell comprising the polynucleotide or the vector of the invention. In some embodiments the host cell is a eukaryotic cell, particularly a mammalian cell.

In another aspect, provided is a method for producing bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, comprising the steps of a) transforming a host cell with vectors comprising polynucleotides encoding said bispecific antibody, b) culturing the host cell according under conditions suitable for the expression of the bispecific antibody and c) recovering the bispecific antibody from the culture. The invention also encompasses a bispecific antibody produced by the method of the invention.

The invention further provides a pharmaceutical composition comprising a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, and at least one pharmaceutically acceptable excipient.

Also encompassed by the invention is the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, or the pharmaceutical composition comprising the bispecific antibody, for use as a medicament.

In another aspect, the invention provides a bispecific antibody comprising a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, or the pharmaceutical composition comprising the bispecific antibody, for use

i) in the modulation of immune responses, such as restoring T cell activity,

ii) in stimulating an immune response or function,

iii) in the treatment of infections,

iv) in the treatment of cancer,

v) in delaying progression of cancer,

vi) in prolonging the survival of a patient suffering from cancer.

In one aspect, provided is the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, or the pharmaceutical composition comprising the bispecific antibody, for use in the treatment of a disease in an individual in need thereof. In a specific aspect, the invention provides a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, or the pharmaceutical composition comprising the bispecific antibody, for use in the treatment of cancer. In a further specific aspect, a bispecific antibody comprising a first antigen

binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, or the pharmaceutical composition comprising the bispecific antibody, for use in the modulation of immune responses is provided. In another aspect, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and
5 a second antigen binding domain that specifically binds to LAG3, or a pharmaceutical composition comprising the bispecific antibody for use in the treatment of a chronic viral infection is provided.

The invention also provides a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically
10 binds to LAG3 as described herein, or a pharmaceutical composition comprising the bispecific antibody for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/or other agents for use in cancer immunotherapy. In a particular aspect, provided is bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain
15 that specifically binds to LAG3 as described herein, or a pharmaceutical composition comprising the bispecific antibody for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with an anti-CEA/anti-CD3 bispecific antibody.

Also provided is the use of the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically
20 binds to LAG3 as described herein for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, in particular for the manufacture of a medicament for the treatment of cancer, as well as a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1
25 and a second antigen binding domain that specifically binds to LAG3 as described herein in a pharmaceutically acceptable form. In a specific aspect, the disease is cancer. In another specific aspect, the disease is a chronic viral infection. In another aspect, a method of modulating of immune responses in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the bispecific antibody comprising a first antigen
30 binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein in a pharmaceutically acceptable form is provided. In any of the above aspects the individual is preferably a mammal, particularly a human.

The invention also provides a bispecific antibody comprising a first antigen binding
35 domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, or a pharmaceutical composition comprising the bispecific

antibody for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/or other agents for use in cancer immunotherapy.

Furthermore, provided is a method of inhibiting the growth of tumor cells in an individual comprising administering to the individual an effective amount of a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein to inhibit the growth of the tumor cells. The individual is preferably a mammal, particularly a human.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Schematic illustration of the different formats of the bispecific anti-PD1/anti-LAG3 antibodies described herein. **Fig. 1A** shows the bispecific 1+1 format, wherein the PD1 binding domain comprises a crossFab (with VH/VL domain exchange) and the LAG3 binding domain comprises CH1 and CK domains with amino acid mutations to support correct pairing (“charged variants”). The Fc part comprises the knob into hole mutations (illustrated by the black arrow) and the amino acid mutations L234A, L235A and P329G almost completely abolishing Fcγ receptor binding of the human IgG1 Fc domain (illustrated by the white area). **Fig. 1B** shows a 2+1 format with two anti-LAG3 binding Fab domains comprising mutations in CH1/CK and a PD1 binding Fab domain fused at the C-terminus of one heavy chain. **Fig. 1C** shows a similar 2+1 format with two anti-LAG3 binding FAB domains comprising mutations in CH1/CK, but a PD1 binding single chain scFab domain fused at the C-terminus of one heavy chain. In **Fig. 1D** is shown a 2+1 format with two anti-LAG3 binding Fab domains and a PD1 binding VH and VL fused each to one of the C-termini of the heavy chains. **Fig. 1E** shows a construct similar to said of Figure 1D, however with an engineered disulfide bond between VH and VL and in **Fig. 1F** a variant with a Furin site is shown. **Fig. 1G** shows the bispecific 2+2 format with with two anti-LAG3 binding Fab domains comprising mutations in CH1/CK and two PD1 binding crossFab domains fused at the C-terminus of each heavy chain. In **Fig. 1H** a bispecific 1+1 format is shown (called “trans”), wherein the PD1 binding domain comprises a crossFab (with VH/VL domain exchange) and the LAG3 binding domain is fused with its VH domain at the C-terminus of the Fc hole chain. The Lag3 domain comprises CH1 and CK domains with amino acid mutations to support correct pairing (“charged variants”). **Fig. 1I** shows a 2+1 trans format, wherein the PD1 binding domain comprises a crossFab (with VH/VL domain exchange) and one LAG3 binding domain comprising CH1 and CK domains with amino acid mutations

to support correct pairing (“charged variants”) and a second LAG3 binding domain is fused with its VH domain at the C-terminus of the Fc hole chain.

Figure 2: Effect of aLAG-3 antibodies on cytotoxic Granzyme B release and IL-2 secretion by human CD4 T cells cocultured with allogeneic mature dendritic cells. In **Fig.2A** the effect of aLAG3 antibodies as described herein on Granzyme B secretion and in **Fig.2B** the effect of aLAG3 antibodies on IL-2 secretion is shown.

Figure 3: Effect of aLAG3 antibodies in combination with aPD1 antibody (0376) on cytotoxic Granzyme B release by human CD4 T cells cocultured with a B cell-lymphoblatoid cell line (ARH77). Shown is a comparison of different aLAG3 antibodies in combination with aPD1 antibody (0376) and with aPD1 antibody (0376) alone.

Figure 4: Effect of aLAG3 antibodies in combination with aPD1 antibody (0376) on Treg suppression of Granzyme B and IFN- γ release by human CD4 T cells cocultured with irradiated allogeneic PBMCs. **Fig. 4A** shows the Granzyme B release in comparison with aPD1 (0376) alone and **Fig.4B** shows the IFN- γ release in comparison with aPD1 (0376) alone.

Figure 5: Simultaneous binding and receptor dimerization caused by binding of bispecific anti-PD1/anti-LAG3 antibodies to recombinant PD1⁺Lag3⁺ cells. Plotted is the chemoluminescence (measured in RU) against the antibody concentration. **Fig. 5A** and **Fig.5B** show a comparison of bispecific anti-PD1/ anti-LAG3 antibodies and monospecific anti-LAG3 antibodies. Only the bispecific formats were able to induce chemoluminescence. A competition experiment is shown in **Fig, 5C**. If the same bispecific antibody was provided in the presence of either an aLAG3 antibody (0156, MDX25F7) or anti-PD1 antibody (0376), the signal was either almost inhibited (for PD1 competition) or at least significantly reduced (Lag3). A further competition experiment is shown in **Fig. 5D**. Competition of the bispecific anti-PD1/ anti-LAG3 antibody with the same anti-PD1 antibody (0376) and also recombinant LAG3:Fc protein (0160) almost abolished the signal, whereas presence of the same aLAG3 binder (0156) only led to partial inhibition and two further anti-LAG3 antibodies 0414 and 0416 did not modulate the signal significantly.

Figure 6: Comparison of the simultaneous binding of bispecific anti-PD1/ anti-LAG3 antibodies in different formats (1+1 vs. 2+1) and with different aLAG3 binders. **Fig.6A** shows the binding curve for construct 0799 (anti-PD1(0376)/anti-LAG3(0416) in 1+1 format). The binding curve for construct 8311 (anti-PD1(0376)/anti-LAG3(0416) in 1+2 format) is shown in **Fig.6B**. **Fig.6C** shows the binding curve for construct 0927 (anti-PD1(0376)/anti-LAG3(0414) in 1+1 format).

The binding curve for construct 8310 (anti-PD1(0376)/anti-LAG3(0414) in 1+2 format) is shown in **Fig.6D**.

Figure 7: Comparison of the simultaneous binding of bispecific anti-PD1/ anti-LAG3 antibodies in different formats (2+1 vs. 2+2) and with different aLAG3 binders.

5 **Fig.7A** shows the binding curve for construct 8310 (anti-PD1(0376)/anti-LAG3(0414) in 1+2 format). The binding curve for construct 8970 (anti-PD1(0376)/anti-LAG3(0414) in 2+2 format) is shown in **Fig.7B**. **Fig.7C** shows the binding curve for construct 8311 (anti-PD1(0376)/anti-LAG3(0416) in 1+2 format). The binding curve for construct 8984 (anti-PD1(0376)/anti-LAG3(0416) in 2+2
10 format) is shown in **Fig.7D**. The binding curves for constructs 0725 (anti-PD1(0376)/anti-LAG3(0414) in trans 1+1 format) and 0750 (anti-PD1(0376)/anti-LAG3(0414) in trans 1+2 format) are shown in **Fig. 7E** in comparison to the binding curve of construct 0927 (anti-PD1(0376)/anti-LAG3(0414) in 1+1 format). These 3 constructs were also compared in the commercially available PD1/LAG3 combo
15 Reporter assay and the corresponding binding curves are shown in **Fig. 7F**.

Figure 8: Internalization of bispecific anti-PD1/ anti-LAG3 antibodies in different formats^and parental anti-LAG3 antibody after 3 hours from the addition to administration to activated T cells as measured with flow cytometry. **Fig. 8A** shows the representative histogram of the experiment, the percentage of internalization for the different
20 formats is shown in **Fig. 8B**.

Figure 9: Analysis over time shows higher membrane localization of the 1+1 format of the bispecific anti-PD1/anti-LAG3 antibody (0927) when compared to the other formats which show a higher degree of internalization. **Fig. 9A** shows the fluorescent images as detected by confocal microscopy after 15 minutes, 1 hour and 3 hours. The
25 activated CD4 cells are shown as black balls. The fluorescent images for a TIM3 antibody are shown as an example for strong internalization. A quantitative analysis of the images is shown in **Fig. 9B**.

Figure 10: Binding to conventional T cells versus Tregs. **Fig. 10A to 10C** show data from one representative donor showing the binding to conventional T cells (black curve) and
30 Tregs (grey area). The binding of an anti-LAG3 antibody 0414 (hu IgG1 PGLALA) is shown in **Fig 10A**, **Fig. 10B** and **10C** show the binding of anti-PD1 antibody 0376 and bispecific anti-PD1/anti-LAG3 antibody (0927), respectively. In **Fig. 10D** the Delta of the geometric fluorescent mean intensity of a given molecule bound on conventional T cells versus the one on Tregs within the same sample are shown.
35 Results (Median) are from 3 independent experiments with 3 different donors.

Figure 11: PD1 and Treg co-blockade rescues tconv effector functions from Treg suppression. Shown is the percentage of suppression by Tregs of granzyme B secreted by Tconv after 5 days of coculture. Results (Median) are from 10 independent experiments with 10 different donors. P was calculated using two-way ANOVA.

5 **Figure 12:** Effect of PD-1 and LAG-3 blockade on Granzyme B and IFN- γ secretion by CD4 T cells from melanoma patient PBMCs after recall with immunogenic melanoma-antigen peptide pools. **Fig.12** shows a comparison of the effect on Granzyme B and IFN- γ release caused by anti-PD1(0376) alone, the combination of anti-PD1(0376) with aLAG3(0414) and the bispecific antibody 0927 (anti-PD1(0376)/anti-
10 LAG3(0414) in 1+1 format). Shown is the fold increase in granzyme B and IFN γ production relative to peptide-pool stimulated CD4 T cells from 12 melanoma patient PBMCs.

Figure 13: Effect of aPD1/aLAG3 bispecific antibodies on cytotoxic Granzyme B release by human CD4 T cells cocultured with a B cell-lymphoblatoid cell line (ARH77).
15 Different bispecific anti-PD1/ anti-LAG3 antibodies as described herein are compared with antibodies used in standard of care or clinical trials.

Figure 14: Efficacy study in humanized mice challenged with pancreatic adenocarcinoma, BxPC3. In combination with CEACAM CD3 TCB, only the aPD1/aLAG3 bispecific antibody provided a statistical significant tumor protection when compared to
20 conventional PD1 antibodies. Shown are the tumor growth curves in humanized mice challenged subcutaneously with BxPC3 cells and treated with the indicated molecules in combination with CEACAM5-TCB.

Figure 15: The measurements of tumor volumes (mm^3 +/- SEM), over a period of 47 days, are shown for each individual animal showing the homogeneity of group anti-tumor
25 response. The tumor growth curves are shown for the vehicle group in **Fig. 15A**, for CEACAM5 CD3 TCB alone (2.5 mg/kg) in **Fig. 15B**, for the combination of CEACAM5 CD3 TCB with Nivolumab (1.5 mg/kg) in **Fig. 15C**, for the combination of CEACAM5 CD3 TCB with Pembrolizumab (1.5 mg/kg) in **Fig. 15D**, for the combination of CEACAM5 CD3 TCB with PD1/LAG3 0927 in **Fig 15E** (1.5 mg/kg)
30 and in **Fig. 15F** (3 mg/kg bispecific antibody).

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as generally used in the art to which this invention belongs. For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa.

In the claims which follow and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the word “**comprise**” or variations such as “**comprises**” or “**comprising**” is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

As used herein, the term “**antigen binding molecule**” refers in its broadest sense to a molecule that specifically binds an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments and scaffold antigen binding proteins.

The term “**antibody**” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

The term “**monoclonal antibody**” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g. containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.

The term “**monospecific**” antibody as used herein denotes an antibody that has one or more binding sites each of which bind to the same epitope of the same antigen. The term “**bispecific**” means that the antibody is able to specifically bind to at least two distinct antigenic determinants, for example two binding sites each formed by a pair of an antibody heavy chain variable domain (VH) and an antibody light chain variable domain (VL) binding to different antigens or to different epitopes on the same antigen. Such a bispecific antibody is an 1+1 format. Other bispecific antibody formats are 2+1 formats (comprising two binding sites for a

-20a-

first antigen or epitope and one binding site for a second antigen or epitope) or 2+2 formats (comprising two binding sites for a first antigen or epitope and two binding sites for a second antigen or epitope). Typically, a bispecific antibody comprises two antigen binding sites, each of which is specific for a different antigenic determinant.

The term “**valent**” as used within the current application denotes the presence of a specified number of binding domains in an antigen binding molecule. As such, the terms “bivalent”, “tetravalent”, and “hexavalent” denote the presence of two binding domain, four binding domains, and six binding domains, respectively, in an antigen binding molecule. The bispecific antibodies according to the invention are at least “bivalent” and may be “trivalent” or “multivalent” (e.g. “tetravalent” or “hexavalent”). In a particular aspect, the antibodies of the present invention have two or more binding sites and are bispecific. That is, the antibodies may be bispecific even in cases where there are more than two binding sites (i.e. that the antibody is trivalent or multivalent).

The terms “full length antibody”, “intact antibody”, and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure. “**Native antibodies**” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG-class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two light chains and two heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called a heavy chain constant region. Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chain of an antibody may be assigned to one of five types, called α (IgA), δ (IgD), ϵ (IgE), γ (IgG), or μ (IgM), some of which may be further divided into subtypes, e.g. $\gamma 1$ (IgG1), $\gamma 2$ (IgG2), $\gamma 3$ (IgG3), $\gamma 4$ (IgG4), $\alpha 1$ (IgA1) and $\alpha 2$ (IgA2). The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

An “**antibody fragment**” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g. scFv); multispecific antibodies formed from antibody fragments and single domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see e.g. Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046. Diabodies are antibody fragments with two antigen binding domains that may be bivalent or bispecific, see, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al.,

Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see e.g. U.S. Patent No. 6,248,516 B1). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.

Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.

Papain digestion of intact antibodies produces two identical antigen-binding fragments, called "Fab" fragments containing each the heavy- and light-chain variable domains and also the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. As used herein, Thus, the term "**Fab fragment**" refers to an antibody fragment comprising a light chain fragment comprising a VL domain and a constant domain of a light chain (CL), and a VH domain and a first constant domain (CH1) of a heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteins from the antibody hinge region. Fab'-SH are Fab' fragments wherein the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab')₂ fragment that has two antigen-combining sites (two Fab fragments) and a part of the Fc region.

The term "**cross-Fab fragment**" or "xFab fragment" or "crossover Fab fragment" refers to a Fab fragment, wherein either the variable regions or the constant regions of the heavy and light chain are exchanged. Two different chain compositions of a crossover Fab molecule are possible and comprised in the bispecific antibodies of the invention: On the one hand, the variable regions of the Fab heavy and light chain are exchanged, i.e. the crossover Fab molecule comprises a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1), and a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL). This crossover Fab molecule is also referred to as CrossFab_(VLVH). On the other hand, when the constant regions of the Fab heavy and light chain are exchanged, the crossover Fab molecule comprises a peptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL), and a peptide chain composed of the light chain variable region (VL) and the heavy chain constant region (CH1). This crossover Fab molecule is also referred to as CrossFab_(CLCH1).

A “single chain Fab fragment” or “**scFab**” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL; and wherein said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CH1 domain. In addition, these single chain Fab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

A “crossover single chain Fab fragment” or “**x-scFab**” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL form together an antigen binding domain which binds specifically to an antigen and wherein said linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g. position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

A “**single-chain variable fragment (scFv)**” is a fusion protein of the variable regions of the heavy (V_H) and light chains (V_L) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the V_H with the C-terminus of the V_L, or *vice versa*. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. scFv antibodies are, e.g. described in Houston, J.S., Methods in Enzymol. 203 (1991) 46-96). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.

“**Scaffold antigen binding proteins**” are known in the art, for example, fibronectin and designed ankyrin repeat proteins (DARPs) have been used as alternative scaffolds for antigen-binding domains, see, e.g., Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A

new generation of protein therapeutics. Drug Discovery Today 13: 695-701 (2008). In one aspect of the invention, a scaffold antigen binding protein is selected from the group consisting of CTLA-4 (Evibody), Lipocalins (Anticalin), a Protein A-derived molecule such as Z-domain of Protein A (Affibody), an A-domain (Avimer/Maxibody), a serum transferrin (*trans*-body); a
5 designed ankyrin repeat protein (DARPin), a variable domain of antibody light chain or heavy chain (single-domain antibody, sdAb), a variable domain of antibody heavy chain (nanobody, aVH), V_{NAR} fragments, a fibronectin (AdNectin), a C-type lectin domain (Tetranectin); a variable domain of a new antigen receptor beta-lactamase (V_{NAR} fragments), a human gamma-crystallin or ubiquitin (Affilin molecules); a kunitz type domain of human protease inhibitors,
10 microbodies such as the proteins from the knottin family, peptide aptamers and fibronectin (adnectin). CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T-cells. Its extracellular domain has a variable domain- like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with heterologous sequence to confer different binding properties. CTLA-4 molecules engineered to have different binding
15 specificities are also known as Evibodies (e.g. US7166697B1). Evibodies are around the same size as the isolated variable region of an antibody (e.g. a domain antibody). For further details see Journal of Immunological Methods 248 (1-2), 31-45 (2001). Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid beta-sheet secondary structure with a number of loops at
20 the open end of the conical structure which can be engineered to bind to different target antigens. Anticalins are between 160-180 amino acids in size, and are derived from lipocalins. For further details see Biochim Biophys Acta 1482: 337-350 (2000), US7250297B1 and US20070224633. An affibody is a scaffold derived from Protein A of Staphylococcus aureus which can be engineered to bind to antigen. The domain consists of a three-helical bundle of approximately 58
25 amino acids. Libraries have been generated by randomization of surface residues. For further details see Protein Eng. Des. Sel. 2004, 17, 455-462 and EP 1641818A1. Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulfide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details see
30 Nature Biotechnology 23(12), 1556 - 1561 (2005) and Expert Opinion on Investigational Drugs 16(6), 909-917 (June 2007). A transferrin is a monomeric serum transport glycoprotein. Transferrins can be engineered to bind different target antigens by insertion of peptide sequences in a permissive surface loop. Examples of engineered transferrin scaffolds include the Trans-body. For further details see J. Biol. Chem 274, 24066-24073 (1999). Designed Ankyrin Repeat
35 Proteins (DARPins) are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33 residue motif consisting of two alpha-helices and a beta-turn. They can be engineered to bind different target antigens by randomizing residues in the first alpha-helix and a beta-turn of each

repeat. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details see J. Mol. Biol. 332, 489-503 (2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1.

A single-domain antibody is an antibody fragment consisting of a single monomeric
5 variable antibody domain. The first single domains were derived from the variable domain of the antibody heavy chain from camelids (nanobodies or V_HH fragments). Furthermore, the term single-domain antibody includes an autonomous human heavy chain variable domain (aVH) or V_{NAR} fragments derived from sharks. Fibronectin is a scaffold which can be engineered to bind to antigen. Adnectins consists of a backbone of the natural amino acid sequence of the 10th
10 domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the .beta.-sandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details see Protein Eng. Des. Sel. 18, 435- 444 (2005), US20080139791, WO2005056764 and US6818418B1. Peptide aptamers are combinatorial recognition molecules that consist of a constant scaffold protein, typically thioredoxin (TrxA)
15 which contains a constrained variable peptide loop inserted at the active site. For further details see Expert Opin. Biol. Ther. 5, 783-797 (2005). Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges - examples of microproteins include KalataBI and conotoxin and knottins. The microproteins have a loop which can be engineered to include upto 25 amino acids without affecting the overall fold
20 of the microprotein. For further details of engineered knottin domains, see WO2008098796.

An “**antigen binding molecule that binds to the same epitope**” as a reference molecule refers to an antigen binding molecule that blocks binding of the reference molecule to its antigen in a competition assay by 50% or more, and conversely, the reference molecule blocks binding of the antigen binding molecule to its antigen in a competition assay by 50% or more.

25 As used herein, the term “**antigen binding domain**” or “**antigen-binding site**” refers to the part of the antigen binding molecule that specifically binds to an antigenic determinant. More particularly, the term “antigen-binding domain” refers the part of an antibody that comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antigen binding molecule may only bind to a particular part of the antigen,
30 which part is termed an epitope. An antigen binding domain may be provided by, for example, one or more variable domains (also called variable regions). Preferably, an antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). In one aspect, the antigen binding domain is able to bind to its antigen and block or partly block its function. Antigen binding domains that specifically bind to PD1 or to
35 LAG3 include antibodies and fragments thereof as further defined herein. In addition, antigen

binding domains may include scaffold antigen binding proteins, e.g. binding domains which are based on designed repeat proteins or designed repeat domains (see e.g. WO 2002/020565).

As used herein, the term "**antigenic determinant**" is synonymous with "antigen" and "epitope," and refers to a site (e.g. a contiguous stretch of amino acids or a conformational configuration made up of different regions of non-contiguous amino acids) on a polypeptide macromolecule to which an antigen binding moiety binds, forming an antigen binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surfaces of tumor cells, on the surfaces of virus-infected cells, on the surfaces of other diseased cells, on the surface of immune cells, free in blood serum, and/or in the extracellular matrix (ECM). The proteins useful as antigens herein can be any native form the proteins from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g. mice and rats), unless otherwise indicated. In a particular embodiment the antigen is a human protein. Where reference is made to a specific protein herein, the term encompasses the "full-length", unprocessed protein as well as any form of the protein that results from processing in the cell. The term also encompasses naturally occurring variants of the protein, e.g. splice variants or allelic variants.

By "**specific binding**" is meant that the binding is selective for the antigen and can be discriminated from unwanted or non-specific interactions. The ability of an antigen binding molecule to bind to a specific antigen can be measured either through an enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to one of skill in the art, e.g. Surface Plasmon Resonance (SPR) technique (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent of binding of an antigen binding molecule to an unrelated protein is less than about 10% of the binding of the antigen binding molecule to the antigen as measured, e.g. by SPR. In certain embodiments, an molecule that binds to the antigen has a dissociation constant (K_d) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g. 10^{-7} M or less, e.g. from 10^{-7} M to 10^{-13} M , e.g. from 10^{-9} M to 10^{-13} M).

"**Affinity**" or "binding affinity" refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g. an antibody) and its binding partner (e.g. an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g. antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_d), which is the ratio of dissociation and association rate constants (k_{off} and k_{on} , respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).

As used herein, the term “**high affinity**” of an antibody refers to an antibody having a K_d of 10^{-9} M or less and even more particularly 10^{-10} M or less for a target antigen. The term “**low affinity**” of an antibody refers to an antibody having a K_d of 10^{-8} or higher.

5 An “**affinity matured**” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

The term “**a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to**
10 **LAG3**” “a bispecific antibody that specifically binds PD1 and LAG3”, “bispecific antigen binding molecule specific for PD1 and LAG3” or an “anti-PD1/anti-LAG3 antibody” are used interchangeably herein and refer to a bispecific antibody that is capable of binding PD1 and LAG3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting PD1 and LAG3.

15 The term “**PD1**”, also known as Programmed cell death protein 1, is a type I membrane protein of 288 amino acids that was first described in 1992 (Ishida et al., EMBO J., 11 (1992), 3887–3895). PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators and has two ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273). The protein's structure includes an extracellular IgV domain followed by a transmembrane region and an intracellular
20 tail. The intracellular tail contains two phosphorylation sites located in an immunoreceptor tyrosine-based inhibitory motif and an immunoreceptor tyrosine-based switch motif, which suggests that PD-1 negatively regulates TCR signals. This is consistent with binding of SHP-1 and SHP-2 phosphatases to the cytoplasmic tail of PD-1 upon ligand binding. While PD-1 is not expressed on naïve T cells, it is upregulated following T cell receptor (TCR)-mediated activation
25 and is observed on both activated and exhausted T cells (Agata et al., Int. Immunology 8 (1996), 765-772). These exhausted T-cells have a dysfunctional phenotype and are unable to respond appropriately. Although PD-1 has a relatively wide expression pattern its most important role is likely as a coinhibitory receptor on T cells (Chinai et al, Trends in Pharmacological Sciences 36 (2015), 587-595). Current therapeutic approaches thus focus on blocking the interaction of PD-1
30 with its ligands to enhance T cell response. The terms “Programmed Death 1,” “Programmed Cell Death 1,” “Protein PD-1,” “PD-1,” PD1,” “PDCD1,” “hPD-1” and “hPD-I” can be used interchangeably, and include variants, isoforms, species homologs of human PD-1, and analogs having at least one common epitope with PD-1. The amino acid sequence of human PD1 is shown in UniProt (www.uniprot.org) accession no. Q15116 (SEQ ID NO:128).

The terms “**anti-PD1 antibody**” and “an antibody comprising an antigen binding domain that binds to PD1” refer to an antibody that is capable of binding PD1, especially a PD1 polypeptide expressed on a cell surface, with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting PD1. In one aspect, the extent of binding of an anti-PD1 antibody to an unrelated, non-PD1 protein is less than about 10% of the binding of the antibody to PD1 as measured, e.g., by radioimmunoassay (RIA) or flow cytometry (FACS) or by a Surface Plasmon Resonance assay using a biosensor system such as a Biacore® system. In certain aspects, an antigen binding protein that binds to human PD1 has a K_D value of the binding affinity for binding to human PD1 of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M). In one preferred embodiment the respective K_D value of the binding affinities is determined in a Surface Plasmon Resonance assay using the Extracellular domain (ECD) of human PD1 (PD1-ECD) for the PD1 binding affinity. The term “anti-PD1 antibody” also encompasses bispecific antibodies that are capable of binding PD1 and a second antigen.

The terms “**LAG3**” or “Lag-3” or “Lymphocyte activation gene-3” or “CD223” as used herein refer to any native LAG3 from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed LAG3 as well as any form of LAG3 resulting from processing in the cell. The term also encompasses naturally occurring variants of LAG3, e.g., splice variants or allelic variants. In one preferred embodiment the term “LAG3” refers to human LAG3. The amino acid sequence of an exemplary processed (without signal sequences) LAG3 is shown in SEQ ID NO:73. The amino acid sequence of an exemplary Extracellular Domain (ECD) LAG3 is shown in SEQ ID NO:74.

The terms “anti-LAG3 antibody” and “an antibody that binds to LAG3” refer to an antibody that is capable of binding LAG3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting LAG3. In one aspect, the extent of binding of an anti-LAG3 antibody to an unrelated, non-LAG3 protein is less than about 10% of the binding of the antibody to LAG3 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to LAG3 has a dissociation constant (K_d) of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M). In certain aspects, an anti-LAG3 antibody binds to an epitope of LAG3 that is conserved among LAG3 from different species. In one preferred embodiment, an “anti-LAG3 antibody”, “an antibody that specifically binds to human LAG3”, and “an antibody that binds to human LAG3” refers to an antibody specifically binding to the human LAG3 antigen or its Extracellular Domain (ECD) with a binding affinity of a K_D -value of $1.0 \times 10^{-8} \text{ mol/l}$ or lower, in one embodiment of a K_D -value of $1.0 \times 10^{-9} \text{ mol/l}$ or lower, in one embodiment of a K_D -value of $1.0 \times 10^{-9} \text{ mol/l}$ to $1.0 \times 10^{-13} \text{ mol/l}$. In this context the binding

affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE-Healthcare Uppsala, Sweden) e.g. using the LAG3 extracellular domain. The term “anti-LAG3 antibody” also encompasses bispecific antibodies that are capable of binding LAG3 and a second antigen.

5 A "**blocking**" antibody or an "antagonist" antibody is one that inhibits or reduces a biological activity of the antigen it binds. In some embodiments, blocking antibodies or antagonist antibodies substantially or completely inhibit the biological activity of the antigen. For example, the bispecific antibodies of the invention block the signaling through PD- 1 and LAG3 so as to restore a functional response by T cells (e.g., proliferation, cytokine production,
10 target cell killing) from a dysfunctional state to antigen stimulation.

The term “**variable region**” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antigen binding molecule to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved
15 framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

The term “**hypervariable region**” or “HVR,” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally
20 defined loops (“hypervariable loops”). Generally, native four-chain antibodies comprise six HVRs; three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and/or from the “complementarity determining regions” (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-
25 52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). (Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987).) Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).)
30 Hypervariable regions (HVRs) are also referred to as complementarity determining regions (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen binding regions. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and by Chothia *et al.*, *J. Mol. Biol.* 196:901-917 (1987), where the definitions
35 include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof

is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table A as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

TABLE A. CDR Definitions¹

CDR	Kabat	Chothia	AbM ²
V _H CDR1	31-35	26-32	26-35
V _H CDR2	50-65	52-58	50-58
V _H CDR3	95-102	95-102	95-102
V _L CDR1	24-34	26-32	24-34
V _L CDR2	50-56	50-52	50-56
V _L CDR3	89-97	91-96	89-97

¹ Numbering of all CDR definitions in Table A is according to the numbering conventions set forth by Kabat et al. (see below).

² "AbM" with a lowercase "b" as used in Table A refers to the CDRs as defined by Oxford Molecular's "AbM" antibody modeling software.

Kabat *et al.* also defined a numbering system for variable region sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of "Kabat numbering" to any variable region sequence, without reliance on any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system set forth by Kabat et al., U.S. Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, references to the numbering of specific amino acid residue positions in an antibody variable region are according to the Kabat numbering system.

With the exception of CDR1 in V_H, CDRs generally comprise the amino acid residues that form the hypervariable loops. CDRs also comprise "specificity determining residues," or "SDRs," which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, *Front. Biosci.* 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al.

"**Framework**" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

5 An "**acceptor human framework**" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino
10 acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

15 The term "**chimeric**" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

 The "**class**" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and
20 IgM, and several of these may be further divided into subclasses (isotypes), e.g. IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ respectively.

 A "**humanized**" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a
25 humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "**humanized form**" of an antibody, e.g., a non-human
30 antibody, refers to an antibody that has undergone humanization. Other forms of "humanized antibodies" encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding.

A “**human**” antibody is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

The term “**monoclonal antibody**” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

The term “Fc domain” or “**Fc region**” herein is used to define a C-terminal region of an antibody heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. Particularly, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. The amino acid sequences of the heavy chains are always presented with the C-terminal lysine, however variants without the C-terminal lysine are included in the invention.

An IgG Fc region comprises an IgG CH2 and an IgG CH3 domain. The “CH2 domain” of a human IgG Fc region usually extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or variant CH2 domain. The “CH3 domain” comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e. from an amino acid residue at about position 341 to an amino acid residue at about position 447 of an IgG). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g. a CH3 domain with an introduced “protuberance” (“knob”) in one

chain thereof and a corresponding introduced “cavity” (“hole”) in the other chain thereof; see US Patent No. 5,821,333, expressly incorporated herein by reference). Such variant CH3 domains may be used to promote heterodimerization of two non-identical antibody heavy chains as herein described. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

The “**knob-into-hole**” technology is described e.g. in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001).

Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment a knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other one of the two subunits of the Fc domain. In a further specific embodiment, the subunit of the Fc domain comprising the knob modification additionally comprises the amino acid substitution S354C, and the subunit of the Fc domain comprising the hole modification additionally comprises the amino acid substitution Y349C. Introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

A “region equivalent to the Fc region of an immunoglobulin” is intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin as well as variants having alterations which produce substitutions, additions, or deletions but which do not decrease substantially the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular cytotoxicity). For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants can be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, J. U. et al., Science 247:1306-10 (1990)).

The term “**effector functions**” refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation.

An “**activating Fc receptor**” is an Fc receptor that following engagement by an Fc region of an antibody elicits signaling events that stimulate the receptor-bearing cell to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A particular activating Fc receptor is human FcγRIIIa (see UniProt accession no. P08637, version 141).

The term “**peptide linker**” refers to a peptide comprising one or more amino acids, typically about 2 to 20 amino acids. Peptide linkers are known in the art or are described herein. Suitable, non-immunogenic linker peptides are, for example, (G₄S)_n, (SG₄)_n or G₄(SG₄)_n peptide linkers, wherein “n” is generally a number between 1 and 10, typically between 2 and 4, in particular 2, i.e. the peptides selected from the group consisting of GGGGS (SEQ ID NO:129) GGGGSGGGGS (SEQ ID NO:130), SGGGSGGGG (SEQ ID NO:131) and GGGGSGGGGSGGGG (SEQ ID NO:132), but also include the sequences GSPGSSSSGS (SEQ ID NO:133), (G₄S)₃ (SEQ ID NO:134), (G₄S)₄ (SEQ ID NO:135), GSGSGSGS (SEQ ID NO:136), GSGSGNGS (SEQ ID NO:137), GGSGSGSG (SEQ ID NO:138), GGSGSG (SEQ ID NO:139), GGSG (SEQ ID NO:140), GGSGNGSG (SEQ ID NO:141), GGNGSGSG (SEQ ID NO:142) and GGNGSG (SEQ ID NO:143). Peptide linkers of particular interest are (G₄S) (SEQ ID NO:129), (G₄S)₂ or GGGGSGGGGS (SEQ ID NO:130), (G₄S)₃ (SEQ ID NO:134) and (G₄S)₄ (SEQ ID NO:135), more particularly (G₄S)₂ or GGGGSGGGGS (SEQ ID NO:130).

By “fused to” or “connected to” is meant that the components (e.g. an antigen binding domain and a FC domain) are linked by peptide bonds, either directly or via one or more peptide linkers.

The term “**amino acid**” as used within this application denotes the group of naturally occurring carboxy α-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

"Percent (%) amino acid sequence identity" with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, SAWI or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

100 times the fraction X/Y

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

In certain aspects, **amino acid sequence variants** of the bispecific antibodies of the invention provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the bispecific antibodies. Amino acid sequence variants of the bispecific antibodies may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the molecules, or by peptide synthesis.

Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. Sites of interest for substitutional mutagenesis include the HVRs and Framework (FRs). Conservative substitutions are provided in Table B under the heading “Preferred Substitutions” and further described below in reference to amino acid side chain classes (1) to (6). Amino acid substitutions may be introduced into the molecule of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

TABLE B

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

Amino acids may be grouped according to common side-chain properties:

- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;
- 5 (4) basic: His, Lys, Arg;
- (5) residues that influence chain orientation: Gly, Pro;
- (6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

10 The term “**amino acid sequence variants**” includes substantial variants wherein there are amino acid substitutions in one or more hypervariable region residues of a parent antigen binding molecule (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antigen
15 binding molecule and/or will have substantially retained certain biological properties of the parent antigen binding molecule. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antigen binding molecules displayed on phage and screened for a
20 particular biological activity (e.g. binding affinity). In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antigen binding molecule to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. A useful method for identification
25 of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is
30 affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antigen binding molecule complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the
35 desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include bispecific antibodies with an N-terminal methionyl residue. Other insertional
5 variants of the molecule include the fusion to the N- or C-terminus to a polypeptide which increases the serum half-life of the bispecific antibody.

In certain aspects, the bispecific antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Glycosylation variants of the molecules may be conveniently obtained by altering the amino acid sequence such that one or
10 more glycosylation sites is created or removed, e.g. the carbohydrates attached to the Fc domain may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. *TIBTECH* 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose,
15 and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in the bispecific antibodies of the invention may be made in order to create variants with certain improved properties. In one aspect, variants of bispecific antibodies are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. Such
20 fucosylation variants may have improved ADCC function, see e.g. US Patent Publication Nos. US 2003/0157108 (Presta, L.) or US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Further variants of the bispecific antibodies of the invention include those with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and/or improved ADCC
25 function., see for example WO 2003/011878 (Jean-Mairet et al.); US Patent No. 6,602,684 (Umana et al.); and US 2005/0123546 (Umana *et al.*). Variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.).

In certain aspects, it may be desirable to create **cysteine engineered variants** of the bispecific antibodies of the invention, e.g., “thioMAbs,” in which one or more residues of the molecule are substituted with cysteine residues. In particular embodiments, the substituted
30 residues occur at accessible sites of the molecule. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of

the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antigen binding molecules may be generated as described, e.g., in U.S. Patent No. 7,521,541.

In certain aspects, the bispecific antibodies provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available.

5 The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either
10 homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of
15 polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used in a therapy under defined conditions, etc.

20 In another aspect, conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N.W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to
25 a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.

An "**immunoconjugate**" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

The term "**polynucleotide**" refers to an isolated nucleic acid molecule or construct, e.g. messenger RNA (mRNA), virally-derived RNA, or plasmid DNA (pDNA). A polynucleotide
30 may comprise a conventional phosphodiester bond or a non-conventional bond (e.g. an amide bond, such as found in peptide nucleic acids (PNA)). The term "nucleic acid molecule" refers to any one or more nucleic acid segments, e.g. DNA or RNA fragments, present in a polynucleotide.

By "**isolated**" nucleic acid molecule or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a
35 recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated

for the purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in cells that ordinarily contain the polynucleotide molecule, but the
5 polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically. In addition, a polynucleotide or
10 a nucleic acid may be or may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator.

By a nucleic acid or polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the
15 polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the
20 reference sequence. These alterations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%
25 identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs, such as the ones discussed above for polypeptides (e.g. ALIGN-2).

The term "**expression cassette**" refers to a polynucleotide generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a
30 particular nucleic acid in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the invention comprises polynucleotide sequences that
35 encode bispecific antigen binding molecules of the invention or fragments thereof.

The term “**vector**” or “expression vector” is synonymous with “expression construct” and refers to a DNA molecule that is used to introduce and direct the expression of a specific gene to which it is operably associated in a target cell. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. Expression vectors allow transcription of large amounts of stable mRNA. Once the expression vector is inside the target cell, the ribonucleic acid molecule or protein that is encoded by the gene is produced by the cellular transcription and/or translation machinery. In one embodiment, the expression vector of the invention comprises an expression cassette that comprises polynucleotide sequences that encode bispecific antigen binding molecules of the invention or fragments thereof.

The terms “**host cell**”, “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate the bispecific antigen binding molecules of the present invention. In particular, the host cell is a prokaryotic or eukaryotic host cell. Host cells include cultured cells, e.g. mammalian cultured cells, such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.

An “**effective amount**” of an agent refers to the amount that is necessary to result in a physiological change in the cell or tissue to which it is administered.

A “**therapeutically effective amount**” of an agent, e.g. a pharmaceutical composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A therapeutically effective amount of an agent for example eliminates, decreases, delays, minimizes or prevents adverse effects of a disease.

An “**individual**” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g. cows, sheep, cats, dogs, and horses), primates (e.g. humans and non-human primates such as monkeys), rabbits, and rodents (e.g. mice and rats). Particularly, the individual or subject is a human.

The term "**pharmaceutical composition**" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

- 5 A "**pharmaceutically acceptable excipient**" refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable excipient includes, but is not limited to, a buffer, a stabilizer, or a preservative.

- 10 The term "**package insert**" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

- 15 As used herein, "**treatment**" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, the molecules of the invention are used to delay development of a disease or to slow the progression of a disease.

- 20 The term "**cancer**" as used herein refers to proliferative diseases, such as lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwannomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.

Bispecific antibodies of the invention

The invention provides novel bispecific antibodies comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency and reduced toxicity.

In certain aspects, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that shows reduced internalization upon binding to the T cell surface. The internalization represents an important sink for the molecule which can be degraded within a few hours while the targeted receptors are rapidly re-expressed on the cell-surface ready to inhibit TCR-signalling. In further aspects, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that preferentially binds to conventional T cells rather than to Tregs. This is advantageous because targeting LAG-3 on Tregs with blocking antibodies could be detrimental by increasing their suppressive function and eventually mask the positive blocking effect on other T cells. In a further aspect, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that is able to rescue T cell effector functions from Treg suppression. In another aspect, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that is able to induce Granzyme B secretion by CD4 T cells, when co-cultured with the tumor cell line ARH77 as shown in the assay provided herein. In a further aspect, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that shows increased tumor-specific T cell effector functions and/or enhances the cytotoxic effect of T cells. In another aspect, a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is provided that shows increased tumor eradication *in vivo*.

A. Exemplary bispecific antibodies that bind to PD1 and LAG3

In one aspect, the invention provides a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein said first antigen binding domain specifically binding to PD1 comprises

a VH domain comprising

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and
a VL domain comprising

- 5 (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.

In one aspect, the bispecific antibody comprises a Fc domain that is an IgG, particularly an
IgG1 Fc domain or an IgG4 Fc domain and wherein the Fc domain has reduced or even
10 abolished effector function. In particular, the Fc domain comprises one or more amino acid
substitution that reduces binding to an Fc receptor, in particular towards Fc γ receptor.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding
domain that specifically binds to PD1 and a second antigen binding domain that specifically
binds to LAG3, wherein the bispecific antibody comprises a Fc domain that is an IgG,
15 particularly an IgG1 Fc domain or an IgG4 Fc domain and wherein the Fc domain comprises one
or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fc γ
receptor.

In another aspect, provided is a bispecific antibody comprising a first antigen binding
domain that specifically binds to PD1 and a second antigen binding domain that specifically
20 binds to LAG3, wherein the second antigen binding domain that specifically binds to LAG3
comprises

(a) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and
25 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:16; and
a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19; or

30 (b) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:23, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:24; and
a VL domain comprising

- 35 (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:25,

- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:26, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27; or

(c) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:30,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:31, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:32; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:33,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:34, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:35; or

(d) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:40; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:41,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:43; or

(e) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:46,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:48; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:49,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:50, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:51.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the first antigen binding domain specifically binding to PD1 comprises

- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain comprising the amino acid sequence of SEQ ID NO: 8, or
- (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10, or
- (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 11, or

- (d) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 12, or
- (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 13.

5 In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the first antigen binding domain that specifically binds to PD1 comprises

(a) a VH domain comprising

- 10 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:80,
- (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:81, and
- (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:82; and
- a VL domain comprising
- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:83,
- 15 (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:84, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:85; or

(b) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88,
- (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:89, and
- 20 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:90; and
- a VL domain comprising
- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:91,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:92, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:93.

25 In one aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the first antigen binding domain specifically binding to PD1 comprises

- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 86 and a VL domain comprising the amino acid sequence of SEQ ID NO: 87, or
- 30 (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 94 and a VL domain comprising the amino acid sequence of SEQ ID NO: 95.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically

binds to LAG3, wherein the second antigen binding domain specifically binding to LAG3 comprises

- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21, or
- 5 (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 28 and a VL domain comprising the amino acid sequence of SEQ ID NO: 29, or
- (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 36 and a VL domain comprising the amino acid sequence of SEQ ID NO: 37, or
- 10 (d) a VH domain comprising the amino acid sequence of SEQ ID NO: 44 and a VL domain comprising the amino acid sequence of SEQ ID NO: 45, or
- (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

In another aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the second antigen binding domain that specifically binds to LAG3 comprises a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:56,
- (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:57, and
- (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:58; and
- 20 a VL domain comprising
- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:59,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:60, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:61.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the second antigen binding domain specifically binding to LAG3 comprises

- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 54 and a VL domain comprising the amino acid sequence of SEQ ID NO: 55, or
- 30 (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63, or
- (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 64 and a VL domain comprising the amino acid sequence of SEQ ID NO: 65, or

(d) a VH domain comprising the amino acid sequence of SEQ ID NO: 66 and a VL domain comprising the amino acid sequence of SEQ ID NO: 67.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically
5 binds to LAG3, wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

10 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21 or a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

15 In one aspect, the bispecific antibody of the invention comprises a first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10 and a second antigen binding domain specifically binding to LAG3 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21.

20 In a further aspect, the bispecific antibody of the invention comprises a first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10 and a second antigen binding domain specifically binding to LAG3 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising
25 the amino acid sequence of SEQ ID NO: 53.

In another aspect, the bispecific antibody of the invention comprises a first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10 and a second antigen binding domain specifically binding to LAG3 comprising a VH
30 domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63.

In yet another aspect, the bispecific antibody of the invention comprises a first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 86 and a VL domain comprising the amino acid sequence of SEQ ID
35 NO: 87 and a second antigen binding domain specifically binding to LAG3 comprising a VH

domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63.

5 In yet another aspect, the bispecific antibody of the invention comprises a first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 94 and a VL domain comprising the amino acid sequence of SEQ ID NO: 95 and a second antigen binding domain specifically binding to LAG3 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63.

10 In a further aspect, the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is a human, humanized or chimeric antibody. In particular, it is a humanized or chimeric antibody.

15 In one aspect, the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 is bivalent. This means that the bispecific antibody comprises one antigen binding domain that specifically binds to PD1 and one antigen binding domain that specifically binds to LAG3 (1+1 format).

20 In one aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1 and a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3. In a particular aspect, in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain. In a particular aspect, in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises

30 (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 97, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 99, or

35

- (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 102, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 104, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105, or
- (d) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 106, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 107, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

More particularly, the bispecific antibody comprises

- (a) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 97, and a second light chain comprising an amino acid sequence of SEQ ID NO:99, or
- (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence of SEQ ID NO:101, or
- (c) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 102, a first light chain comprising an amino acid sequence of SEQ ID NO: 104, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence of SEQ ID NO:105, or
- (d) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 106, a first light chain comprising an amino acid sequence of SEQ ID NO: 107, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence of SEQ ID NO:105.

More particularly, the bispecific antibody comprises a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence of SEQ ID NO:101.

5 In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1 and a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 that is fused to the C-
10 terminus of the Fc domain. Particularly, the Fab fragment comprising the antigen binding domain that specifically binds to LAG3 is fused to the C-terminus of the FC domain via its VH domain (trans 1+1 format).

In a particular aspect, the bispecific antibody comprises a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a
15 first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 144, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101. More particularly, the bispecific antibody comprises a first heavy chain comprising
20 an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 144, and a second light chain comprising an amino acid sequence of SEQ ID NO:101.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically
25 binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1, a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 and a third Fab fragment comprising an antigen binding domain that specifically binds to LAG3. In a particular aspect, the the Fab fragment comprising the antigen binding domain that specifically binds to PD1 is fused
30 via a peptide linker to the C-terminus of one of the heavy chains.

In this aspect, the bispecific antibody is trivalent with bivalent binding to LAG3 and monovalent binding to PD1. This means that the bispecific antibody comprises one antigen binding domain that specifically binds to PD1 and two antigen binding domains that specifically bind to LAG3 (2+1 format).

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises

- 5 (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 118, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- 10 (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 120, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two second light chains comprising an amino acid
- 15 sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 122, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
- 20 to the sequence of SEQ ID NO: 103, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

More particularly, the bispecific antibody comprises

- (a) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 118, a first light chain comprising an amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 119, and two second light chains comprising an amino acid sequence of SEQ ID NO:101, or
- 25 (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 120, a first light chain comprising an amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 121, and two second light chains comprising an amino acid sequence of SEQ ID NO:99, or
- 30 (c) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 122, a first light chain comprising an amino acid sequence of SEQ ID NO: 115, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 103, and two second light chains comprising an amino acid sequence of SEQ ID NO:105.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1, a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 and a third Fab fragment comprising an antigen binding domain that specifically binds to LAG3, wherein one of the Fab fragments comprising the antigen binding domain that specifically binds to LAG3 is fused via a peptide linker to the C-terminus of one of the heavy chains (trans 2+1 format).

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 145, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101. More particularly, the bispecific antibody comprises a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 145, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a single chain Fab (scFab) comprising the antigen binding domain that specifically binds to PD1. In particular, the scFab comprising an antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus to one of the heavy chains.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 123, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two light chains

comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 124, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 125, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

More particularly, the bispecific antibody comprises

(a) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 123, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 119, and two light chains comprising each an amino acid sequence of SEQ ID NO: 101, or

(b) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 124, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 121, and two light chains comprising each an amino acid sequence of SEQ ID NO:99, or

(c) a first heavy chain comprising an amino acid sequence of SEQ ID NO: 125, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 103, and two light chains comprising each an amino acid sequence of SEQ ID NO:105.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a VH and VL domain comprising the antigen binding domain that specifically binds to PD1. In particular, the the VH domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of one of the heavy chains and the VL domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of the other one of the heavy chains.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises a first heavy chain comprising an

amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 126, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 127, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 109. More particularly, the
5 bispecific antibody comprises a first heavy chain comprising an amino acid sequence of SEQ ID NO: 126, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 127, and two light chains comprising each an amino acid sequence of SEQ ID NO: 109.

In a further aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically
10 binds to LAG3, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1, a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3, a third Fab fragment comprising an antigen binding domain that specifically binds to LAG3, and a fourth Fab fragment comprising an antigen binding domain that specifically binds to PD1.

15 In this aspect, the bispecific antibody is tetravalent with bivalent binding to LAG3 and bivalent binding to PD1. This means that the bispecific antibody comprises two antigen binding domains that specifically bind to PD1 and two antigen binding domains that specifically bind to LAG3 (2+2 format).

In one aspect, the bispecific antibody of the invention comprises
20 (a) two light chains and two heavy chains of an antibody comprising two Fab fragments comprising the antigen binding domains that specifically bind to LAG3, and
(b) two additional Fab fragments comprising the antigen binding domains that specifically bind to PD1, wherein said additional Fab fragments are each connected via a peptide linker to the C-terminus of the heavy chains of (a).

25 In a particular aspect, the peptide linker is (G₄S)₄. In another aspect, the two additional Fab fragments comprising the antigen binding domains that specifically bind to PD1 are crossover Fab fragments wherein the variable domains VL and VH are replaced by each other and the VL-CH chains are each connected via a peptide linker to the C-terminus of the heavy chains of (a).

30 In one aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are each fused via a peptide linker to the C-terminus to one of the heavy chains, respectively.

In a particular aspect, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises

- 5 (a) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 114, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or
- 10 (b) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 116, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- 15 (c) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 117, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

More particularly, the bispecific antibody comprises

- 20 (a) two heavy chains comprising each an amino acid sequence of SEQ ID NO: 114, two first light chains comprising each an amino acid sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence of SEQ ID NO: 101, or
- (b) two heavy chains comprising each an amino acid sequence of SEQ ID NO: 116, two first light chains comprising each an amino acid sequence of SEQ ID NO: 115, and two second
- 25 light chains comprising each an amino acid sequence of SEQ ID NO:99, or
- (c) two heavy chains comprising each an amino acid sequence of SEQ ID NO: 117, two first light chains comprising each an amino acid sequence of SEQ ID NO: 115, and two second light chains comprising an amino acid sequence of SEQ ID NO:105.

Fc domain modifications reducing Fc receptor binding and/or effector function

- 30 In certain aspects, provided is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the bispecific antibody comprises a Fc domain comprising one or more

amino acid modifications that reduce binding to an Fc receptor, in particular towards Fc γ receptor, and reduce or abolish effector function.

In certain aspects, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region
5 variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

The following section describes preferred aspects of the bispecific antigen binding molecules of the invention comprising Fc domain modifications reducing Fc receptor binding
10 and/or effector function. In one aspect, the invention relates to a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fc γ receptor. In particular, the Fc domain is of human IgG1 subclass with the amino acid mutations L234A,
15 L235A and P329G (numbering according to Kabat EU index).

The Fc domain confers favorable pharmacokinetic properties to the bispecific antibodies of the invention, including a long serum half-life which contributes to good accumulation in the target tissue and a favorable tissue-blood distribution ratio. At the same time it may, however, lead to undesirable targeting of the bispecific antibodies of the invention to cells expressing Fc
20 receptors rather than to the preferred antigen-bearing cells. Accordingly, in particular embodiments the Fc domain of the the bispecific antibodies of the invention exhibits reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a native IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain. More particularly, the Fc domain is an IgG1 FC domain.

In one such aspect the Fc domain (or the bispecific antigen binding molecule of the invention comprising said Fc domain) exhibits less than 50%, preferably less than 20%, more preferably less than 10% and most preferably less than 5% of the binding affinity to an Fc receptor, as compared to a native IgG1 Fc domain (or the bispecific antigen binding molecule of the invention comprising a native IgG1 Fc domain), and/or less than 50%, preferably less than
30 20%, more preferably less than 10% and most preferably less than 5% of the effector function, as compared to a native IgG1 Fc domain (or the bispecific antigen binding molecule of the invention comprising a native IgG1 Fc domain). In one aspect, the Fc domain (or the bispecific antigen binding molecule of the invention comprising said Fc domain) does not substantially bind to an Fc receptor and/or induce effector function. In a particular aspect the Fc receptor is an
35 Fc γ receptor. In one aspect, the Fc receptor is a human Fc receptor. In one aspect, the Fc receptor

is an activating Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc receptor is an inhibitory Fc receptor. In a specific aspect, the Fc receptor is an inhibitory human Fcγ receptor, more specifically human FcγRIIB. In one aspect the effector function is one or more of CDC, ADCC, ADCP, and cytokine secretion. In a particular aspect, the effector function is ADCC. In one aspect, the Fc domain domain exhibits substantially similar binding affinity to neonatal Fc receptor (FcRn), as compared to a native IgG1 Fc domain. Substantially similar binding to FcRn is achieved when the Fc domain (or the the bispecific antigen binding molecule of the invention comprising said Fc domain) exhibits greater than about 70%, particularly greater than about 80%, more particularly greater than about 90% of the binding affinity of a native IgG1 Fc domain (or the the bispecific antigen binding molecule of the invention comprising a native IgG1 Fc domain) to FcRn.

In a particular aspect, the Fc domain is engineered to have reduced binding affinity to an Fc receptor and/or reduced effector function, as compared to a non-engineered Fc domain. In a particular aspect, the Fc domain of the bispecific antigen binding molecule of the invention comprises one or more amino acid mutation that reduces the binding affinity of the Fc domain to an Fc receptor and/or effector function. Typically, the same one or more amino acid mutation is present in each of the two subunits of the Fc domain. In one aspect, the amino acid mutation reduces the binding affinity of the Fc domain to an Fc receptor. In another aspect, the amino acid mutation reduces the binding affinity of the Fc domain to an Fc receptor by at least 2-fold, at least 5-fold, or at least 10-fold. In one aspect, the bispecific antigen binding molecule of the invention comprising an engineered Fc domain exhibits less than 20%, particularly less than 10%, more particularly less than 5% of the binding affinity to an Fc receptor as compared to bispecific antibodies of the invention comprising a non-engineered Fc domain. In a particular aspect, the Fc receptor is an Fcγ receptor. In other aspects, the Fc receptor is a human Fc receptor. In one aspect, the Fc receptor is an inhibitory Fc receptor. In a specific aspect, the Fc receptor is an inhibitory human Fcγ receptor, more specifically human FcγRIIB. In some aspects the Fc receptor is an activating Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. Preferably, binding to each of these receptors is reduced. In some aspects, binding affinity to a complement component, specifically binding affinity to C1q, is also reduced. In one aspect, binding affinity to neonatal Fc receptor (FcRn) is not reduced. Substantially similar binding to FcRn, i.e. preservation of the binding affinity of the Fc domain to said receptor, is achieved when the Fc domain (or the bispecific antigen binding molecule of the invention comprising said Fc domain) exhibits greater than about 70% of the binding affinity of a non-engineered form of the Fc domain (or the bispecific antigen binding molecule of the invention comprising said non-engineered form of the Fc domain) to FcRn. The Fc domain, or the the

bispecific antigen binding molecule of the invention comprising said Fc domain, may exhibit greater than about 80% and even greater than about 90% of such affinity. In certain embodiments the Fc domain of the bispecific antigen binding molecule of the invention is engineered to have reduced effector function, as compared to a non-engineered Fc domain. The reduced effector function can include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated antigen uptake by antigen-presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling inducing apoptosis, reduced dendritic cell maturation, or reduced T cell priming.

Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581). Certain antibody variants with improved or diminished binding to FcRs are described. (e.g. U.S. Patent No. 6,737,056; WO 2004/056312, and Shields, R.L. et al., J. Biol. Chem. 276 (2001) 6591-6604).

In one aspect of the invention, the Fc domain comprises an amino acid substitution at a position of E233, L234, L235, N297, P331 and P329. In some aspects, the Fc domain comprises the amino acid substitutions L234A and L235A ("LALA"). In one such embodiment, the Fc domain is an IgG1 Fc domain, particularly a human IgG1 Fc domain. In one aspect, the Fc domain comprises an amino acid substitution at position P329. In a more specific aspect, the amino acid substitution is P329A or P329G, particularly P329G. In one embodiment the Fc domain comprises an amino acid substitution at position P329 and a further amino acid substitution selected from the group consisting of E233P, L234A, L235A, L235E, N297A, N297D or P331S. In more particular embodiments the Fc domain comprises the amino acid mutations L234A, L235A and P329G ("P329G LALA"). The "P329G LALA" combination of amino acid substitutions almost completely abolishes Fcγ receptor binding of a human IgG1 Fc domain, as described in PCT Patent Application No. WO 2012/130831 A1. Said document also describes methods of preparing such mutant Fc domains and methods for determining its properties such as Fc receptor binding or effector functions. Such antibody is an IgG1 with mutations L234A and L235A or with mutations L234A, L235A and P329G (numbering according to EU index of Kabat et al., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991).

In one aspect, the bispecific antibody of the invention comprises (all positions according to EU index of Kabat) (i) a homodimeric Fc-region of the human IgG1 subclass optionally with the mutations P329G, L234A and L235A, or (ii) a homodimeric Fc-region of the human IgG4 subclass optionally with the mutations P329G, S228P and L235E, or (iii) a homodimeric Fc-region of the human IgG1 subclass optionally with the mutations P329G, L234A, L235A, I253A, H310A, and H435A, or optionally with the mutations P329G, L234A, L235A, H310A, H433A, and Y436A, or (iv) a heterodimeric Fc-region wherein one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or wherein one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or wherein one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C, or (v) a heterodimeric Fc-region of the human IgG1 subclass wherein both Fc-region polypeptides comprise the mutations P329G, L234A and L235A and one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or wherein one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or wherein one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C.

In one aspect, the Fc domain is an IgG4 Fc domain. In a more specific embodiment, the Fc domain is an IgG4 Fc domain comprising an amino acid substitution at position S228 (Kabat numbering), particularly the amino acid substitution S228P. In a more specific embodiment, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G. This amino acid substitution reduces in vivo Fab arm exchange of IgG4 antibodies (see Stubenrauch et al., Drug Metabolism and Disposition 38, 84-91 (2010)). Thus, in one aspect, provided is a bispecific antibody, comprising (all positions according to EU index of Kabat) a heterodimeric Fc-region of the human IgG4 subclass wherein both Fc-region polypeptides comprise the mutations P329G, S228P and L235E and one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or wherein one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or wherein one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C.

Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer, R.L. et al., J. Immunol. 117 (1976) 587-593, and Kim, J.K. et al., J. Immunol. 24 (1994) 2429-2434), are described in US 2005/0014934. Those antibodies comprise an Fc region with one or more

substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826). See also Duncan, A.R. and Winter, G., Nature
5 322 (1988) 738-740; US 5,648,260; US 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

Binding to Fc receptors can be easily determined e.g. by ELISA, or by Surface Plasmon Resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare), and Fc receptors such as may be obtained by recombinant expression. A suitable such binding
10 assay is described herein. Alternatively, binding affinity of Fc domains or cell activating bispecific antigen binding molecules comprising an Fc domain for Fc receptors may be evaluated using cell lines known to express particular Fc receptors, such as human NK cells expressing FcγIIIa receptor. Effector function of an Fc domain, or bispecific antibodies of the invention comprising an Fc domain, can be measured by methods known in the art. A suitable assay for
15 measuring ADCC is described herein. Other examples of *in vitro* assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362; Hellstrom et al. Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Patent No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-
20 radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g. in a animal model such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95,
25 652-656 (1998).

The following section describes preferred aspects of the bispecific antibodies of the invention comprising Fc domain modifications reducing Fc receptor binding and/or effector function. In one aspect, the invention relates to the bispecific comprising a first antigen binding
30 domain that specifically binds PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the Fc domain comprises one or more amino acid substitution that reduces the binding affinity of the antibody to an Fc receptor, in particular towards Fcγ receptor. In another aspect, the invention relates to the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the Fc domain comprises one or more amino acid substitution that reduces
35 effector function. In particular aspect, the Fc domain is of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

Fc domain modifications promoting heterodimerization

The bispecific antigen binding molecules of the invention comprise different antigen binding domains, fused to one or the other of the two subunits of the Fc domain, thus the two subunits of the Fc domain may be comprised in two non-identical polypeptide chains.

5 Recombinant co-expression of these polypeptides and subsequent dimerization leads to several possible combinations of the two polypeptides. To improve the yield and purity of the bispecific antibodies of the invention in recombinant production, it will thus be advantageous to introduce in the Fc domain of the bispecific antigen binding molecules of the invention a modification promoting the association of the desired polypeptides.

10 Accordingly, in particular aspects the invention relates to a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3, wherein the Fc domain comprises a modification promoting the association of the first and second subunit of the Fc domain. The site of most extensive protein-protein interaction between the two subunits of a human IgG Fc domain is in
15 the CH3 domain of the Fc domain. Thus, in one aspect said modification is in the CH3 domain of the Fc domain.

In a specific aspect said modification is a so-called “knob-into-hole” modification, comprising a “knob” modification in one of the two subunits of the Fc domain and a “hole” modification in the other one of the two subunits of the Fc domain. Thus, the invention relates to
20 a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen-binding site that specifically binds to LAG3, wherein the first subunit of the Fc domain comprises knobs and the second subunit of the Fc domain comprises holes according to the knobs into holes method. In a particular aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the
25 second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

The knob-into-hole technology is described e.g. in US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance (“knob”) at the interface of a first polypeptide and a
30 corresponding cavity (“hole”) in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the

interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).

Accordingly, in one aspect, in the CH3 domain of the first subunit of the Fc domain of the bispecific antigen binding molecules of the invention an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the CH3 domain of the first subunit which is positionable in a cavity within the CH3 domain of the second subunit, and in the CH3 domain of the second subunit of the Fc domain an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the CH3 domain of the second subunit within which the protuberance within the CH3 domain of the first subunit is positionable. The protuberance and cavity can be made by altering the nucleic acid encoding the polypeptides, e.g. by site-specific mutagenesis, or by peptide synthesis. In a specific aspect, in the CH3 domain of the first subunit of the Fc domain the threonine residue at position 366 is replaced with a tryptophan residue (T366W), and in the CH3 domain of the second subunit of the Fc domain the tyrosine residue at position 407 is replaced with a valine residue (Y407V). In one aspect, in the second subunit of the Fc domain additionally the threonine residue at position 366 is replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A).

In yet a further aspect, in the first subunit of the Fc domain additionally the serine residue at position 354 is replaced with a cysteine residue (S354C), and in the second subunit of the Fc domain additionally the tyrosine residue at position 349 is replaced by a cysteine residue (Y349C). Introduction of these two cysteine residues leads to the formation of a disulfide bridge between the two subunits of the Fc domain, further stabilizing the dimer (Carter (2001), J Immunol Methods 248, 7-15). In a particular aspect, the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

But also other knobs-in-holes technologies as described by EP 1 870 459, can be used alternatively or additionally. In one embodiment the multispecific antibody comprises the mutations R409D and K370E in the CH3 domain of the “knobs chain” and the mutations D399K and E357K in the CH3 domain of the “hole-chain” (numbering according to Kabat EU index).

In one aspect, the bispecific antibody comprises a T366W mutation in the CH3 domain of the “knobs chain” and the mutations T366S, L368A and Y407V in the CH3 domain of the “hole chain” and additionally the mutations R409D and K370E in the CH3 domain of the “knobs chain” and the mutations D399K and E357K in the CH3 domain of the “hole chain” (numbering according to the Kabat EU index).

In one aspect, the bispecific antibody comprises the mutations Y349C and T366W in one of the two CH3 domains and the mutations S354C, T366S, L368A and Y407V in the other of the two CH3 domains, or the multispecific antibody comprises the mutations Y349C and T366W in one of the two CH3 domains and the mutations S354C, T366S, L368A and Y407V in the other of the two CH3 domains and additionally the mutations R409D and K370E in the CH3 domain of the “knobs chain” and the mutations D399K and E357K in the CH3 domain of the “hole chain” (numbering according to the Kabat EU index).

In an alternative aspect, a modification promoting association of the first and the second subunit of the Fc domain comprises a modification mediating electrostatic steering effects, e.g. as described in PCT publication WO 2009/089004. Generally, this method involves replacement of one or more amino acid residues at the interface of the two Fc domain subunits by charged amino acid residues so that homodimer formation becomes electrostatically unfavorable but heterodimerization electrostatically favorable.

Apart from the “knob-into-hole technology” other techniques for modifying the CH3 domains of the heavy chains of a multispecific antibody to enforce heterodimerization are known in the art. These technologies, especially the ones described in WO 96/27011, WO 98/050431, EP 1870459, WO 2007/110205, WO 2007/147901, WO 2009/089004, WO 2010/129304, WO 2011/90754, WO 2011/143545, WO 2012/058768, WO 2013/157954 and WO 2013/096291 are contemplated herein as alternatives to the “knob-into-hole technology” in combination with a bispecific antibody.

In one aspect, in the bispecific antibody the approach described in EP 1870459 is used to support heterodimerization of the first heavy chain and the second heavy chain of the multispecific antibody. This approach is based on the introduction of charged amino acids with opposite charges at specific amino acid positions in the CH3/CH3-domain-interface between both, the first and the second heavy chain.

Accordingly, in this aspect in the tertiary structure of the multispecific antibody the CH3 domain of the first heavy chain and the CH3 domain of the second heavy chain form an interface that is located between the respective antibody CH3 domains, wherein the respective amino acid sequences of the CH3 domain of the first heavy chain and the amino acid sequence of the CH3 domain of the second heavy chain each comprise a set of amino acids that is located within said interface in the tertiary structure of the antibody, wherein from the set of amino acids that is located in the interface in the CH3 domain of one heavy chain a first amino acid is substituted by a positively charged amino acid and from the set of amino acids that is located in the interface in the CH3 domain of the other heavy chain a second amino acid is substituted by a negatively charged amino acid. The bispecific antibody according to this aspect is herein also referred to as

“CH3(+/-)-engineered bispecific antibody” (wherein the abbreviation “+/-” stands for the oppositely charged amino acids that were introduced in the respective CH3 domains).

In one aspect, in the CH3(+/-)-engineered bispecific antibody the positively charged amino acid is selected from K, R and H, and the negatively charged amino acid is selected from E or D.

5 In one aspect, in the CH3(+/-)-engineered bispecific antibody the positively charged amino acid is selected from K and R, and the negatively charged amino acid is selected from E or D.

In one aspect, in the CH3(+/-)-engineered bispecific antibody the positively charged amino acid is K, and the negatively charged amino acid is E.

10 In one aspect, in the CH3(+/-)-engineered bispecific antibody in the CH3 domain of one heavy chain the amino acid R at position 409 is substituted by D and the amino acid K at position is substituted by E, and in the CH3 domain of the other heavy chain the amino acid D at position 399 is substituted by K and the amino acid E at position 357 is substituted by K (numbering according to Kabat EU index).

15 In one aspect, the approach described in WO 2013/157953 is used to support heterodimerization of the first heavy chain and the second heavy chain of the multispecific antibody. In one embodiment in the CH3 domain of one heavy chain the amino acid T at position 366 is substituted by K, and in the CH3 domain of the other heavy chain the amino acid L at position 351 is substituted by D (numbering according to Kabat EU index). In another embodiment in the CH3 domain of one heavy chain the amino acid T at position 366 is
20 substituted by K and the amino acid L at position 351 is substituted by K, and in the CH3 domain of the other heavy chain the amino acid L at position 351 is substituted by D (numbering according to Kabat EU index).

25 In another aspect, in the CH3 domain of one heavy chain the amino acid T at position 366 is substituted by K and the amino acid L at position 351 is substituted by K, and in the CH3 domain of the other heavy chain the amino acid L at position 351 is substituted by D (numbering according to Kabat EU index). Additionally at least one of the following substitutions is comprised in the CH3 domain of the other heavy chain: the amino acid Y at position 349 is substituted by E, the amino acid Y at position 349 is substituted by D and the amino acid L at position 368 is substituted by E (numbering according to Kabat EU index). In one embodiment
30 the amino acid L at position 368 is substituted by E (numbering according to Kabat EU index).

In one aspect, the approach described in WO 2012/058768 is used to support heterodimerization of the first heavy chain and the second heavy chain of the multispecific antibody. In one aspect, in the CH3 domain of one heavy chain the amino acid L at position 351

is substituted by Y and the amino acid Y at position 407 is substituted by A, and in the CH3 domain of the other heavy chain the amino acid T at position 366 is substituted by A and the amino acid K at position 409 is substituted by F (numbering according to Kabat EU index). In another embodiment, in addition to the aforementioned substitutions, in the CH3 domain of the
5 other heavy chain at least one of the amino acids at positions 411 (originally T), 399 (originally D), 400 (originally S), 405 (originally F), 390 (originally N) and 392 (originally K) is substituted (numbering according to Kabat EU index). Preferred substitutions are:

- substituting the amino acid T at position 411 by an amino acid selected from N, R, Q, K, D, E and W (numbering according to Kabat EU index),

10 - substituting the amino acid D at position 399 by an amino acid selected from R, W, Y, and K (numbering according to Kabat EU index),

- substituting the amino acid S at position 400 by an amino acid selected from E, D, R and K (numbering according to Kabat EU index),

15 - substituting the amino acid F at position 405 by an amino acid selected from I, M, T, S, V and W (numbering according to Kabat EU index);

- substituting the amino acid N at position 390 by an amino acid selected from R, K and D (numbering according to Kabat EU index; and

- substituting the amino acid K at position 392 by an amino acid selected from V, M, R, L, F and E (numbering according to Kabat EU index).

20 In another aspect, the bispecific antibody is engineered according to WO 2012/058768), i.e. in the CH3 domain of one heavy chain the amino acid L at position 351 is substituted by Y and the amino acid Y at position 407 is substituted by A, and in the CH3 domain of the other heavy chain the amino acid T at position 366 is substituted by V and the amino acid K at position 409 is substituted by F (numbering according to Kabat EU index). In another embodiment of the
25 multispecific antibody, in the CH3 domain of one heavy chain the amino acid Y at position 407 is substituted by A, and in the CH3 domain of the other heavy chain the amino acid T at position 366 is substituted by A and the amino acid K at position 409 is substituted by F (numbering according to Kabat EU index). In the last aforementioned embodiment, in the CH3 domain of the other heavy chain the amino acid K at position 392 is substituted by E, the amino acid T at
30 position 411 is substituted by E, the amino acid D at position 399 is substituted by R and the amino acid S at position 400 is substituted by R (numbering according to Kabat EU index).

In one aspect, the approach described in WO 2011/143545 is used to support heterodimerization of the first heavy chain and the second heavy chain of the multispecific

antibody. In one aspect, amino acid modifications in the CH3 domains of both heavy chains are introduced at positions 368 and/or 409 (numbering according to Kabat EU index).

In one aspect, the approach described in WO 2011/090762 is used to support heterodimerization of the first heavy chain and the second heavy chain of the bispecific antibody.

5 WO 2011/090762 relates to amino acid modifications according to the “knob-into-hole” (KiH) technology. In one embodiment in the CH3 domain of one heavy chain the amino acid T at position 366 is substituted by W, and in the CH3 domain of the other heavy chain the amino acid Y at position 407 is substituted by A (numbering according to Kabat EU index). In another embodiment in the CH3 domain of one heavy chain the amino acid T at position 366 is
10 substituted by Y, and in the CH3 domain of the other heavy chain the amino acid Y at position 407 is substituted by T (numbering according to Kabat EU index).

In one aspect, the approach described in WO 2009/089004 is used to support heterodimerization of the first heavy chain and the second heavy chain of the bispecific antibody.

In one embodiment in the CH3 domain of one heavy chain the amino acid K or N at position 392
15 is substituted by a negatively charged amino acid (in one embodiment by E or D, in one preferred embodiment by D), and in the CH3 domain of the other heavy chain the amino acid D at position 399 the amino acid E or D at position 356 or the amino acid E at position 357 is substituted by a positively charged amino acid (in one embodiment K or R, in one preferred embodiment by K, in one preferred embodiment the amino acids at positions 399 or 356 are
20 substituted by K) (numbering according to Kabat EU index). In one further embodiment, in addition to the aforementioned substitutions, in the CH3 domain of the one heavy chain the amino acid K or R at position 409 is substituted by a negatively charged amino acid (in one embodiment by E or D, in one preferred embodiment by D) (numbering according to Kabat EU index). In one even further aspect, in addition to or alternatively to the aforementioned
25 substitutions, in the CH3 domain of the one heavy chain the amino acid K at position 439 and/or the amino acid K at position 370 is substituted independently from each other by a negatively charged amino acid (in one embodiment by E or D, in one preferred embodiment by D) (numbering according to Kabat EU index).

In one aspect, the approach described in WO 2007/147901 is used to support

30 heterodimerization of the first heavy chain and the second heavy chain of the multispecific antibody. In one embodiment in the CH3 domain of one heavy chain the amino acid K at position 253 is substituted by E, the amino acid D at position 282 is substituted by K and the amino acid K at position 322 is substituted by D, and in the CH3 domain of the other heavy chain the amino acid D at position 239 is substituted by K, the amino acid E at position 240 is
35 substituted by K and the amino acid K at position 292 is substituted by D (numbering according to Kabat EU index).

The C-terminus of the heavy chain of the bispecific antibody as reported herein can be a complete C-terminus ending with the amino acid residues PGK. The C-terminus of the heavy chain can be a shortened C-terminus in which one or two of the C terminal amino acid residues have been removed. In one preferred aspect, the C-terminus of the heavy chain is a shortened C-terminus ending PG.

In one aspect of all aspects as reported herein, a bispecific antibody comprising a heavy chain including a C-terminal CH3 domain as specified herein, comprises the C-terminal glycine-lysine dipeptide (G446 and K447, numbering according to Kabat EU index). In one embodiment of all aspects as reported herein, a bispecific antibody comprising a heavy chain including a C-terminal CH3 domain, as specified herein, comprises a C-terminal glycine residue (G446, numbering according to Kabat EU index).

Modifications in the Fab domains

In one aspect, the invention relates to a bispecific antibody comprising a first Fab fragment that specifically binds to PD1 and a second Fab fragment that specifically binds to LAG3, wherein in one of the Fab fragments either the variable domains VH and VL or the constant domains CH1 and CL are exchanged. The bispecific antibodies are prepared according to the Crossmab technology.

Multispecific antibodies with a domain replacement/exchange in one binding arm (CrossMabVH-VL or CrossMabCH-CL) are described in detail in WO2009/080252, WO2009/080253 and Schaefer, W. et al, PNAS, 108 (2011) 11187-1191. They clearly reduce the byproducts caused by the mismatch of a light chain against a first antigen with the wrong heavy chain against the second antigen (compared to approaches without such domain exchange).

In a particular aspect, the invention relates to a bispecific antibody comprising a first Fab fragment that specifically binds to PD1 and a second Fab fragment that specifically binds to LAG3, wherein in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain. In a particular aspect, the bispecific antibody is one, wherein in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.

In another aspect, and to further improve correct pairing, the bispecific antibody comprising a first Fab fragment that specifically binds to PD1 and a second Fab fragment that specifically binds to LAG3, can contain different charged amino acid substitutions (so-called "charged residues"). These modifications are introduced in the crossed or non-crossed CH1 and

CL domains. Such modifications are described e.g. in WO2015/150447, WO2016/020309 and PCT/EP2016/073408.

In a particular aspect, the invention is concerned with a bispecific antibody comprising a first Fab fragment that specifically binds to PD1 and a second Fab fragment that specifically binds to LAG3, wherein in one of the Fab fragments in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index). In a particular aspect, the bispecific antibody is one, wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to TIM3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

In a particular aspect, the invention relates to a bispecific antibody comprising a first Fab fragment that specifically binds to PD1 and a second Fab fragment that specifically binds to LAG3, wherein in one of CL domains the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and wherein in one of the CH1 domains the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E). In a particular aspect, the bispecific antibody is one, wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 the amino acid at position 123 (EU numbering) has been replaced by arginine (R) and the amino acid at position 124 (EU numbering) has been substituted by lysine (K) and wherein in one of the CH1 domains the amino acids at position 147 (EU numbering) and at position 213 (EU numbering) have been substituted by glutamic acid (E).

In a further aspect, the bispecific antibody is a bivalent antibody comprising

- a) a first light chain and a first heavy chain of an antibody specifically binding to a first antigen, and
- b) a second light chain and a second heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH of the second light chain and the second heavy chain are replaced by each other.

The antibody under a) does not contain a modification as reported under b) and the heavy chain and the light chain under a) are isolated chains.

In the antibody under b) within the light chain the variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody, and within the heavy chain the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody.

5 In one aspect, (i) in the constant domain CL of the first light chain under a) the amino acid at position 124 (numbering according to Kabat) is substituted by a positively charged amino acid, and wherein in the constant domain CH1 of the first heavy chain under a) the amino acid at position 147 or the amino acid at position 213 (numbering according to Kabat EU index) is substituted by a negatively charged amino acid, or (ii) in the constant domain CL of the second
10 light chain under b) the amino acid at position 124 (numbering according to Kabat) is substituted by a positively charged amino acid, and wherein in the constant domain CH1 of the second heavy chain under b) the amino acid at position 147 or the amino acid at position 213 (numbering according to Kabat EU index) is substituted by a negatively charged amino acid.

In another aspect, (i) in the constant domain CL of the first light chain under a) the amino
15 acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) (in one preferred embodiment independently by lysine (K) or arginine (R)), and wherein in the constant domain CH1 of the first heavy chain under a) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index), or (ii) in the
20 constant domain CL of the second light chain under b) the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) (in one preferred embodiment independently by lysine (K) or arginine (R)), and wherein in the constant domain CH1 of the second heavy chain under b) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid
25 (D) (numbering according to Kabat EU index).

In one aspect, in the constant domain CL of the second heavy chain the amino acids at position 124 and 123 are substituted by K (numbering according to Kabat EU index).

In one aspect, in the constant domain CL of the second heavy chain the amino acid at position 123 is substituted by R and the amino acid as position 124 is substituted by K
30 (numbering according to Kabat EU index).

In one aspect, in the constant domain CH1 of the second light chain the amino acids at position 147 and 213 are substituted by E (numbering according to EU index of Kabat).

In one aspect, in the constant domain CL of the first light chain the amino acids at position 124 and 123 are substituted by K, and in the constant domain CH1 of the first heavy chain the

amino acids at position 147 and 213 are substituted by E (numbering according to Kabat EU index).

5 In one aspect, in the constant domain CL of the first light chain the amino acid at position 123 is substituted by R and the amino acid at position 124 is substituted by K, and in the constant domain CH1 of the first heavy chain the amino acids at position 147 and 213 are both substituted by E (numbering according to Kabat EU index).

10 In one aspect, in the constant domain CL of the second heavy chain the amino acids at position 124 and 123 are substituted by K, and wherein in the constant domain CH1 of the second light chain the amino acids at position 147 and 213 are substituted by E, and in the variable domain VL of the first light chain the amino acid at position 38 is substituted by K, in the variable domain VH of the first heavy chain the amino acid at position 39 is substituted by E, in the variable domain VL of the second heavy chain the amino acid at position 38 is substituted by K, and in the variable domain VH of the second light chain the amino acid at position 39 is substituted by E (numbering according to Kabat EU index).

15 In one aspect, the bispecific antibody is a bivalent antibody comprising
a) a first light chain and a first heavy chain of an antibody specifically binding to a first antigen, and
b) a second light chain and a second heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH of the second light chain and the
20 second heavy chain are replaced by each other, and wherein the constant domains CL and CH1 of the second light chain and the second heavy chain are replaced by each other.

The antibody under a) does not contain a modification as reported under b) and the heavy chain and the light chain und a) are isolated chains. In the antibody under b) within the light chain the variable light chain domain VL is replaced by the variable heavy chain domain VH of
25 said antibody, and the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody; and within the heavy chain the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody, and the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody.

30 In one aspect, the bispecific antibody is a bivalent antibody comprising
a) a first light chain and a first heavy chain of an antibody specifically binding to a first antigen, and
b) a second light chain and a second heavy chain of an antibody specifically binding to a second antigen, wherein the constant domains CL and CH1 of the second light chain and the second heavy chain are replaced by each other.

The antibody under a) does not contain a modification as reported under b) and the heavy chain and the light chain under a) are isolated chains. In the antibody under b) within the light chain the constant light chain domain CL is replaced by the constant heavy chain domain CH1 of said antibody; and within the heavy chain the constant heavy chain domain CH1 is replaced by the constant light chain domain CL of said antibody.

In one aspect, the bispecific antibody is a bispecific antibody comprising

a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains, and

b) one, two, three or four single chain Fab fragments specifically binding to a second antigen,

wherein said single chain Fab fragments under b) are fused to said full length antibody under a) via a peptide linker at the C- or N- terminus of the heavy or light chain of said full length antibody.

In one aspect, one or two identical single chain Fab fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C terminus of the heavy or light chains of said full length antibody.

In one aspect, one or two identical single chain Fab (scFab) fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C terminus of the heavy chains of said full length antibody.

In one aspect, one or two identical single chain Fab (scFab) fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C terminus of the light chains of said full length antibody.

In one aspect, two identical single chain Fab (scFab) fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C-terminus of each heavy or light chain of said full length antibody.

In one aspect, two identical single chain Fab (scFab) fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C-terminus of each heavy chain of said full length antibody.

In one aspect, two identical single chain Fab (scFab) fragments binding to a second antigen are fused to the full length antibody via a peptide linker at the C-terminus of each light chain of said full length antibody.

In one aspect, the bispecific antibody is a trivalent antibody comprising

a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains,

b) a first polypeptide consisting of

ba) an antibody heavy chain variable domain (VH), or

5 bb) an antibody heavy chain variable domain (VH) and an antibody constant domain 1 (CH1),

wherein said first polypeptide is fused with the N-terminus of its VH domain via a peptidic linker to the C-terminus of one of the two heavy chains of said full length antibody,

c) a second polypeptide consisting of

10 ca) an antibody light chain variable domain (VL), or

cb) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL),

wherein said second polypeptide is fused with the N-terminus of the VL domain via a peptide linker to the C-terminus of the other of the two heavy chains of said full length antibody,

15 and

wherein the antibody heavy chain variable domain (VH) of the first polypeptide and the antibody light chain variable domain (VL) of the second polypeptide together form an antigen binding domain specifically binding to a second antigen.

20 In one aspect, the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) are linked and stabilized via an interchain disulfide bridge by introduction of a disulfide bond between the following positions:

(i) heavy chain variable domain position 44 to light chain variable domain position 100, or

(ii) heavy chain variable domain position 105 to light chain variable domain position 43, or

25 (iii) heavy chain variable domain position 101 to light chain variable domain position 100 (numbering always according to Kabat EU index).

30 Techniques to introduce unnatural disulfide bridges for stabilization are described e.g. in WO 94/029350, Rajagopal, V., et al., Prot. Eng. (1997) 1453-1459; Kobayashi, H., et al., Nucl. Med. Biol. 25 (1998) 387-393; and Schmidt, M., et al., Oncogene 18 (1999) 1711-1721. In one embodiment the optional disulfide bond between the variable domains of the polypeptides under b) and c) is between heavy chain variable domain position 44 and light chain variable domain position 100. In one embodiment the optional disulfide bond between the variable domains of the polypeptides under b) and c) is between heavy chain variable domain position 105 and light chain variable domain position 43 (numbering always according to Kabat). In one embodiment a trivalent, bispecific antibody without said optional disulfide stabilization between the variable domains VH and VL of the single chain Fab fragments is preferred.

35

In one aspect, the bispecific antibody is a trispecific or tetraspecific antibody, comprising
a) a first light chain and a first heavy chain of a full length antibody which specifically
binds to a first antigen, and

5 b) a second (modified) light chain and a second (modified) heavy chain of a full length
antibody which specifically binds to a second antigen, wherein the variable domains VL and VH
are replaced by each other, and/or wherein the constant domains CL and CH1 are replaced by
each other, and

10 c) wherein one to four antigen binding domains which specifically bind to one or two
further antigens (i.e. to a third and/or fourth antigen) are fused via a peptide linker to the C- or N-
terminus of the light chains or heavy chains of a) and/or b).

The antibody under a) does not contain a modification as reported under b) and the heavy
chain and the light chain und a) are isolated chains.

In one aspect, the trispecific or tetraspecific antibody comprises under c) one or two
antigen binding domains which specifically bind to one or two further antigens.

15 In one aspect, the antigen binding domains are selected from the group of a scFv fragment
and a scFab fragment.

In one aspect, the antigen binding domains are scFv fragments.

In one aspect, the antigen binding domains are scFab fragments.

20 In one aspect, the antigen binding domains are fused to the C-terminus of the heavy chains
of a) and/or b).

In one aspect, the trispecific or tetraspecific antibody comprises under c) one or two
antigen binding domains which specifically bind to one further antigen.

25 In one aspect, the trispecific or tetraspecific antibody comprises under c) two identical
antigen binding domains which specifically bind to a third antigen. In one preferred embodiment
such two identical antigen binding domains are fused both via the same peptidic linker to the C-
terminus of the heavy chains of a) and b). In one preferred embodiment the two identical antigen
binding domains are either a scFv fragment or a scFab fragment.

30 In one aspect, the trispecific or tetraspecific antibody comprises under c) two antigen
binding domains which specifically bind to a third and a fourth antigen. In one embodiment said
two antigen binding domains are fused both via the same peptide connector to the C-terminus of
the heavy chains of a) and b). In one preferred embodiment said two antigen binding domains are
either a scFv fragment or a scFab fragment.

In one aspect, the bispecific antibody is a bispecific, tetravalent antibody comprising
a) two light chains and two heavy chains of an antibody, which specifically bind to a first antigen (and comprise two Fab fragments),

b) two additional Fab fragments of an antibody, which specifically bind to a second
5 antigen, wherein said additional Fab fragments are fused both via a peptidic linker either to the C- or N-termini of the heavy chains of a), and

wherein in the Fab fragments the following modifications were performed

(i) in both Fab fragments of a), or in both Fab fragments of b), the variable domains VL and VH are replaced by each other, and/or the constant domains CL and CH1 are replaced by
10 each other, or

(ii) in both Fab fragments of a) the variable domains VL and VH are replaced by each other, and the constant domains CL and CH1 are replaced by each other, and in both Fab fragments of b) the variable domains VL and VH are replaced by each other, or the constant domains CL and CH1 are replaced by each other, or

(iii) in both Fab fragments of a) the variable domains VL and VH are replaced by each other, or the constant domains CL and CH1 are replaced by each other, and in both Fab fragments of b) the variable domains VL and VH are replaced by each other, and the constant domains CL and CH1 are replaced by each other, or

(iv) in both Fab fragments of a) the variable domains VL and VH are replaced by each other, and in both Fab fragments of b) the constant domains CL and CH1 are replaced by each other, or

(v) in both Fab fragments of a) the constant domains CL and CH1 are replaced by each other, and in both Fab fragments of b) the variable domains VL and VH are replaced by each other.

25 In one aspect, said additional Fab fragments are fused both via a peptidic linker either to the C-termini of the heavy chains of a), or to the N-termini of the heavy chains of a).

In one aspect, said additional Fab fragments are fused both via a peptidic linker either to the C-termini of the heavy chains of a).

30 In one aspect, said additional Fab fragments are fused both via a peptide linker to the N-termini of the heavy chains of a).

In one aspect, in the Fab fragments the following modifications are performed: in both Fab fragments of a), or in both Fab fragments of b), the variable domains VL and VH are replaced by each other, and/or the constant domains CL and CH1 are replaced by each other.

In one aspect, the bispecific antibody is a tetravalent antibody comprising:

a) a (modified) heavy chain of a first antibody, which specifically binds to a first antigen and comprises a first VH-CH1 domain pair, wherein to the C terminus of said heavy chain the N-terminus of a second VH-CH1 domain pair of said first antibody is fused via a peptide linker,

b) two light chains of said first antibody of a),

5 c) a (modified) heavy chain of a second antibody, which specifically binds to a second antigen and comprises a first VH-CL domain pair, wherein to the C-terminus of said heavy chain the N-terminus of a second VH-CL domain pair of said second antibody is fused via a peptide linker, and

10 d) two (modified) light chains of said second antibody of c), each comprising a CL-CH1 domain pair.

In one aspect, the bispecific antibody comprises

a) the heavy chain and the light chain of a first full length antibody that specifically binds to a first antigen, and

15 b) the heavy chain and the light chain of a second full length antibody that specifically binds to a second antigen, wherein the N-terminus of the heavy chain is connected to the C-terminus of the light chain via a peptide linker.

The antibody under a) does not contain a modification as reported under b) and the heavy chain and the light chain are isolated chains.

In one aspect, the bispecific antibody comprises

20 a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains, and

b) an Fv fragment specifically binding to a second antigen comprising a VH2 domain and a VL2 domain, wherein both domains are connected to each other via a disulfide bridge,

25 wherein only either the VH2 domain or the VL2 domain is fused via a peptide linker to the heavy or light chain of the full length antibody specifically binding to a first antigen.

In the bispecific antibody the heavy chains and the light chains under a) are isolated chains.

In one aspect, the other of the VH2 domain or the VL2 domain is not fused via a peptide linker to the heavy or light chain of the full length antibody specifically binding to a first antigen.

30 In all aspects as reported herein the first light chain comprises a VL domain and a CL domain and the first heavy chain comprises a VH domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain.

In one aspect, the bispecific antibody is a trivalent antibody comprising

a) two Fab fragments that specifically binds to a first antigen,

b) one CrossFab fragment that specifically binds to a second antigen in which the CH1 and the CL domain are exchanged for each other,

c) one Fc-region comprising a first Fc-region heavy chain and a second Fc region heavy chain,

5 wherein the C-terminus of CH1 domains of the two Fab fragments are connected to the N-terminus of the heavy chain Fc-region polypeptides, and wherein the C-terminus of the CL domain of the CrossFab fragment is connected to the N-terminus of the VH domain of one of the Fab fragments.

In one aspect, the bispecific antibody is a trivalent antibody comprising

10 a) two Fab fragments that specifically binds to a first antigen,

b) one CrossFab fragment that specifically binds to a second antigen in which the CH1 and the CL domain are exchanged for each other,

c) one Fc-region comprising a first Fc-region heavy chain and a second Fc region heavy chain,

15 wherein the C-terminus of CH1 domain of the first Fab fragment is connected to the N-terminus of one of the heavy chain Fc-region polypeptides and the C-terminus of the CL-domain of the CrossFab fragment is connected to the N-terminus of the other heavy chain Fc-region polypeptide, and wherein the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or to the N-terminus of
20 the VH domain of the CrossFab fragment.

In one aspect, the bispecific antibody comprises

a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains, and

b) a Fab fragment specifically binding to a second antigen comprising a VH2 domain and a
25 VL2 domain comprising a heavy chain fragment and a light chain fragment, wherein within the light chain fragment the variable light chain domain VL2 is replaced by the variable heavy chain domain VH2 of said antibody, and within the heavy chain fragment the variable heavy chain domain VH2 is replaced by the variable light chain domain VL2 of said antibody

30 wherein the heavy chain Fab fragment is inserted between the CH1 domain of one of the heavy chains of the full length antibody and the respective Fc-region of the full length antibody, and the N-terminus of the light chain Fab fragment is conjugated to the C-terminus of the light chain of the full length antibody that is paired with the heavy chain of the full length antibody into which the heavy chain Fab fragment has been inserted.

In one aspect, the bispecific antibody comprises

35 a) a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains, and

b) a Fab fragment specifically binding to a second antigen comprising a VH2 domain and a VL2 domain comprising a heavy chain fragment and a light chain fragment, wherein within the light chain fragment the variable light chain domain VL2 is replaced by the variable heavy chain domain VH2 of said antibody, and within the heavy chain fragment the variable heavy chain domain VH2 is replaced by the variable light chain domain VL2 of said antibody and wherein the C-terminus of the heavy chain fragment of the Fab fragment is conjugated to the N-terminus of one of the heavy chains of the full length antibody and the C-terminus of the light chain fragment of the Fab fragment is conjugated to the N-terminus of the light chain of the full length antibody that pairs with the heavy chain of the full length antibody to which the heavy chain fragment of the Fab fragment is conjugated.

Polynucleotides

The invention further provides isolated polynucleotides encoding a bispecific antibody as described herein or a fragment thereof.

The term “nucleic acid molecule” or “polynucleotide” includes any compound and/or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5' to 3'. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the invention *in vitro* and/or *in vivo*, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors, can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody *in vivo* (see e.g., Stadler et al, Nature Medicine 2017, published online 12 June 2017, doi:10.1038/nm.4356 or EP 2 101 823 B1).

An “isolated” polynucleotide refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated polynucleotide includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

The isolated polynucleotides encoding bispecific antibodies of the invention may be expressed as a single polynucleotide that encodes the entire antigen binding molecule or as multiple (e.g., two or more) polynucleotides that are co-expressed. Polypeptides encoded by polynucleotides that are co-expressed may associate through, e.g., disulfide bonds or other means to form a functional antigen binding molecule. For example, the light chain portion of an immunoglobulin may be encoded by a separate polynucleotide from the heavy chain portion of the immunoglobulin. When co-expressed, the heavy chain polypeptides will associate with the light chain polypeptides to form the immunoglobulin.

In some aspects, the isolated polynucleotide encodes a polypeptide comprised in the bispecific antibody according to the invention as described herein.

In one aspect, the present invention is directed to isolated polynucleotides encoding a bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein said first antigen binding domain specifically binding to PD1 comprises a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.

B. Recombinant Methods

Antibodies may be produced using recombinant methods and compositions, e.g., as described in US 4,816,567. For these methods one or more isolated nucleic acid(s) encoding an antibody are provided.

In case of a native antibody or native antibody fragment two nucleic acids are required, one for the light chain or a fragment thereof and one for the heavy chain or a fragment thereof. Such nucleic acid(s) encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chain(s) of the antibody). These nucleic acids can be on the same expression vector or on different expression

vectors. In case of certain bispecific antibodies with heterodimeric heavy chains four nucleic acids are required, one for the first light chain, one for the first heavy chain comprising the first heteromonomeric Fc-region polypeptide, one for the second light chain, and one for the second heavy chain comprising the second heteromonomeric Fc-region polypeptide. The four nucleic acids can be comprised in one or more nucleic acid molecules or expression vectors. For example, such nucleic acid(s) encode an amino acid sequence comprising the first VL and/or an amino acid sequence comprising the first VH including the first heteromonomeric Fc-region and/or an amino acid sequence comprising the second VL and/or an amino acid sequence comprising the second VH including the second heteromonomeric Fc-region of the antibody (e.g., the first and/or second light and/or the first and/or second heavy chains of the antibody). These nucleic acids can be on the same expression vector or on different expression vectors, normally these nucleic acids are located on two or three expression vectors, i.e. one vector can comprise more than one of these nucleic acids. Examples of these bispecific antibodies are CrossMabs and T-cell bispecifics (see, e.g. Schaefer, W. et al, PNAS, 108 (2011) 11187-11191). For example, one of the heteromonomeric heavy chain comprises the so-called “knob mutations” (T366W and optionally one of S354C or Y349C) and the other comprises the so-called “hole mutations” (T366S, L368A and Y407V and optionally Y349C or S354C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

In one aspect, isolated nucleic acid encoding a bispecific antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antigen binding domains that specifically bind to PD1 and LAG3, respectively (e.g., in the light and/or heavy chains of the antibody). In a further aspect, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further aspect, a host cell comprising such nucleic acid is provided. In one such aspect, a host cell comprises (e.g., has been transformed with): (1) a first vector comprising a first pair of nucleic acids that encode amino acid sequences one of them comprising the first VL and the other comprising the first VH of the antibody and a second vector comprising a second pair of nucleic acids that encode amino acid sequences one of them comprising the second VL and the other comprising the second VH of the antibody, or (2) a first vector comprising a first nucleic acid that encode an amino acid sequence comprising one of the variable domains (preferably a light chain variable domain), a second vector comprising a pair of nucleic acids that encode amino acid sequences one of them comprising a light chain variable domain and the other comprising the first heavy chain variable domain, and a third vector comprising a pair of nucleic acids that encode amino acid sequences one of them comprising the respective other light chain variable domain as in the second vector and the other comprising the second heavy chain variable domain, or (3) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the first VL of the antibody, a second vector comprising a nucleic acid that

encodes an amino acid sequence comprising the first VH of the antibody, a third vector comprising a nucleic acid that encodes an amino acid sequence comprising the second VL of the antibody, and a fourth vector comprising a nucleic acid that encodes an amino acid sequence comprising the second VH of the antibody. In one aspect, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one aspect, a method of making a bispecific antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of the bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, nucleic acid encoding the bispecific antibodies, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., US 5,648,237, US 5,789,199, and US 5,840,523. (See also Charlton, K.A., In: *Methods in Molecular Biology*, Vol. 248, Lo, B.K.C. (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, T.U., *Nat. Biotech.* 22 (2004) 1409-1414; and Li, H. et al., *Nat. Biotech.* 24 (2006) 210-215.

Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham, F.L. et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, J.P., Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, J.P. et al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, A.M., Methods in Molecular Biology, Vol. 248, Lo, B.K.C. (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

C. Assays

The bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

1. Affinity assays

The affinity of the bispecific antigen binding molecules, antibodies and antibody fragments provided herein for the corresponding antigens can be determined in accordance with the methods set forth in the Examples by surface plasmon resonance (SPR), using standard instrumentation such as a Biacore® instrument (GE Healthcare), and receptors or target proteins such as may be obtained by recombinant expression. A specific illustrative and exemplary embodiment for measuring binding affinity is described in Examples 2, 8 or 11. According to one aspect, K_D is measured by surface plasmon resonance using a BIACORE® T100 machine (GE Healthcare) at 25 °C.

2. Binding assays and other assays

In one aspect, the bispecific antibodies of the invention are tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc. Binding of the bispecific antibodies provided herein to the corresponding recombinant antigen or to antigen-expressing cells may be evaluated by ELISA as described in Examples 8 or 11.

In a further aspect, fresh peripheral blood mononuclear cells (PBMCs) are used in binding assays to show binding to different peripheral blood mononuclear cells (PBMC) such as monocytes, NK cells and T cells.

In another aspect, a cellular dimerization assay was used to demonstrate the dimerization or at least binding/interaction of two different receptors PD1 and LAG3, which are cytosolically fused with two fragments of an enzyme, upon ligation or cross-linking with a bispecific antibody against both targets. Hereby only one receptor alone shows no enzymatic activity. For this specific interaction, the cytosolic C-terminal ends of both receptors were individually fused to heterologous subunits of a reporter enzyme. A single enzyme subunit alone showed no reporter activity. However, simultaneous binding to both receptors was expected to lead to local cytosolic accumulation of both receptors, complementation of the two heterologous enzyme subunits, and finally to result in the formation of a specific and functional enzyme that hydrolyzes a substrate thereby generating a chemiluminescent signal (Example 11).

3. Activity assays

In one aspect, assays are provided for identifying a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 having biological activity. Biological activity may include, e.g., the ability to enhance the activation and/or proliferation of different immune cells, especially T-cells, secretion of immune-modulating cytokines such as IFN γ or TNF- α , blocking the PD1 pathway, blocking the LAG3 pathway, killing of tumor cells. Antibodies having such biological activity in vivo and/or in vitro are also provided.

In certain aspects, an antibody of the invention is tested for such biological activity. In one aspect, provided is an immune cell assay which measures the activation of lymphocytes from one individual (donor X) to lymphocytes from another individual (donor Y). The mixed lymphocyte reaction (MLR) can demonstrate the effect of blocking the PD1 pathway to lymphocyte effector cells. T cells in the assay were tested for activation and their IFN- γ secretion in the presence or absence of bispecific antibodies of the invention. The assay is described in more detail in Example 9.

D. Immunoconjugates

The invention also provides immunoconjugates comprising a bispecific antibody of the invention conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.

E. Methods and Compositions for Diagnostics and Detection

In certain aspects, any of the bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 provided herein may be useful for detecting the presence of both PD1 and LAG3 in a biological sample. The term “detecting” as used herein encompasses quantitative or qualitative detection. In certain embodiments, a biological sample comprises a cell or tissue, such as AML stem cancer cells.

In one aspect, a bispecific antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of both PD1 and LAG3 in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with a bispecific antibody as described herein under conditions permissive for binding of the bispecific antibody to both PD1 and LAG3, and detecting whether a complex is formed between the bispecific antibody and both antigens. Such method may be an in vitro or in vivo method. In one embodiment, the bispecific antibody is used to select subjects eligible for therapy with a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 antibody, e.g. where PD1 and LAG3 are biomarkers for selection of patients.

In certain aspects, labeled bispecific antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes ³²P, ¹⁴C, ¹²⁵I, ³H, and ¹³¹I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP,

lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels or stable free radicals.

F. Pharmaceutical Compositions, Formulations and Routes of Administration

In a further aspect, the invention provides pharmaceutical compositions comprising any of
5 the bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1
and a second antigen binding domain that specifically binds to LAG3 provided herein, e.g., for
use in any of the below therapeutic methods. In one embodiment, a pharmaceutical composition
comprises any of the bispecific antibodies provided herein and at least one pharmaceutically
acceptable excipient. In another embodiment, a pharmaceutical composition comprises any of
10 the bispecific antibodies provided herein and at least one additional therapeutic agent, e.g., as
described below.

Pharmaceutical compositions of the present invention comprise a therapeutically effective
amount of one or more bispecific antibodies dissolved or dispersed in a pharmaceutically
acceptable excipient. The phrases "pharmaceutical or pharmacologically acceptable" refers to
15 molecular entities and compositions that are generally non-toxic to recipients at the dosages and
concentrations employed, i.e. do not produce an adverse, allergic or other untoward reaction
when administered to an animal, such as, for example, a human, as appropriate. The preparation
of a pharmaceutical composition that contains at least one bispecific antibody and optionally an
additional active ingredient will be known to those of skill in the art in light of the present
20 disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing
Company, 1990, incorporated herein by reference. In particular, the compositions are lyophilized
formulations or aqueous solutions. As used herein, "pharmaceutically acceptable excipient"
includes any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants,
preservatives (e.g. antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and
25 combinations thereof, as would be known to one of ordinary skill in the art.

Parenteral compositions include those designed for administration by injection, e.g.
subcutaneous, intradermal, intralesional, intravenous, intraarterial intramuscular, intrathecal or
intrapertoneal injection. For injection, the bispecific antibodies of the invention may be
formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks'
30 solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory
agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the bispecific
antibodies may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-
free water, before use. Sterile injectable solutions are prepared by incorporating the fusion
proteins of the invention in the required amount in the appropriate solvent with various of the
35 other ingredients enumerated below, as required. Sterility may be readily accomplished, e.g., by

filtration through sterile filtration membranes. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsion, the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof. The liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose. The composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less than 0.5 ng/mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, dextran, or the like. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleates or triglycerides, or liposomes.

Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include

semipermeable matrices of solid hydrophobic polymers containing the polypeptide, which matrices are in the form of shaped articles, e.g. films, or microcapsules. In particular embodiments, prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.

Exemplary pharmaceutically acceptable excipients herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958. Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.

In addition to the compositions described previously, the bispecific antibodies may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the bispecific antibodies may be formulated with suitable polymeric or hydrophobic materials (for example as emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Pharmaceutical compositions comprising the bispecific antibodies of the invention may be manufactured by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the proteins into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

The bispecific antibodies may be formulated into a composition in a free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include the acid addition salts, e.g. those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine.

Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

The composition herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.

G. Therapeutic methods and compositions

Any of the bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 provided herein may be used in therapeutic methods.

For use in therapeutic methods, bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein before can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

In one aspect, bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein for use as a medicament are provided. In further aspects, bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein for use in treating a disease, in particular for use in the treatment of cancer, are provided. In certain embodiments, bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 for use in a method of treatment are provided. In one embodiment, the invention provides bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein for use in the treatment of a disease in an individual in need thereof. In certain embodiments, the invention provides bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 for use in a method of treating an individual

having a disease comprising administering to the individual a therapeutically effective amount of the bispecific antibody. In certain embodiments the disease to be treated is cancer. In another aspect, the disease to be treated is an infectious disease, in particular a chronic viral infection like HIV (human immunodeficiency virus), HBV (hepatitis B virus), HCV (hepatitis C), HSV1
5 (herpes simplex virus type 1), CMV (cytomegalovirus), LCMV (lymphocytic choriomeningitis virus) or EBV (Epstein-Barr virus). The subject, patient, or “individual” in need of treatment is typically a mammal, more specifically a human.

In a further aspect, the invention provides for the use of bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain
10 that specifically binds to LAG3 as defined herein before in the manufacture or preparation of a medicament for the treatment of a disease in an individual in need thereof. In one embodiment, the medicament is for use in a method of treating a disease comprising administering to an individual having the disease a therapeutically effective amount of the medicament.

In certain aspects, the disease to be treated is a proliferative disorder, particularly cancer.
15 Examples of cancers include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophageal cancer, colon cancer, colorectal cancer, rectal cancer, gastric cancer, prostate cancer, blood cancer, skin cancer, squamous cell carcinoma, bone cancer, and kidney cancer. Other cell proliferation disorders that can be treated using bispecific antibodies comprising a first
20 antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 according to the invention include, but are not limited to neoplasms located in the abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen,
25 thoracic region, and urogenital system. Also included are pre-cancerous conditions or lesions and cancer metastases. In certain aspects, the cancer is chosen from the group consisting of renal cell cancer, skin cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, head and neck cancer. In further aspects, the cancer is chosen from carcinoma, lymphoma (e.g., Hodgkin’s and non-Hodgkin’s lymphoma), blastoma, sarcoma, and leukemia. In another aspect, the cancer is to
30 be treated is selected from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate
35 cancer, vulval cancer, thyroid cancer, hepatic carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.

In a further aspect, the disease to be treated is an infectious disease, in particular a chronic viral infection. The term "chronic viral infection" refers to a subject afflicted or infected with a chronic virus. Examples for chronic viral infections are human immunodeficiency virus (HIV), hepatitis B viral infection (HBV), hepatitis C viral infection (HCV), herpes simplex virus 1 (HSV1), cytomegalovirus (CMV), lymphocytic choriomeningitis virus (LCMV) or Epstein-Barr virus (EBV).

A skilled artisan readily recognizes that in many cases the bispecific molecule may not provide a cure but may only provide partial benefit. In some embodiments, a physiological change having some benefit is also considered therapeutically beneficial. Thus, in some embodiments, an amount of the bispecific antibody that provides a physiological change is considered an "effective amount" or a "therapeutically effective amount".

In a further aspect, the invention provides a method for treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 of the invention. In one embodiment a composition is administered to said individual, comprising a bispecific antibody of the invention in a pharmaceutically acceptable form. In certain embodiments the disease to be treated is a proliferative disorder. In a particular embodiment the disease is cancer. In certain embodiments the method further comprises administering to the individual a therapeutically effective amount of at least one additional therapeutic agent, e.g. an anti-cancer agent if the disease to be treated is cancer. In another aspect, the disease is a chronic viral infection. An "individual" according to any of the above embodiments may be a mammal, preferably a human.

For the prevention or treatment of disease, the appropriate dosage of a bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the route of administration, the body weight of the patient, the type of fusion protein, the severity and course of the disease, whether the bispecific antibody is administered for preventive or therapeutic purposes, previous or concurrent therapeutic interventions, the patient's clinical history and response to the fusion protein, and the discretion of the attending physician. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

The bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 µg/kg to 15 mg/kg (e.g. 0.1 mg/kg – 10 mg/kg) of the bispecific antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the bispecific antibody would be in the range from about 0.005 mg/kg to about 10 mg/kg. In other examples, a dose may also comprise from about 1 µg/kg body weight, about 5 µg/kg body weight, about 10 µg/kg body weight, about 50 µg/kg body weight, about 100 µg/kg body weight, about 200 µg/kg body weight, about 350 µg/kg body weight, about 500 µg/kg body weight, about 1 mg/kg body weight, about 5 mg/kg body weight, about 10 mg/kg body weight, about 50 mg/kg body weight, about 100 mg/kg body weight, about 200 mg/kg body weight, about 350 mg/kg body weight, about 500 mg/kg body weight, to about 1000 mg/kg body weight or more per administration, and any range derivable therein. In examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg body weight to about 100 mg/kg body weight, about 5 µg/kg body weight to about 500 mg/kg body weight etc., can be administered, based on the numbers described above. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 5.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the fusion protein). An initial higher loading dose, followed by one or more lower doses may be administered. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

The bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein will generally be used in an amount effective to achieve the intended purpose. For use to treat or prevent a disease condition, the bispecific antibodies of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays, such as cell culture assays. A dose can then be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

5 Dosage amount and interval may be adjusted individually to provide plasma levels of the bispecific antibody which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 50 mg/kg/day, typically from about 0.5 to 1 mg/kg/day. Therapeutically effective plasma levels may be achieved by administering multiple doses each day. Levels in plasma may be measured, for example, by HPLC.

10 In cases of local administration or selective uptake, the effective local concentration of the bispecific antibody may not be related to plasma concentration. One skilled in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

A therapeutically effective dose of the bispecific antibodies described herein will generally provide therapeutic benefit without causing substantial toxicity. Toxicity and therapeutic efficacy of a fusion protein can be determined by standard pharmaceutical procedures in cell culture or experimental animals. Cell culture assays and animal studies can be used to determine the LD₅₀ (the dose lethal to 50% of a population) and the ED₅₀ (the dose therapeutically effective in 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD₅₀/ED₅₀. Bispecific antibodies that exhibit large therapeutic indices are preferred. In one embodiment, the bispecific antibody according to the present invention exhibits a high therapeutic index. The data obtained from cell culture assays and animal studies can be used in formulating a range of dosages suitable for use in humans. The dosage lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon a variety of factors, e.g., the dosage form employed, the route of administration utilized, the condition of the subject, and the like. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, in: The Pharmacological Basis of Therapeutics, Ch. 1, p. 1, incorporated herein by reference in its entirety).

30 The attending physician for patients treated with bispecific antibodies of the invention would know how and when to terminate, interrupt, or adjust administration due to toxicity, organ dysfunction, and the like. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of the disorder of interest will vary with the severity of the condition to be treated, with the route of administration, and the like. The severity of the condition may, for example, be evaluated, in part, by standard prognostic

evaluation methods. Further, the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient.

Other agents and treatments

The bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein before may be administered in combination with one or more other agents in therapy. For instance, a bispecific antibody of the invention may be co-administered with at least one additional therapeutic agent. The term "therapeutic agent" encompasses any agent that can be administered for treating a symptom or disease in an individual in need of such treatment. Such additional therapeutic agent may comprise any active ingredients suitable for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. In certain embodiments, an additional therapeutic agent is another anti-cancer agent.

In one aspect of the invention, the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein or a pharmaceutical composition comprising said bispecific antibody is for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/ or other agents for use in cancer immunotherapy.

In a particular aspect of the invention, the bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein or a pharmaceutical composition comprising said bispecific antibody is for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with an T-cell activating anti-CD3 bispecific antibody, in particular an anti-CEA/anti-CD3 bispecific antibody. In one aspect, the anti-CEA/anti-CD3 bispecific antibody is a T-cell activating anti-CD3 bispecific antibody comprising a second antigen binding domain comprising (a) a heavy chain variable region (V_H CEA) comprising CDR-H1 sequence of SEQ ID NO:154, CDR-H2 sequence of SEQ ID NO:155, and CDR-H3 sequence of SEQ ID NO:156, and/or a light chain variable region (V_L CEA) comprising CDR-L1 sequence of SEQ ID NO:157, CDR-L2 sequence of SEQ ID NO:158, and CDR-L3 sequence of SEQ ID NO:159, or (b) a heavy chain variable region (V_H CEA) comprising CDR-H1 sequence of SEQ ID NO:162, CDR-H2 sequence of SEQ ID NO:163, and CDR-H3 sequence of SEQ ID NO:164, and/or a light chain variable region (V_L CEA) comprising CDR-L1 sequence of SEQ ID NO:165, CDR-L2 sequence of SEQ ID NO:166, and CDR-L3 sequence of SEQ ID NO:167. In one aspect, the the anti-CEA/anti-CD3 bispecific antibody is a T-cell activating anti-CD3

bispecific antibody comprising a heavy chain variable region (V_HCEA) comprising the amino acid sequence of SEQ ID NO:160 and/or a light chain variable region (V_LCEA) comprising the amino acid sequence of SEQ ID NO:161 or a second antigen binding domain comprising a heavy chain variable region (V_HCEA) comprising the amino acid sequence of SEQ ID NO:168 and/or a
5 light chain variable region (V_LCEA) comprising the amino acid sequence of SEQ ID NO:169.

In a further aspect, the anti-CEA/anti-CD3 bispecific antibody comprises an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and/or effector function. In particular, the anti-CEA/anti-CD3 bispecific antibody comprises an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and P329G.

10 In a particular aspect, the anti-CEA/anti-CD3 bispecific antibody comprises a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 146, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 147, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of
15 SEQ ID NO: 148, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 149. In a further particular embodiment, the bispecific antibody comprises a polypeptide sequence of SEQ ID NO: 146, a polypeptide sequence of SEQ ID NO: 147, a polypeptide sequence of SEQ ID NO: 148 and a polypeptide sequence of SEQ ID NO: 149 (CEA CD3 TCB).

In a further particular aspect, the anti-CEA/anti-CD3 bispecific antibody comprises a
20 polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:150, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:151, a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:152, and a polypeptide that is at least 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:153. In a further particular embodiment, the bispecific
25 antibody comprises a polypeptide sequence of SEQ ID NO:150, a polypeptide sequence of SEQ ID NO:151, a polypeptide sequence of SEQ ID NO:152 and a polypeptide sequence of SEQ ID NO:153 (CEACAM5 CD3 TCB).

In another aspect, a pharmaceutical composition comprising a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen
30 binding domain that specifically binds to LAG3 as described herein, and a T-cell activating anti-CD3 bispecific antibody, in particular an anti-CEA/anti-CD3 bispecific antibody is provided. In a particular aspect, the pharmaceutical composition is for use in the combined, sequential or simultaneous treatment of a disease, in particular for the treatment of cancer. More particularly, the composition is for use in the treatment of solid tumors.

35 In another aspect, the invention provides a method for treating or delaying progression of cancer in an individual comprising administering to the subject an effective amount of bispecific

antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as described herein, in combination with a T-cell activating anti-CD3 bispecific antibody, in particular an anti-CEA/anti-CD3 bispecific antibody or anti-FolR1/anti-CD3 bispecific antibody.

5 Such other agents are suitably present in combination in amounts that are effective for the purpose intended. The effective amount of such other agents depends on the amount of fusion protein used, the type of disorder or treatment, and other factors discussed above. The bispecific antibodies are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any
10 route that is empirically/clinically determined to be appropriate.

Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate compositions), and separate administration, in which case, administration of the bispecific antibody can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or
15 adjuvant.

H. Articles of Manufacture

In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with
20 the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is
25 pierceable by a hypodermic injection needle). At least one active agent in the composition is a bispecific antibody comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3 as defined herein before.

The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a
30 composition contained therein, wherein the composition comprises the bispecific antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.

Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Table C (Sequences):

SEQ ID NO:	Name	Sequence
1	heavy chain HVR-H1, PD1-0103	GFSSFSSY
2	heavy chain HVR-H2, PD1-0103	GGR
3	heavy chain HVR-H3, PD1-0103	TGRVYFALD
4	light chain HVR-L1, PD1-0103	SESVDTSNSF
5	light chain HVR-L2, PD1-0103	RSS
6	light chain HVR-L3, PD1-0103	NYDVPW
7	heavy chain variable domain VH, PD1-0103	EVILVESGGGLVKPGGSLKLSCAASGFSFSSYTM SWVRQTPEKRLDWVATISGGGRDIYYPDSVKGRF TISRDNKNTLYLEMSSLMS EDTALYYCVLLTGR VYFALDSWGQGTSTVTVSS
8	light chain variable domain VL, PD1-0103	KIVLTQSPASLPVSLGQRATISCRASESVDTSN SFIHWYQQRPQGQSPKLLIYRSSTLESGVPARFSG SGSRDFTLTIDPVEADAVATYYCQQNYDVPWTF GGGTKLEIK
9	humanized variant -heavy chain variable domain VH of PD1-0103_01 (PD1 0376)	EVQLLES GGGLVQPGGSLRLSCAASGFSFSSYTM SWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRF TISRDNKNTLYLQMNSLRAEDTAVYYCVLLTGR VYFALDSWGQGTSLTVTVSS
10	humanized variant -light chain variable domain VL of PD1-0103_01 (PD1 0376)	DIVMTQSPDSLAVSLGERATINCKASESVDTSN SFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSG SGSGTDFTLTISSLAEDVAVYYCQQNYDVPWTF GQGTKVEIK
11	humanized variant -light chain variable domain VL of PD1-0103_02	DVVMTQSPLSLPVTLGQPASISCRASESVDTSN SFIHWYQQRPQGQSPRLIYRSSTLESGVPDRFSG SGSGTDFTLKISRVEADVGVYYCQQNYDVPWTF GQGTKVEIK
12	humanized variant -light chain variable domain VL of PD1-0103_03	EIVLTQSPATLSLSPGERATLSCASESVDTSN SFIHWYQQKPGQSPRLIYRSSTLESGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQNYDVPWTF GQGTKVEIK
13	humanized variant -light chain variable domain VL of PD1-0103_04	EIVLTQSPATLSLSPGERATLSCASESVDTSN SFIHWYQQKPGQSPRLIYRSSTLESGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQNYDVPWTF GQGTKVEIK
14	heavy chain HVR-H1, aLAG3(0414)	DYTMN
15	heavy chain HVR-H2, aLAG3(0414)	VISWDGGGTY YTDSVKG
16	heavy chain HVR-H3,	GLTDTTLYGS DY

	aLAG3(0414)	
17	light chain HVR-L1, aLAG3(0414)	RASQSISSYL N
18	light chain HVR-L2, aLAG3(0414)	AASTLQS
19	light chain HVR-L3, aLAG3(0414)	QQTYSSPLT
20	heavy chain variable domain VH, aLAG3(0414)	EVQLLES GGG LVQPGGSLRL SCAASGFIFD DYTMNWVRQA PGKGLEWVAV ISWDGGGTY TDSVKGRFTI SRDDFKNTLY LQMNSLRAED TAVYYCAKGL TDTTLYGSDY WGQGTLVTVS S
21	light chain variable domain VL, aLAG3(0414)	DIQMTQSPSS LSASVGDRVIT ITCRASQSI SYLNWYQQKP GKAPKLLIYA ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSSPLTFGG GTKVEIK
22	heavy chain HVR-H1, aLAG3(0403)	DYTMH
23	heavy chain HVR-H2, aLAG3(0403)	LVSWDGGGTY YTNSVKG
24	heavy chain HVR-H3, aLAG3(0403)	AITDTSLYGY DY
25	light chain HVR-L1, aLAG3(0403)	RASQSISSYL N
26	light chain HVR-L2, aLAG3(0403)	AASSLQS
27	light chain HVR-L3, aLAG3(0403)	QQTYSTPLT
28	heavy chain variable domain VH, aLAG3(0403)	EVQLLES GGG LVQPGGSLRL SCAASGFTFD DYTMHWVRQA PGKGLEWVSL VSWDGGGTY TNSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAKAI TDTSLYGYDY WGQGILVTVS S
29	light chain variable domain VL, aLAG3(0403)	DIQMTQSPSS LSASVGDRVIT ITCRASQSI SYLNWYQQKP GNAPKLLIYA ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSTPLTFGG GTKVEIK
30	heavy chain HVR-H1, aLAG3(0411)	DYTMN
31	heavy chain HVR-H2, aLAG3(0411)	VISWDGGGATY YADSVKG
32	heavy chain HVR-H3, aLAG3(0411)	GLTDDTLYGS DY
33	light chain HVR-L1, aLAG3(0411)	RASQSIVSYL N
34	light chain HVR-L2, aLAG3(0411)	ASSSLQS
35	light chain HVR-L3, aLAG3(0411)	QQTYSTPLT
36	heavy chain variable domain VH, aLAG3(0411)	EVHLLS GGG LVQPGGSLRL SCAASGFIFD DYTMNWVRQA PGKGLEWVSV ISWDGGATY ADSVKGRFTI SRDDFKNTLY LQMNSLRAED TAVYYCAKGL TDDTLYGSDY WGQGTLVTVS S
37	light chain variable domain VL, aLAG3(0411)	DIQMTQSPSS LSASVGDRVIT ITCRASQSI SYLNWYQQKP GKAPKLLIYA SSSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSTPLTFGG GTKVEIK
38	heavy chain HVR-H1, aLAG3(0417)	DYAMS
39	heavy chain HVR-H2, aLAG3(0417)	GIDNSGYITY YTDSVKG
40	heavy chain HVR-H3, aLAG3(0417)	THSGLIVNDA FDI

	aLAG3(0417)	
41	light chain HVR-L1, aLAG3(0417)	RASQSISSYL N
42	light chain HVR-L2, aLAG3(0417)	AASSLQS
43	light chain HVR-L3, aLAG3(0417)	QQTYSTPLT
44	heavy chain variable domain VH, aLAG3(0417)	EVQLVESGGG LVQPGGSLRL ACAASGFTFS DYAMSWVRQA PGKGLEWVSG IDNSGYITYY TDSVKGRFTI SRDDVKNTLY LQMNSLRAED TAVYLCTKTH SGLIVNDAFD IWGQGTMTV SS
45	light chain variable domain VL, aLAG3(0417)	DIQMTQSPSS LSASVGDRVT ITCRASQSI SYLNWYQQKP GKAPKLLIYA ASSLSQGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ TYSTPLTFGG GTKVEIK
46	heavy chain HVR-H1, aLAG3(0416)	DYAMS
47	heavy chain HVR-H2, aLAG3(0416)	GIDNSGYITY YTDSVKG
48	heavy chain HVR-H3, aLAG3(0416)	THSGLIVNDA FDI
49	light chain HVR-L1, aLAG3(0416)	RASQSISSYL N
50	light chain HVR-L2, aLAG3(0416)	DASSLES
51	light chain HVR-L3, aLAG3(0416)	QQSYSTPLT
52	heavy chain variable domain VH, aLAG3(0416)	EVQLVESGGG LVQPGGSLRL ACAASGFTFS DYAMSWVRQA PGKGLEWVSG IDNSGYITYY TDSVKGRFTI SRDDVKNTLY LQMNSLRAED TAVYLCTKTH SGLIVNDAFD IWGQGTMTV SS
53	light chain variable domain VL, aLAG3(0416)	DIQLTQSPSS LSASVGDRVT ITCRASQSI SYLNWYQQKP GKAPKLLIYD ASSLESQGVPS RFSGSGSGTD ATLTISLQP EDFATYYCQQ SYSTPLTFGG GTKVEIK
54	heavy chain variable domain VH, BMS-986016 (WO2014/008218 and US2016/0326248)	QVQLQQWGAG LLKPSETLSL TCAVYGGSF DYYWNWIRQP PGKGLEWIGE INHRGSTNSN PSLKSRVTLT LDTSKNQFSL KLRSVTAADT AVYYCAFGYS DYEYNWFDPW GQGTLVTVSS
55	light chain variable domain VL BMS-986016 (WO2014/008218 and US2016/0326248)	EIVLTQSPAT LSLSPGERAT LSCRASQSI SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPLTFGQ GTNLEIK
56	heavy chain HVR-H1, MDX25F7 (25F7)	DYYWN
57	heavy chain HVR-H2, MDX25F7 (25F7)	EINHNGNTNSNPSLKS
58	heavy chain HVR-H3, MDX25F7 (25F7)	GYSDEYNWF
59	light chain HVR-L1, MDX25F7 (25F7)	RASQSISSYLA
60	light chain HVR-L2, MDX25F7 (25F7)	DASNRAT
61	light chain HVR-L3, MDX25F7 (25F7)	QQRSNWPLT

62	heavy chain variable domain VH, MDX25F7 (25F7) (US2011/0150892 and WO2014/008218)	QVQLQQWGAG LLKPSETLSL TCAVYGGSF DYYWNWIRQP PGKGLEWIGE INHNGNTNSN PSLKSRVTL SLDTSKNQFSL KLRSVTAADT AVYYCAFGYS DYEYNWFDPW GQGTLLVTVSS
63	light chain variable domain VL, MDX25F7 (25F7) (US2011/0150892 and WO2014/008218)	EIVLTQSPAT LSLSPGERAT LSCRASQSI SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISLEP EDFAVYYCQ RSNWPLTFGQ GTNLEIK
64	heavy chain variable domain VH, humanized BAP050 (LAG525) (US2015/0259420)	QIQLVQSGPE LKKPGETVKI SCKASGFTLT NYGMNWVRQT PGKGLKWMGW INTDTGEPTY ADDFKGRFAF SLETSASTAS LQINNKNAD TATYFCARNP PYYYGTNNAE AMDYWGQGT VTVSS
65	light chain variable domain VL, humanized BAP050 (LAG525) (US2015/0259420)	DIQMTQTSS LSASLGDRVT ISCSSSQDIS NYLMWYQQKP DGTVKVLIYY TSTLHLGVPS RFSGSGSGTD YSLTISNLEL EDIATYYCQ YYNLPWTFGQ GTKVEIK
66	heavy chain variable domain VH, MDX26H10 (26H10) (US 2011/0150892)	QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV IWYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAREW AVASWDYGMD VWGQGTITV SS
67	light chain variable domain VL, MDX26H10 (26H10) (US 2011/0150892)	EIVLTQSPGT LSLSPGERAT LSCRASQSV SSYLAWYQQK PGQAPRLLIY GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPFTFG PGTKVDIK
68	human kappa light chain constant region	RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLKADYE KHKVYACEVT HQGLSSPVT KSFNRGEC
69	human lambda light chain constant region	QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
70	human heavy chain constant region derived from IgG1	ASTKGPSVF LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTPEVTCVVDV HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVSVLT VLHQDWLNGK EYCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLT LKVGFPYPSDI AVEWESNGQP ENNYKTTTPV LKSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG
71	human heavy chain constant region derived from IgG1 with mutations L234A, L235A and P329G	ASTKGPSVF LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKHTCP PCPAPEAAGG PSVFLFPPKP KDTLMISRTPEVTCVVDV HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVSVLT VLHQDWLNGK EYCKVSNKA LGAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLT LKVGFPYPSDI AVEWESNGQP

		ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFCSCSV MHEALHNHYT QKSLSLSPG
72	human heavy chain constant region derived from IgG4	ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDPKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSEQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLDSD DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLG
73	exemplary human LAG3 sequence (without signal sequence)	VPVWVAQEGA PAQLPCSPTI PLQDLSLLRR AGVTWQHQPDP SGPPAAAPGH PLAPGPHPAA PSSWGPRPRR YTVLSVGP GG LRSGRPLQ RVQLDERGRQ RGDFSLWLRP ARRADAGEYR AAVHLRDRA L SCRLRLRLGQ ASMTASPPGS LRASDWILN CSFSRPDRPA SVHWFRNRGQ GRVPVRESPH HHLAESFLFL PQVSPMDSGP WGCILTYRDG FNVSIMYNLT VLGLEPPTPL TVYAGAGSRV GLPCRLPAGV GTRSFLTAKW TPPGGGPDLL VTGDNGDFTL RLEDVSQAQA GTYTCHILH EQQLNATVTL AIITVTPKSF GSPGSLGKLL CEVTPVSGQE RFVWSSLDTP SQRSESGPWL EAQEAQLLSQ PWQCQLYQGE RLLGAAYYFT ELSSPGAQRS GRAPGALPAG HLLFLILGV LSLLLLV TGA FGFHLWRRQW RPRRFSALEQ GIHPPQAQSK IEELEQEPEP EPEPEPEPEP EPEPEQL
74	human LAG3 Extracellular Domain (ECD)	VPVWVAQEGA PAQLPCSPTI PLQDLSLLRR AGVTWQHQPDP SGPPAAAPGH PLAPGPHPAA PSSWGPRPRR YTVLSVGP GG LRSGRPLQ RVQLDERGRQ RGDFSLWLRP ARRADAGEYR AAVHLRDRA L SCRLRLRLGQ ASMTASPPGS LRASDWILN CSFSRPDRPA SVHWFRNRGQ GRVPVRESPH HHLAESFLFL PQVSPMDSGP WGCILTYRDG FNVSIMYNLT VLGLEPPTPL TVYAGAGSRV GLPCRLPAGV GTRSFLTAKW TPPGGGPDLL VTGDNGDFTL RLEDVSQAQA GTYTCHILH EQQLNATVTL AIITVTPKSF GSPGSLGKLL CEVTPVSGQE RFVWSSLDTP SQRSESGPWL EAQEAQLLSQ PWQCQLYQGE RLLGAAYYFT ELSSPGAQRS GRAPGALPAG HL
75	KIEELE (part of LAG3 intracellular domain)	KIEELE
76	primer rbHC.up	aagcttgcca ccatggagac tgggctgcgc tggcttc
77	primer rbHCf.do	ccattggtga gggcgcccg g
78	primer BcPCR_FHLC_leader.fw	atggacatga ggggtccccgc
79	primer BcPCR_huCkappa.rev	gatttcaact gctcatcaga tggc
80	heavy chain HVR-H1, PD1-0098	<u>GYSITS</u>SDY
81	heavy chain HVR-H2, PD1-0098	<u>YSG</u>

82	heavy chain HVR-H3, PD1-0098	<u>HGSAPWYFD</u>
83	light chain HVR-L1, PD1-0098	<u>SONIVHSDGNTY</u>
84	light chain HVR-L2, PD1-0098	<u>KVS</u>
85	light chain HVR-L3, PD1-0098	<u>GSHFPL</u>
86	heavy chain variable domain VH, PD1-0098	DVQLQESGPGGLVKPSQSLSLTCTVT <u>GYSITSDYA</u> WNWIRQFPQDKLEWLGYITY <u>YSG</u> FTNYPNPSLKSRIS SISRDTSKNQFFLQLNSVATEDTATYYCARW <u>HGS</u> <u>APWYFD</u> YWGRGTTTLTVSS
87	light chain variable domain VL, PD1-0098	DVLMQTPLSLPVS LGDQASISCRS <u>SONIVHSDG</u> <u>NTY</u> LEWYLQKPGQSPNLLIY <u>KVS</u> RRFSGVPDRFS GSGSGTDFTLKISRVEAEDLGYYCFQ <u>GSHFPLT</u> FGAGTKLELK
88	heavy chain HVR-H1, PD1-0069	<u>GYTFTDY</u>
89	heavy chain HVR-H2, PD1-0069	<u>YSG</u>
90	heavy chain HVR-H3, PD1-0069	<u>GITTGFA</u>
91	light chain HVR-L1, PD1-0069	<u>SKGVSTSSYSF</u>
92	light chain HVR-L2, PD1-0069	<u>YAS</u>
93	light chain HVR-L3, PD1-0069	<u>SREFPW</u>
94	heavy chain variable domain VH, PD1-0069	QVQLQQSGPELVPRGVSVKISCKGS <u>GYTFTDY</u> AM HWVKQSHARTLEWIGVIST <u>YSG</u> DTNYNQKFKDKA TMTVDKSSSTAYLELARMTSEDSAIYYCARL <u>GIT</u> <u>TGFA</u> YWGQGLTVSA
95	light chain variable domain VL, PD1-0069	DIVLTQSPASLAVSLGQRATISCRAS <u>SKGVSTSSY</u> <u>SF</u> MHWYQQKPRQPPLIKIY <u>YAS</u> YLESGVPARFSG SGSGTDFTLNIHPVEEEDAATYYCHH <u>SREFPW</u> TF GGGKLEIK
96	heavy chain 1 of 1+1 PD1/LAG3 0799 based on PD1(0376)/ aLAG3(0416)	DIVMTQSPDSLAVSLGERATINCKASESVDTSDN SFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSG SGSGTDFLTITISLQAEDVAVYYCQQNYDVPWTF GQGTKVEIKSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKEPKKCDKTHTCPPCPAPEAAGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPR EPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPG K
97	heavy chain 2 of 1+1 PD1/LAG3 0799	EVQLVESGGGLVQPGGSLRLACAASGFTFSDYAM SWVRQAPGKLEWVSGIDNSGYTYTYTDSVKGRF TISRDDVKNTLYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDIWGQGMVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDEKVEPKCDKTHTCPPCPAPE AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKT ISKAKGQPREPQVCTLPSPRDELTKNQVSLSCAV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLVSKLTVDKSRWQQGNVFCSCVMHEALHNHYT

		QKSLSLSPGK
98	light chain 1 of 1+1 PD1/LAG3 0799	EVQLLES GGGLVQPGGSLRL SCAASGFSFSSYTM SWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRF TISRDN SKNTLYLQMN SLRAEDTAVYYCVLLTGR VYFALDSWGQGT LVTVSSASVA APSVFIFPPSDE QLKSGTASVVCLLN NFY PREAKVQWKVDNALQSG NSQESVTEQDSKDSTYSL SSTLTLSKADYE KHKV YACEVTHQGLSSPVT KSFNRGEC
99	light chain 2 of 1+1 PD1/LAG3 0799	DIQLTQSPSSLSASVGDRVTITCRASQSISSYLN WYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSG TDATLT ISSLPEDFATYYCQ QSYSTPLTFGGGT KVEIKRTVAAPSVFIFPPSDRKLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSL SSTLTLSKADYE KHKVYACEVTHQGLSSP VT KSFNRGEC
100	heavy chain 2 of 1+1 PD1/LAG3 0927 based on PD1(0376)/ aLAG3(0414)	EVQLLES GGGLVQPGGSLRL SCAASGFI FDDY TM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMN SLRAEDTAVYYCAKGLTD TTLYGSDYWGQGT LVTVSSASTKGPSVF PLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVN NHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI SKAKGQPREPQVCTLP PSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLVSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQ KSLSLSPGK
101	light chain 2 of 1+1 PD1/LAG3 0927	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLN WYQQKPGKAPKLLIYA ASTLQSGVPSRFSGSGSG TDFTLT ISSLPEDFATYYCQ QTYSSPLTFGGGT KVEIKRTVAAPSVFIFPPSDRKLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSL SSTLTLSKADYE KHKVYACEVTHQGLSSP VT KSFNRGEC
102	heavy chain 1 of 1+1 PD1/LAG3 0222 based on PD1(0069)/ aLAG3(MDX25F7)	DIVLTQSPASLAVSLGQRATISCRAS SGKVSTSSY SFM HWYQQKPRQP PKLLIKYAS YLESGVPARFSG SGSGTDFTLNIHPVEEEDAATYYCH HSREFPW TF GGG TKLEIKSSASTKGPSVF PLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVN NHKPSN TKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALGAPIEKTI SKAKGQPR EPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPG K
103	heavy chain 2 of 1+1 PD1/LAG3 0222	QVQLQQWGAGLLKPSETLSLTC AVYGGSFSDYYW NWIRQPPGKGLEWIGEINHN GNNTNSNPSL KSRVT LSLDTSKNQFSLK LRSVTAADTAVYYCAFGYSDY EYNWFD WPWGQGT LVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVEDYFPEPVTVSWNSGALTSGV

		HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVKDEKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVCTLPSPSRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LVSKLTVDKSRWQQGNVFSQSVMHEALHNHYTQK SLSLSPGK
104	light chain 1 of 1+1 PD1/LAG3 0222	QVQLQQSGPELVPRGVSVKISCKGS GYTF TDY AM HWVKQSHARTLEWIGVIST YSG DTNYNQKFKDKA TMTVDKSSSTAYLELARMTSEDSAIYYCARL GIT TGFA YWGGQGLTVTVSAASVAAPSVFIFPPSDEQL KSGTASVVCLLNNFYPPREAKVQWKVDNALQSGNS QESVTEQDSKDYSLSSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNREGC
105	light chain 2 of 1+1 PD1/LAG3 0222	EIVLTQSPATLSLSPGERATLSCRASQSISSYLA WYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGT NLEIKRTVAAPSVFIFPPSDRKLKSGTASVVCLL NNFYPPREAKVQWKVDNALQSGNSQESVTEQDSK STYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNREGC
106	heavy chain 1 of 1+1 PD1/LAG3 0224 based on PD1(0098)/ aLAG3(MDX25F7)	DVLMTQTPLSLPVSLGDQASISCRS SQNI VHSDG NTY LEWYLQKPGQSPNLLIY KVS RRFSGVPDRFS GSGSGTDFTLKISRVEAEDLGYYCFQ GSHF PLT FGAGTKLELKSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHPKS NTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVF LFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP REPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSQSVMHEALHNHYTQKSLSLSP GK
107	light chain 1 of 1+1 PD1/LAG3 0224	DVQLQESGPGLVKPSQSLSLTCTVT GY SITS SDYA WNWIRQFPQDKLEWLGYYIT YSG FTNYPNLSKSR SISRDTSKNQFFLQLNSVATEDTATYYCARW HGS APWY FDY WGRGTTTLTVSSASVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPPREAKVQWKVDNALQSG NSQESVTEQDSKDYSLSSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNREGC
108	aLAG3(0156) heavy chain (MDX25F7)	QVQLQQWGAGLLKPSETLSLTCVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNGNTNSNPSLKSRT LSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDY EYNWFDWPWGQGLTVTVSSGQPKAPSVFPLAPCCG DTPSSVTTLGCLVKGYLPEPVTVTVNSGTLTNGV RTFPSVRQSSGLYSLSSVSVTSSSQPVTCNVAH PATNTKVDKTVAPSTCCKPTCPPPELLGGPSVFI FPPKPKDTLMISRTPEVTCVVDVSDDEPVQFT WYINNEQVRTARPPLREQQFNSTIRVVSTLPIAH QDWLRGKEFKCKVHNKALPAPIEKTISKARGQPL EPKVYTMGPPREELSSRSVSLTCMINGFYPSDIS

		VEWEKNGKAEDNYKTTTAVLSDSGSYFLYNKLSV PTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPG K
109	aLAG3(0156) light chain (MDX25F7)	EIVLTQSPATLSLSPGERATLSCRASQSISSYLA WYQQKPGQAPRLLIYDASNRATGIPARFSGSGSG TDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGT NLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC
110	aLAG3(0414) heavy chain	EVQLLESQGGGLVQPGGSLRLSCAASGFI FDDYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD TTLYGSDYWQGTTLTVSSGQPKAPSVFPLAPCC GDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNG VRTFP SVRQSSGLYSLSSVSVTSSSQPVTCNVA HPATNTKVDKTVAPSTCSKPTCPPPELLGGPSVF IFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQF TWYINNEQVRTARPLREQQFNSTIRVVSTLPIA HQDWLRGKEFKCKVHNKALPAPI EKTISKARGQP LEPKVYTMGPPREELSSRSVSLTCMINGFYPSDI SVEWEKNGKAEDNYKTTTAVLSDSGSYFLYNKLS VPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSP GK
111	aLAG3(0414) light chain	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLN WYQQKPGKAPKLLIYAASLTQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQTYSPLTFGGGT KVEIKGTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC
112	aLAG3(0416) heavy chain	EVQLVESGGGLVQPGGSLRLACAASGFTFSDYAM SWVRQAPGKGLEWVSGIDNSGYTTYTDSVKGRF TISRDDVKNTLYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDI WGQGTMTVTVSSGQPKAPSVFPLAPC CGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTN GVRTFP SVRQSSGLYSLSSVSVTSSSQPVTCNV AHPATNTKVDKTVAPSTCSKPTCPPPELLGGPSV FIFPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQ FTWYINNEQVRTARPLREQQFNSTIRVVSTLPI AHQDWLRGKEFKCKVHNKALPAPI EKTISKARGQ PLEPKVYTMGPPREELSSRSVSLTCMINGFYPSD ISVEWEKNGKAEDNYKTTTAVLSDSGSYFLYNKL SVPTSEWQRGDVFTCSVMHEALHNHYTQKSISR PGK
113	aLAG3(0416) light chain	DIQLTQSPSSLSASVGDRVTITCRASQSISSYLN WYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSG TDA TLTISSLQPEDFATYYCQQSYSTPLTFGGGT KVEIKGTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYLSSTLTLSKADYEKHKVYACEVTHQGLSSP VTKSFNRGEC
114	heavy chain of 2+2 PD1/LAG3 8970	EVQLLESQGGGLVQPGGSLRLSCAASGFI FDDYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD

	based on PD1(0376)/ aLAG3(0414)	TTLYGSDYWGGTLTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPI EKT I SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQ KSLSLSPGGGSGGGGSGGGGSGGGGSEVQLLES GGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPG KGLEWVATISGGGRDIYYPDSVKGRFTISRDNK NTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSW GGTLTVTVSSASVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPRQAKVQWKVDNALQSGNSQESVTE QDSKDYSLSSLTLSKADYEEKHKVYACEVTHQ GLSSPVTKSFNRGEC
115	light chain 1 of 2+2 PD1/LAG3 8970	DIVMTQSPDSLAVSLGERATINCKASESVDTSDN SFIHWYQQKPGQSPKLLIYRSSTLESQVDFRSG SGSGTDFLTITISLQAEDVAVYYCQNYDVPWTF GQGTKVEIKSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC
116	heavy chain of 2+2 PD1/LAG3 8984 based on PD1(0376)/ aLAG3(0416)	EVQLVESGGGLVQPGGSLRLACAASGFTFSDYAM SWVRQAPGKGLEWVSGIDNSGYYTYTDSVKGRF TISRDDVKNLTLYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDIWGQGTMTVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPE AAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VSVLTVLHQDWLNGKEYKCKVSNKALGAPI EKT I SKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFCSSVMHEALHNHYT QKSLSLSPGGGSGGGGSGGGGSGGGGSEVQLLES GGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAP GKLEWVATISGGGRDIYYPDSVKGRFTISRDNK KNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDS WGQGTTLTVTVSSASVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPRQAKVQWKVDNALQSGNSQESVT EQDSKDYSLSSLTLSKADYEEKHKVYACEVTH QGLSSPVTKSFNRGEC
117	heavy chain of 2+2 PD1/LAG3 9010 based on PD1(0376)/ aLAG3(MDX25F7)	QVQLQQWAGALLKPSSETLSLTCAVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNGNTNSNPSLKSRT LSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDY EYNWFDWPWGQGTTLTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVEDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV

		SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFF LYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQK SLSLSPGGSGGGSGGGSGGGSGGGSEVQLLESGG GLVQPGGSLRLSCAASGFSFSSYTMWVRQAPGK GLEWVATISGGGRDIYYPDSVKGRFTISRDN SKN TLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWG QGT LVT VSSASVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC
118	heavy chain 1 of 2+1 PD1/LAG3 8310 based on aLAG3(0414)/PD1(0376)	EVQLLESGGGLVQPGGSLRLSCAASGFI FDDYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD TTLYGSDYWQGQTLVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS SKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSF FLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQ KSLSLSPGGSGGGSGGGSGGGSGGGSEVQLLESG GGLVQPGGSLRLSCAASGFSFSSYTMWVRQAPG KGLEWVATISGGGRDIYYPDSVKGRFTISRDN SK NTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSW GQGT LVT VSSASVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC
119	heavy chain 2 of 2+1 PD1/LAG3 8310	EVQLLESGGGLVQPGGSLRLSCAASGFI FDDYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD TTLYGSDYWQGQTLVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS SKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSF FLVSKLTVDKSRWQQGNVFSQSVMEALHNHYTQ KSLSLSPGK
120	heavy chain 1 of 2+1 PD1/LAG3 8311 based on aLAG3(0416)/PD1(0376)	EVQLVESGGGLVQPGGSLRLACAASGFTFSDYAM SWVRQAPGKGLEWVSGIDNSGYTYTYTDSVKGRF TISRDDVKNTLYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDIWGQGMVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPE AAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDS

		HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKT ISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYT QKSLSLSPGGSGGGSGGGSGGGSGGGSGGGSEVQLLES GGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAP GKGLEWVATISGGGRDIYYPDSVKGRFTISRDN KNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDS WGQGLTVTVSSASVAAPSVFIFPPSDEQLKSGTA SVVCLLNNFYPRKAKVQWKVDNALQSGNSQESVT EQDSKSTYSLSSLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC
121	heavy chain 2 of 2+1 PD1/LAG3 8311	EVQLVESGGGLVQPGGSLRLACAASGFTFSDYAM SWVRQAPGKGLEWVSGIDNSGYTYTDSVKGRF TISRDDVKNLTYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDIWQGTMTVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPE AAGPSVFLFPPKPKDTLMISRTPEVTCVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKT ISKAKGQPREPQVCTLPSPRDELTKNQVSLSCAV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLVSKLTVDKSRWQQGNVFSQSVMEALHNHYT QKSLSLSPGK
122	heavy chain 1 of 2+1 PD1/LAG3 1252 based on aLAG3(25F7)/PD1(0376)	QVQLQQWAGALLKPSETLSLTCAVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNNGTNSNPSLKSRT LSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDY EYNWFDWPWGQGLTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVEDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQK SLSLSPGGSGGGSGGGSGGGSGGGSGGGSEVQLLES GLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGK GLEWVATISGGGRDIYYPDSVKGRFTISRDN KNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWG QGLTVTVSSASVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPRKAKVQWKVDNALQSGNSQESVTEQ DSKSTYSLSSLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC
123	heavy chain 1 of 2+1 PD1/LAG3 8312 based on aLAG3(0414)/PD1(0376)	EVQLLES GGGLVQPGGSLRLSCAASGFI FDDYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD TTLYGSDYWGQGLTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA

		AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKT ISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVSCSVMHEALHNYHTQ KSLSLSPGGGGSGGGSGGGSGGGSGGGSDIVMTQ SPDSLAVSLGERATINCKASESVDTSDNSFIHWY QQKPGQSPKLLIYRSSTLESQVDPDRFSGSGSGTD FTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKV EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN FYFREAKVQWKVDNALQSGNSQESVTEQDSKDS YLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGECGGGGSGGGSGGGSGGGSGGGSGG GGGSEVQLLESGLLVQPGGSLRLSCLASGFSF SYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSV KGRFTISRDNKNTLYLQMNSLRAEDTAVYYCVL LTGRVYFALDSWGQGTLLTVVSSASTKGPSVFPLA PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQT YICNVNHKPSNTKVDKKVEPKSC
124	heavy chain 1 of 2+1 PD1/LAG3 8313 based on aLAG3(0416)/PD1(0376)	EVQLVESGGGLVQPGGSLRLACAAAGSFTFSDYAM SWVRQAPGKGLEWVSGIDNSGYTTYTDSVKGRF TISRDDVKNLTLYLQMNSLRAEDTAVYLCTKTHSG LIVNDAFDIWGQGTMTVTVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVEDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYI CNVNHKPSNTKVDKVEPKSCDKTHTCPPCPAPE AAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKT ISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVSCSVMHEALHNYHT QKSLSLSPGGGGSGGGSGGGSGGGSGGGSDIVMT QSPDSLAVSLGERATINCKASESVDTSDNSFIHW YQQKPGQSPKLLIYRSSTLESQVDPDRFSGSGSGT DFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTK VEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN NFYFREAKVQWKVDNALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV TKSFNRGECGGGGSGGGSGGGSGGGSGGGSGG GGGSEVQLLESGLLVQPGGSLRLSCLASGFSF SSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDS VKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCV LLTGRVYFALDSWGQGTLLTVVSSASTKGPSVFPL APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA LTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEPKSC
125	heavy chain 1 of 2+1 PD1/LAG3 1088 based on aLAG3(25F7)/PD1(0376)	QVQLQQWAGALLKPSSETLSLTCAVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNNGTNSNPSTLKSRT LSLDTSKNQFSLKLRVTAADTAVYYCAFGYSDY EYNWFDWPWGQGTLLTVVSSASTKGPSVFPLAPSSK STSGGTAALGCLVEDYFPEPVTVSWNSGALTS HTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICN

		VNHKPSNTKVDKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF LYSKLTVDKSRWQQGNVFSQVMHEALHNHYTQK SLSLSPGGGGSGGGSGGGSGGGSGGGSDIVMTQS PDSLAVSLGERATINCKASESVDTSDNSFIHWYQ QKPGQSPKLLIYRSSTLESQVDRFSGSGSTDF TLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKE IKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNF YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGECGGGGSGGGSGGGSGGGSGGGSGGGSGG GGSEVQLLESQGGGLVQPGGSLRLSCAASGFSFSS YTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVK GRFTISRDNKNTLYLQMNSLRAEDTAVYYCVLL TGRVYFALDSWGQGTLLTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSC
126	heavy chain 1 of 2+1 PD1/LAG3 0918 based on aLAG3(25F7)/PD1(0376)	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNGNTNSNPSLKSRVT LSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDY EYNWFDWPWGQGTLLTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVCTLPSPRDELTKNQVSLSCAVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF LVSKLTVDKSRWQQGNVFSQVMHEALHNHYTQK SLSLSPGGGGSGGGSGGGSGGGSGGGSEVQLLES GGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAP GKGLEWVATISGGGRDIYYPDSVKGRFTISRDN KNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDS WGQGTLLTVSS
127	heavy chain 2 of 2+1 PD1/LAG3 0918	QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYW NWIRQPPGKGLEWIGEINHNGNTNSNPSLKSRVT LSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDY EYNWFDWPWGQGTLLTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKVEPKSCDKTHTCPPCPAPEAA GGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSHE DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTIS KAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF LYSKLTVDKSRWQQGNVFSQVMHEALHNHYTQK SLSLSPGGGGSGGGSGGGSGGGSGGGSDIVMTQS PDSLAVSLGERATINCKASESVDTSDNSFIHWYQ

		QKPGQSPKLLIYRSSTLESQVDFSGSGSGTDF TLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVE IK
128	human PD1	UniProt accession no. Q15116 MQIPQAPWPV VWAVLQLGWR PGWFLDSPDR PWNPTTFSPA LLVVTEGDNA TFTCSFSNTS ESFVLNWYRM SPSNQTDKLA AFPEDRSQPG QDCRFRVTQL PNGRDFHMSV VRARRNSGT YLCGAISLAP KAQIKESLRA ELRVTERRAE VPTAHPSPSP RPAGQFQTLV VGVVGGLLGS LVLLVWVLAV ICSRAARGTI GARRTGQPLK EDPSAVPVFS VDYGELDFQW REKTPEPPVP CVPEQTEYAT IVFPSGMGTS SPARRGSADG PRSAQPLRPE DGHCSWPL
129	Peptide linker G4S	GGGGS
130	Peptide linker (G4S) ₂	GGGSGGGGS
131	Peptide linker (SG4) ₂	SGGGSGGGG
132	Peptide linker (G4S)2G4	GGGSGGGGSGGGG
133	Peptide linker	GSPGSSSSGS
134	Peptide linker (G ₄ S) ₃	GGGSGGGGSGGGGS
135	Peptide linker (G ₄ S) ₄	GGGSGGGGSGGGGSGGGGS
136	Peptide linker	GSGSGSGS
137	Peptide linker	GSGSGNGS
138	Peptide linker	GGSGSGSG
139	Peptide linker	GGSGSG
140	Peptide linker	GGSG
141	Peptide linker	GGSGNGSG
142	Peptide linker	GGNGSGSG
143	Peptide linker	GGNGSG
144	heavy chain 2 of 1+1 PD1/LAG3 0725 (1+1 trans) based on aLAG3(0414)	DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVSVLTVQLHQLDNLNGKEYKCK VSNKALGAPIIEKTISKAKGQPREPQVCTLPSPSRD ELTKNQVSLTSCAVKGFPYPSDIAVEWESNGQPENN YKTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGKGGGSGGGGSE VQLLESGLLVQPGGSLRLSCAASGFIIDDTYTMN WVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRFT ISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTDT TLYGSDYWGGTLTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVEDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKVEPKSC
145	heavy chain 2 of 2+1 PD1/LAG3 0750 (2+1 trans)	EVQLLESGLLVQPGGSLRLSCAASGFIIDDTYTM NWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRF TISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTD TTLYGSDYWGGTLTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG

	based on aLAG3(0414)	VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI SKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPVLDSDGSF FLVSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQ KSLSLSPGKGGGGSGGGGSEVQLLESGLLVQPG GSLRLSCAASGFI FDDYTMNWVRQAPGKGLEWVA VISWDGGGTYTDSVKGRFTISRDDFKNTLYLQM NSLRAEDTAVYYCAKGLD TTLYGSDYWGQTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVE DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDEKV EPKSC
146	Light chain „CEA _{2F1} ” (CEA TCB)	DIQMTQSPSSLSASVGDRTITCKASAAGVTYVA WYQQKPGKAPKLLIYSAS YRKR GVP SRFSGSGSG TDFLT TISSLPEDFATYYCHQYYTYPLFTFGQG TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVCL LNNFY PREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSTLTLSKADY EKKH VYACEVTHQGLSS PVT KSFNRGEC
147	Light Chain humanized CD3 _{CH2527} (Crossfab, VL-CH1) (CEA TCB)	QAVVTQEP SLTVSPGGTVTLTCGSSTGAVTTSNY ANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSL LGGKAALTLGAQPEDEAEYYCALWYSNLWVFGG GTKLTVLSSASTKGPSVFPLAPSSKSTSGGTAAL GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK VDKKVEPKSC
148	CEA _{CH1A1A 98/99} — humanized CD3 _{CH2527} (Crossfab VH-Ck)—Fc(knob) P329GLALA (CEA TCB)	QVQLVQSGAEVKKPGASVKV SCASGYTFTEFGM NWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRV TFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAY YYVEAMDYWGQGT TVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKV DKKVEPKSCDGGGGSGGGGSEVQ LLESGLLVQPGGSLRLSCAASGFTFSTYAMNWV RQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFT ISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFG NSYVSWFAYWGQGT LTVTVSSASVAAPSVFIFPPS DEQLKSGTASVVCLLN NFY PREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSTLTLSKADY EKH KVYACEVTHQGLSSPVT KSFNRGECDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN STYRVSVLTVLHQDWLNGKEYKCKVSNKALGAP IEKTI SKAKGQPREPQVYTLPPCRDELTKNQVSL WCLVKGFYPSDIAVEWESNGQPENNYKTTPVLD SDGSFFLYSKLTVDKSRWQQGNVFCSSVMHEALH NHYTQKSLSLSPGK
149	CEA _{CH1A1A 98/99} (VH-CH1)—Fc(hole) P329GLALA (CEA TCB)	QVQLVQSGAEVKKPGASVKV SCASGYTFTEFGM NWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRV TFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAY YYVEAMDYWGQGT TVTVSSASTKGPSVFPLAPSS

		KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDDKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI SKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPVLDSDGSF FLVSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQ KSLSLSPGK
150	CD3 VH-CL (CEACAM5 TCB)	EVQLLESQGGGLVQPGGSLRLSCAASGFTTFSTYAM NWVRQAPGKGLVSRIRSKYNNYATYYADSVKG RFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHG NFGNSYVSWFAYWGQGLTVTVSSASVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKSTYSLSTLTLSKADY EKHKVYACEVTHQGLSSPVTKSFNRGEC
151	humanized CEA VH-CH1(EE)-Fc (hole, P329G LALA) (CEACAM5 TCB)	QVQLVQSGAEVKKPGSSVKVSCKASGFNIDKTYM HWVRQAPGQGLEWMGRIDPANGNSKYVPKFQGRV TITADTSTSTAYMELSSLRSEDTAVYYCAPFGYY VSDYAMAYWGQGLTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDKTHTCPPCPAPEA AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTI SKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVK GFYPSDIAVEWESNGQPENNYKTTPVLDSDGSF FLVSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQ KSLSLSP
152	humanized CEA VH-CH1(EE)-CD3 VL-CH1-Fc (knob, P329G LALA) (CEACAM5 TCB)	QVQLVQSGAEVKKPGSSVKVSCKASGFNIDKTYM HWVRQAPGQGLEWMGRIDPANGNSKYVPKFQGRV TITADTSTSTAYMELSSLRSEDTAVYYCAPFGYY VSDYAMAYWGQGLTVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVEDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDEKVEPKSCDGGGSGGGGSQAV VTQEPSTLVSPGGTVTLTCGSSTGAVTTSNYANW VQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGG KAALTLSGAQPEDEAEYYCALWYSLWVFGGGTK LTVLSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK KVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK KDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALGAPIEKTI SKAKGQPREPQVY TLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWES NGQPENNYKTTPVLDSDGSFFLYSKLTVDKSRW QQGNVFCSSVMHEALHNHYTQKSLSLSP
153	humanized CEA VL-CL(RK) (CEACAM5 TCB)	EIVLTQSPATLSLSPGERATLSCRAGESVDIFGV GFLHWYQQKPGQAPRLLIYRASNRATGIPARFSG SGSGTDFTLTISSLEPEDFAVYYCQQTNEDPYTF GQGTKLEIKRTVAAPSVFIFPPSDRKLKSGTASV

		VCLLNIFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSTLTLSKADYEKHKVYACEVTHQG LSSPVTKSFNRGEC
154	CEA-HCDR1	EFGMN
155	CEA-HCDR2	WINTKTGEATYVEEFKG
156	CEA-HCDR3	WDFAYYVEAMDY
157	CEA-LCDR1	KASAAVGTYVA
158	CEA-LCDR2	SASYRKR
159	CEA-LCDR3	HQYYTYPLFT
160	CEA VH	QVQLVQSGAEVKKPGASVKVSCASGYTFTEFGM NWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRV TFTTDTSTSTAYMELRSLRSDDTAVYYCARWDF AYYVEAMDYWGQGTITVTVSS
161	CEA VL	DIQMTQSPSSLSASVGDRTITCKASAAVGTYVA WYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSG TDFLTITISLQPEDFATYYCHQYYTYPLFTFGQG TKLEIK
162	CEA-HCDR1 (CEACAM5)	DTYMH
163	CEA-HCDR2 (CEACAM5)	RIDPANGNSKYVPKFQG
164	CEA-HCDR3 (CEACAM5)	FGYYVSDYAMAY
165	CEA-LCDR1 (CEACAM5)	RAGESVDIFGVGFLH
166	CEA-LCDR2 (CEACAM5)	RASNRAT
167	CEA-LCDR3 (CEACAM5)	QQTNEDPYT
168	CEA VH (CEACAM5)	QVQLVQSGAEVKKPGSSVKVSCASGFNIKDTYM HWVRQAPGQGLEWMGRIDPANGNSKYVPKFQGRV TITADTSTSTAYMELSSLRSEDTAVYYCAPFGYY VSDYAMAYWGQGTITVTVSS
169	CEA VL (CEACAM5)	EIVLTQSPATLSLSPGERATLSCRAGESVDIFGV GFLHWYQQKPGQAPRLLIYRASNRATGIPARFSG SGSGTDFLTITISLQPEDFAVYYCQQTNEDPYTF GQGTKLEIK

The following numbered paragraphs (paras) describe aspects of the present invention:

1. A bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein

said first antigen binding domain specifically binding to PD1 comprises

a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1,
- (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
- (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:3; and

a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;

- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.

2. The bispecific antibody of para 1, wherein the bispecific antibody comprises a Fc domain that is an IgG, particularly an IgG1 Fc domain or an IgG4 Fc domain and wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, in particular towards Fc γ receptor.

3. The bispecific antibody of paras 1 or 2, wherein the second antigen binding domain that specifically binds to LAG3 comprises

(a) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:14,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:15, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:16; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:17,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:18, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:19; or

(b) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:22,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:23, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:24; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:25,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:26, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:27; or

(c) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:30,
 - (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:31, and
 - (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:32; and
- a VL domain comprising

- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:33,
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:34, and
- (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:35; or

(d) a VH domain comprising

- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38,
- (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39, and

- (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:40; and
a VL domain comprising
- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:41,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42, and
5 (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:43; or
- (e) a VH domain comprising
- (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:46,
(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:47, and
(iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:48; and
10 a VL domain comprising
- (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:49,
(ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:50, and
(iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:51.
4. The bispecific antibody according to any one of paras 1 to 3, wherein the first antigen-binding
15 domain specifically binding to PD1 comprises
- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 8, or
- (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 10, or
- 20 (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 11, or
- (d) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 12, or
- (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain
25 comprising the amino acid sequence of SEQ ID NO: 13.
5. The bispecific antibody according to any one of paras 1 to 4, wherein the second antigen-
binding domain specifically binding to LAG3 comprises
- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 21, or
- 30 (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 28 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 29, or
- (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 36 and a VL domain
comprising the amino acid sequence of SEQ ID NO: 37, or

- (d) a VH domain comprising the amino acid sequence of SEQ ID NO: 44 and a VL domain comprising the amino acid sequence of SEQ ID NO: 45, or
- (e) a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

5 6. The bispecific antibody according to any one of paras 1 to 4, wherein the second antigen-binding domain specifically binding to LAG3 comprises

- (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 54 and a VL domain comprising the amino acid sequence of SEQ ID NO: 55, or
- 10 (b) a VH domain comprising the amino acid sequence of SEQ ID NO: 62 and a VL domain comprising the amino acid sequence of SEQ ID NO: 63, or
- (c) a VH domain comprising the amino acid sequence of SEQ ID NO: 64 and a VL domain comprising the amino acid sequence of SEQ ID NO: 65, or
- (d) a VH domain comprising the amino acid sequence of SEQ ID NO: 66 and a VL domain comprising the amino acid sequence of SEQ ID NO: 67.

15 7. The bispecific antibody according any one of paras 1 to 5, wherein

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

20 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21 or a VH domain comprising the amino acid sequence of SEQ ID NO: 52 and a VL domain comprising the amino acid sequence of SEQ ID NO: 53.

8. The bispecific antibody according any one of paras 1 to 5, wherein

25 the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

30 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21.

9. The bispecific antibody according any one of paras 1 to 4 or 6, wherein

-117-

the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10,

5 and the second antigen binding domain specifically binding to LAG3 comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 56 and a VL domain comprising the amino acid sequence of SEQ ID NO: 57.

10. The bispecific antibody according to any one of paras 1 to 5, wherein the bispecific antibody is a humanized or chimeric antibody.

10 11. The bispecific antibody of any one of paras 1 to 10, wherein the bispecific antibody comprises an Fc domain of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).

12. The bispecific antibody of any one of paras 1 to 11, wherein the bispecific antibody comprises an Fc domain comprising a modification promoting the association of the first and second subunit of the Fc domain.

15 13. The bispecific antibody of any one of paras 1 to 12, wherein the first subunit of the Fc domain comprises knobs and the second subunit of the Fc domain comprises holes according to the knobs into holes method.

20 14. The bispecific antibody of any one of paras 1 to 13, wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

25 15. The bispecific antibody of any one of paras 1 to 14, wherein the bispecific antibody comprises an Fc domain, a first Fab fragment comprising the antigen binding domain that specifically binds to PD1 and a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3.

16. The bispecific antibody of any one of paras 1 to 15, wherein in one of the Fab fragments the the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.

17. The bispecific antibody of paras 15 or 16, wherein in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.
18. The bispecific antibody of any one of paras 1 to 17, wherein the bispecific antibody
5 comprises a Fab fragment wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).
- 10 19. The bispecific antibody of any one of paras 15 to 18, wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or
15 aspartic acid (D) (numbering according to Kabat EU index).
20. The bispecific antibody of any one of paras 1 to 19, comprising
- (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 98,
20 a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 97, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence with
25 at least 95% sequence identity to the sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to
30 the sequence of SEQ ID NO: 102, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 104, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105, or

- (d) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 106, a first light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 107,
a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
5 to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid
sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.
21. The bispecific antibody of any one of paras 1 to 19, wherein the bispecific antibody
comprises a third Fab fragment comprising an antigen binding domain that specifically binds
to LAG3.
- 10 22. The bispecific antibody of any one of paras 1 to 19 or 21, wherein the two Fab fragments
comprising each an antigen binding domain that specifically binds to LAG3 are identical.
23. The bispecific antibody of any one of paras 1 to 19 or 21 or 22, wherein the Fab fragment
comprising the antigen binding domain that specifically binds to PD1 is fused via a peptide
linker to the C-terminus of one of the heavy chains.
- 15 24. The bispecific antibody of any one of paras 1 to 19 or 21 to 23, comprising
- (a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to
the sequence of SEQ ID NO: 118, a first light chain comprising an amino acid sequence with
at least 95% sequence identity to the sequence of SEQ ID NO: 115,
a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
20 to the sequence of SEQ ID NO: 119, and a second light chain comprising an amino acid
sequence with at least 95% sequence identity to the sequence of SEQ ID NO:101, or
- (b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to
the sequence of SEQ ID NO: 120, a first light chain comprising an amino acid sequence with
at least 95% sequence identity to the sequence of SEQ ID NO: 115,
25 a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
to the sequence of SEQ ID NO: 121, and a second light chain comprising an amino acid
sequence with at least 95% sequence identity to the sequence of SEQ ID NO:99, or
- (c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to
the sequence of SEQ ID NO: 122, a first light chain comprising an amino acid sequence with
30 at least 95% sequence identity to the sequence of SEQ ID NO: 115,
a second heavy chain comprising an amino acid sequence with at least 95% sequence identity
to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid
sequence with at least 95% sequence identity to the sequence of SEQ ID NO:105.

25. The bispecific antibody of any one of paras 1 to 19 or 21 to 23, wherein the bispecific antibody comprises a fourth Fab fragment comprising an antigen binding domain that specifically binds to PD1.
26. The bispecific antibody of any one of paras 1 to 19 or 21 to 23 or 25, wherein the two Fab
5 fragments comprising each an antigen binding domain that specifically binds to PD1 are identical.
27. The bispecific antibody of any one of paras 1 to 19 or 21 to 23 or 25 or 26, wherein the two Fab fragments comprising each an antigen binding domain that specifically binds to PD1 are each fused via a peptide linker to the C-terminus to one of the heavy chains, respectively.
- 10 28. The bispecific antibody of any one of paras 1 to 19 or 21 to 23 or 25 to 27, comprising
- (a) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 114, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence
15 identity to the sequence of SEQ ID NO: 101, or
- (b) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 116, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising each an amino acid sequence with at least 95% sequence
20 identity to the sequence of SEQ ID NO:99, or
- (c) two heavy chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 117, two first light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 115, and two second light chains comprising an amino acid sequence with at least 95% sequence
25 identity to the sequence of SEQ ID NO:105.
29. The bispecific antibody of any one of paras 1 to 14, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a single chain Fab (scFab) comprising the antigen binding domain that specifically binds to PD1.
- 30 30. The bispecific antibody of any one of paras 1 to 14 or 29, wherein the scFab comprising an antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus to one of the heavy chains.

31. The bispecific antibody of any one of paras 1 to 14 or 29 or 30, comprising

(a) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 123, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 119, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 101, or

(b) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 124, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 121, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 99, or

(c) a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 125, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 103, and a second light chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 105.

32. The bispecific antibody of any one of paras 1 to 14, wherein the bispecific antibody comprises an Fc domain, two Fab fragments comprising each an antigen binding domain that specifically binds to LAG3 and a VH and VL domain comprising the antigen binding domain that specifically binds to PD1.

33. The bispecific antibody of any one of paras 1 to 14 or 32, wherein the VH domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of one of the heavy chains and the VL domain of the antigen binding domain that specifically binds to PD1 is fused via a peptide linker to the C-terminus of the other one of the heavy chains.

34. The bispecific antibody of any one of paras 1 to 14 or 32 or 33, comprising a first heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 126, a second heavy chain comprising an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 127, and two light chains comprising each an amino acid sequence with at least 95% sequence identity to the sequence of SEQ ID NO: 109.

35. A polynucleotide encoding the bispecific antibody of any one of paras 1 to 34.

36. A vector, particularly an expression vector, comprising the polynucleotide according to para 35.
37. A prokaryotic or eukaryotic host cell comprising the polynucleotide according to para 35 or the vector according to para 36.
- 5 38. A method of producing the bispecific antibody according to paras 1 to 34, comprising culturing the host cell of para 37 under conditions suitable for the expression of the bispecific antibody and recovering the bispecific antibody from the culture.
39. A pharmaceutical composition comprising the bispecific antibody according to any one of paras 1 to 34 and at least one pharmaceutically acceptable excipient.
- 10 40. The bispecific antibody according to any one of paras 1 to 34 or the pharmaceutical composition according to para 39 for use as a medicament.
41. The bispecific antibody according to any one of paras 1 to 34 or the pharmaceutical composition according to para 39 for use
- 15 i) in the modulation of immune responses, such as restoring T cell activity,
ii) in stimulating a T cell response,
iii) in the treatment of infections,
iv) in the treatment of cancer,
v) in delaying progression of cancer,
vi) in prolonging the survival of a patient suffering from cancer.
- 20 42. The bispecific antibody according to any one of paras 1 to 34 or the pharmaceutical composition according to para 39 for use in the prevention or treatment of cancer.
43. The bispecific antibody according to any one of paras 1 to 34 or the pharmaceutical composition according to para 39 for use in the treatment of a chronic viral infection.
- 25 44. The bispecific antibody according to any one of paras 1 to 34 or the pharmaceutical composition according to para 39 for use in the prevention or treatment of cancer, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/ or other agents for use in cancer immunotherapy.
- 30 45. A method of inhibiting the growth of tumor cells in an individual comprising administering to the individual an effective amount of the bispecific antibody according to any one of claims 1 to 34 to inhibit the growth of the tumor cells.

EXAMPLES

The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

Materials & general methods

5 General information regarding the nucleotide sequences of human immunoglobulins light and heavy chains is given in: Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). Amino acids of antibody chains are numbered and referred to according to the numbering systems according to Kabat (Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 10 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)) as defined above.

Recombinant DNA techniques

Standard methods were used to manipulate DNA as described in Sambrook, J. *et al.*, Molecular Cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring 15 Harbor, New York, 1989. The molecular biological reagents were used according to the manufacturer's instructions.

Gene synthesis

Desired gene segments were prepared from oligonucleotides made by chemical synthesis. The 600 - 1800 bp long gene segments, which were flanked by singular restriction endonuclease 20 cleavage sites, were assembled by annealing and ligating oligonucleotides including PCR amplification and subsequently cloned via the indicated restriction sites e.g. KpnI/ SacI or AscI/PacI into a pPCRScripT (Stratagene) based pGA4 cloning vector. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Gene synthesis fragments were ordered according to given specifications at Geneart (Regensburg, Germany).

25 **DNA sequence determination**

DNA sequences were determined by double strand sequencing performed at MediGenomix GmbH (Martinsried, Germany) or Sequiserve GmbH (Vaterstetten, Germany).

DNA and protein sequence analysis and sequence data management

The GCG's (Genetics Computer Group, Madison, Wisconsin) software package version 30 10.2 and Infomax's Vector NT1 Advance suite version 8.0 was used for sequence creation, mapping, analysis, annotation and illustration.

Expression vectors

For the expression of the described antibodies, variants of expression plasmids for transient expression (e.g. in HEK293) cells based either on a cDNA organization with or without a CMV-Intron A promoter or on a genomic organization with a CMV promoter were applied.

- 5 Beside the antibody expression cassette the vectors contained:
- an origin of replication which allows replication of this plasmid in *E. coli*, and
 - a β -lactamase gene which confers ampicillin resistance in *E. coli*.

The transcription unit of the antibody gene was composed of the following elements:

- unique restriction site(s) at the 5' end
- 10 - the immediate early enhancer and promoter from the human cytomegalovirus,
- followed by the Intron A sequence in the case of the cDNA organization,
- a 5'-untranslated region of a human antibody gene,
- an immunoglobulin heavy chain signal sequence,
- the human antibody chain (wildtype or with domain exchange) either as cDNA or as genomic
- 15 organization with the immunoglobulin exon-intron organization
- a 3' untranslated region with a polyadenylation signal sequence, and
- unique restriction site(s) at the 3' end.

- The fusion genes comprising the antibody chains as described below were generated by PCR and/or gene synthesis and assembled by known recombinant methods and techniques by
- 20 connection of the according nucleic acid segments e.g. using unique restriction sites in the respective vectors. The subcloned nucleic acid sequences were verified by DNA sequencing. For transient transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed *E. coli* cultures (Nucleobond AX, Macherey-Nagel).

Cell culture techniques

- 25 Standard cell culture techniques were used as described in Current Protocols in Cell Biology (2000), Bonifacino, J.S., Dasso, M., Harford, J.B., Lippincott-Schwartz, J. and Yamada, K.M. (eds.), John Wiley & Sons, Inc.

- Multispecific antibodies were expressed by transient co-transfection of the respective expression plasmids in adherently growing HEK293-EBNA or in HEK29-F cells growing in
- 30 suspension as described below.

Transient transfections in HEK293 system

All antibodies and bispecific antibodies were generated by transient transfection of 293F cells using the Freestyle system (ThermoFisher). Here the 293F cells were cultivated in F17 Medium, transfected with 293Free (Novagene) and feeded after 4 hours with VPA 4mM and
5 Feed 7 and 0,6 % Glucose after 16h. Further the Expi293F™ Expression System Kit (ThermoFisher) was used. Here the Expi293F™ cells were cultivated in Expi293™ Expression Medium and transfected using ExpiFectamine™ 293 Transfection Kit according manufacturer's instructions. Due to the improved stability and purity and reduced aggregation tendency of the **CrossMab**^{Vh-VL} bispecific antibodies with additionally introduced charged pairs of amino acids
10 in th CH1/CL interface (see positions in the respective sequences for further detail) no adjustments of plasmid ratio habe been employed. Therefore the relative plasmid ratio of 1:1:1:1 for 1+1 CrossMab or 1:1:1 for 2+2 CrossMab was used for the co-transfection of LC, HC, crossed LC and crossed HC plasmids. Cell supernatants were harvested after 7 days and purified by standard methods.

15 Protein determination

The protein concentration of purified antibodies and derivatives was determined by determining the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence according to Pace, *et al.*, Protein Science, 1995, 4, 2411-1423.

20 Antibody concentration determination in supernatants

The concentration of antibodies and derivatives in cell culture supernatants was estimated by immunoprecipitation with Protein A Agarose-beads (Roche). 60 µL Protein A Agarose beads were washed three times in TBS-NP40 (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet-P40). Subsequently, 1 -15 mL cell culture supernatant was applied to the Protein A Agarose beads pre-
25 equilibrated in TBS-NP40. After incubation for at 1 hour at room temperature the beads were washed on an Ultrafree-MC-filter column (Amicon) once with 0.5 mL TBS-NP40, twice with 0.5 mL 2x phosphate buffered saline (2xPBS, Roche) and briefly four times with 0.5 mL 100 mM Na-citrate pH 5,0. Bound antibody was eluted by addition of 35 µl NuPAGE® LDS Sample Buffer (Invitrogen). Half of the sample was combined with NuPAGE® Sample Reducing Agent
30 or left unreduced, respectively, and heated for 10 min at 70°C. Consequently, 5-30 µl were applied to a 4-12% NuPAGE® Bis-Tris SDS-PAGE (Invitrogen) (with MOPS buffer for non-reduced SDS-PAGE and MES buffer with NuPAGE® Antioxidant running buffer additive (Invitrogen) for reduced SDS-PAGE) and stained with Coomassie Blue.

The concentration of antibodies and derivatives in cell culture supernatants was quantitatively measured by affinity HPLC chromatography. Briefly, cell culture supernatants containing antibodies and derivatives that bind to Protein A were applied to an Applied Biosystems Poros A/20 column in 200 mM KH₂PO₄, 100 mM sodium citrate, pH 7.4 and eluted from the matrix with 200 mM NaCl, 100 mM citric acid, pH 2.5 on an Agilent HPLC 1100 system. The eluted protein was quantified by UV absorbance and integration of peak areas. A purified standard IgG1 antibody served as a standard.

Alternatively, the concentration of antibodies and derivatives in cell culture supernatants was measured by Sandwich-IgG-ELISA. Briefly, StreptaWell High Bind Streptavidin A-96 well microtiter plates (Roche) are coated with 100 µL/well biotinylated anti-human IgG capture molecule F(ab')₂-h-Fcγ BI (Dianova) at 0.1 µg/mL for 1 hour at room temperature or alternatively overnight at 4°C and subsequently washed three times with 200 µL/well PBS, 0.05% Tween (PBST, Sigma). 100 µL/well of a dilution series in PBS (Sigma) of the respective antibody containing cell culture supernatants was added to the wells and incubated for 1-2 hour on a microtiterplate shaker at room temperature. The wells were washed three times with 200 µL/well PBST and bound antibody was detected with 100 µL F(ab')₂-h-Fcγ-POD (Dianova) at 0.1 µg/mL as the detection antibody for 1-2 hours on a microtiterplate shaker at room temperature. Unbound detection antibody was washed away three times with 200 µL/well PBST and the bound detection antibody was detected by addition of 100 µL ABTS/well. Determination of absorbance was performed on a Tecan Fluor Spectrometer at a measurement wavelength of 405 nm (reference wavelength 492 nm).

Protein purification

Proteins were purified from filtered cell culture supernatants referring to standard protocols. In brief, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8 followed by immediate neutralization of the sample. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM Histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were pooled, concentrated (if required) using e.g., a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at -20°C or -80°C. Part of the samples were provided for subsequent protein analytics and analytical characterization e.g. by SDS-PAGE, size exclusion chromatography (SEC) or mass spectrometry.

SDS-PAGE

The NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instruction. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4)

and a NuPAGE® MES (reduced gels, with NuPAGE® Antioxidant running buffer additive) or MOPS (non-reduced gels) running buffer was used.

Analytical size exclusion chromatography

Size exclusion chromatography (SEC) for the determination of the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, pH 7.5 on an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2 x PBS on a Dionex HPLC-System. The eluted protein was quantified by UV absorbance and integration of peak areas. BioRad Gel Filtration Standard 151–1901 served as a standard.

Mass spectrometry

This section describes the characterization of the multispecific antibodies with VH/VL exchange (VH/VL CrossMabs) with emphasis on their correct assembly. The expected primary structures were analyzed by electrospray ionization mass spectrometry (ESI-MS) of the deglycosylated intact CrossMabs and deglycosylated/plasmin digested or alternatively deglycosylated/limited LysC digested CrossMabs.

The VH/VL CrossMabs were deglycosylated with N-Glycosidase F in a phosphate or Tris buffer at 37°C for up to 17 h at a protein concentration of 1 mg/ml. The plasmin or limited LysC (Roche) digestions were performed with 100 µg deglycosylated VH/VL CrossMabs in a Tris buffer pH 8 at room temperature for 120 hours and at 37°C for 40 min, respectively. Prior to mass spectrometry the samples were desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).

Determination of binding and binding affinity of multispecific antibodies to the respective antigens using surface plasmon resonance (SPR) (BIA CORE)

Binding of the generated antibodies to the respective antigens is investigated by surface plasmon resonance using a BIA CORE instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). The respective Biacore Evaluation Software is used for analysis of sensorgrams and for calculation of affinity data.

Example 1

Generation of anti-PD-1 antibodies

Immunization of mice

NMRI mice were immunized genetically, using a plasmid expression vector coding for full-length human PD-1 by intradermal application of 100 ug vector DNA (plasmid15300_hPD1-fl), followed by Electroporation (2 square pulses of 1000 V/cm, duration 0.1 ms, interval 0.125 s; followed by 4 square pulses of 287.5 V/cm, duration 10 ms, interval 0.125 s. Mice received either 6 consecutive immunizations at days 0, 14, 28, 42, 56, 70, and 84. Blood was taken at days 36, 78 and 92 and serum prepared, which was used for titer determination by ELISA (see below). Animals with highest titers were selected for boosting at day 96, by intravenous injection of 50 ug of recombinant human PD1 human Fc chimera, and monoclonal antibodies were isolated by hybridoma technology, by fusion of splenocytes to myeloma cell line 3 days after boost.

Determination of serum titers (ELISA)

Human recombinant PD1 human Fc chimera was immobilized on a 96-well NUNC Maxisorp plate at 0.3 ug/ml, 100 ul/well, in PBS, followed by: blocking of the plate with 2% Crotein C in PBS, 200 ul/well; application of serial dilutions of antisera, in duplicates, in 0.5% Crotein C in PBS, 100 ul/well; detection with HRP-conjugated goat anti-mouse antibody (Jackson ImmunoResearch/Dianova 115-036-071; 1/16 000). For all steps, plates were incubated for 1 h at 37 °C. Between all steps, plates were washed 3 times with 0.05% Tween 20 in PBS. Signal was developed by addition of BM Blue POD Substrate soluble (Roche), 100 ul/well; and stopped by addition of 1 M HCl, 100 ul/well. Absorbance was read out at 450 nm, against 690 nm as reference. Titer was defined as dilution of antisera resulting in half-maximal signal.

Example 2

Characterization anti-PD1 antibodies/ Binding of anti-PD1 antibodies to human PD1

ELISA for hu PD1

Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 µl/well biotinylated PD1-ECD-AviHis and incubated at 4°C over night. After washing (3x90 µl/well with PBST-buffer) 25 µl anti PD1 samples or reference antibodies (human anti PD1; Roche/mouse anti PD1; Biolegend; cat.:329912) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat-anti-human H+L-POD (JIR, JIR109-036-088)/ Sheep-anti-mouse-POD (GE Healthcare; NA9310) was added in 1:2000/1:1000 dilution and incubated at RT for 1 h on shaker. After washing (3x90 µl/well with PBST-buffer)

25 µl/well TMB substrate (Roche Catalogue No. 11835033001) was added and incubated until OD 2 – 3. Measurement took place at 370/492 nm.

ELISA results are listed as EC₅₀-values [ng/ml] in Summary Tables 1 and 2 below.

Cell ELISA for PD1

- 5 Adherent CHO-K1 cell line stably transfected with plasmid 15311_hPD1-fl_pUC_Neo coding for full-length human PD1 and selection with G418 (Neomycin resistance marker on plasmid) were seeded at a concentration of 0.01x10⁶ cells/well in 384-well flat bottom plates and grown over night.

- 10 The next day 25 µl/well PD1 sample or human anti PD1 (Roche)/mouse anti PD1 (Biolegend; cat.:329912) reference antibody were added and incubated for 2h at 4°C (to avoid internalization). After washing carefully (1x90µl/well PBST) cells were fixed by adding 30µl/well 0,05% Glutaraldehyde (Sigma, Cat.No: G5882, 25%) diluted in 1xPBS-buffer and incubated for 10min at RT. After washing (3x90µl/well PBST) 25 µl/well secondary antibody was added for detection: goat-anti-human H+L-POD (JIR, JIR109-036-088)/Sheep-anti-mouse-
15 POD (GE NA9310) followed by 1h incubation at RT on shaker. After washing (3x90µl/well PBST) 25 µl/well TMB substrate solution (Roche 11835033001) was added and incubated until OD 1.0 – 2.0. Plates were measured at 370/492 nm.

Cell ELISA results are listed as “EC₅₀ CHO-PD1”-values [ng/ml] in Table 2 below.

ELISA for cyno PD1

- 20 Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 µl/well biotinylated cynoPD1-ECD-Biotin and incubated at 4°C over night. After washing (3x90 µl/well with PBST-buffer) 25 µl anti PD1 samples or reference antibodies (human anti PD1; Roche) were added and incubated 1h at RT on shaker. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat-anti-human H+L-POD (JIR, JIR109-036-088) was added in 1:1000
25 dilution and incubated at RT for 1 h on shaker. After washing (3x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place at 370/492 nm.

ELISA results are listed as EC₅₀-values [ng/ml] in Summary Table 1 and 2 below.

PD Ligand 1 replacing assay

- 30 Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 µl/well biotinylated PD1-ECD-AviHis and incubated at 4°C over night. After washing (3x90

5 μl /well with PBST-buffer) 25 μl anti PD1 samples or reference antibodies (mouse anti PD1; Biolegend; cat.:329912) were added and incubated 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well PD-L1 (Recombinant human B7-H1/PD-L1 Fc Chimera; 156-B7, R&D) was added and incubated 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well goat-anti-human H+L-POD (JIR, 109-036-088) was added in 1:1000 dilution and incubated at RT for 1 h on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place at 370/492 nm.

ELISA results are listed as IC_{50} -values [ng/ml] in summary Table 1 below.

10 **PD Ligand 2 replacing assay**

Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 μl /well biotinylated PD1-ECD-AviHis and incubated at 4°C over night. After washing (3x90 μl /well with PBST-buffer) 25 μl anti PD1 samples or reference antibodies (mouse anti huPD1; Roche) were added and incubated 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well PD-L2 (Recombinant human B7-DC/PD-L2 Fc Chimera; 1224-PL-100, R&D) was added and incubated 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well goat-anti-human H+L-POD (JIR, 109-036-088) was added in 1:2000 dilution and incubated at RT for 1 h on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well TMB (tetramethylbenzidine) substrate (Roche, #11835033001) was added and incubated until OD 2 – 3. Measurement took place at 370/492 nm.

ELISA results are listed as IC_{50} -values [ng/ml] in summary Table 1 below.

Epitope mapping ELISA/ Binding competition assay

Nunc maxisorp plates (Nunc #464718) were coated with 25 μl /well capture antibody (goat anti mouse IgG; JIR; 115-006-071) and incubated for 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) plates were blocked for 1h with 2% BSA containing PBS buffer at RT on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl mouse anti PD1 samples were added and incubated 1h at RT on shaker. After washing (3x90 μl /well with PBST-buffer) capture antibody was blocked by 30 μl /well mouse IgG (JIR; 015-000-003) for 1h at RT on shaker. At the same time biotinylated PD1-ECD-AviHis was preincubated with second sample antibody for 1h at RT on shaker. After washing assay plate (3x90 μl /well with PBST-buffer) the PD1 antibody mix was transferred to assay plate and incubated at RT for 1h on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well streptavidin POD (Roche, #11089153001) was added in 1:4000 dilution and incubated at RT for 1 h on shaker. After washing (3x90 μl /well with PBST-buffer) 25 μl /well TMB substrate (Roche, #11089153001) was added and incubated

until OD 1.5 – 2.5. Measurement took place at 370/492 nm. Epitope groups were defined by hierarchical clustering against reference antibodies.

Table 1: Binding, PD-L1 inhibition and epitope region groups of exemplary antibodies (ELISA)

Antibody	ELISA huPD1 EC ₅₀ [ng/ml]	ELISA cyPD1 EC ₅₀ [ng/ml]	ELISA PD-L1 inhibition IC ₅₀ [ng/ml]	ELISA PD-L2 inhibition IC ₅₀ [ng/ml]	Epitope region group (By competition assay)
PD1- 0050	17.9	9.8	128	34	1
PD1- 0069	45.7	22.7	225	89	6
PD1- 0073	15.1	8.3	124	65	5
PD1- 0078	26.3	22.4	x	86	2
PD1- 0098	50.8	54.6	174	45	5
PD1- 0102	34.2	52.7	>35.5 µg/ml	140	4
PD1-0103	33.7	36.9	182	51	5

5

Table 2: Biochemical- and Cell-binding of humanized PD1 antibodies derived from parental mouse antibody PD1-0103 (ELISA)

Humanized antibody	ELISA huPD1 EC ₅₀ [ng/ml]	ELISA cyPD1 EC ₅₀ [ng/ml]	ELISA CHO-PD1 EC ₅₀ [ng/ml]
PD1-103- 0312	11	8.3	10.1
PD1-103- 0313	15	11	10.8
PD1-103-	11	8.3	7.7

-132-

0314			
PD1-103-0315	10	7.9	7.3

Biacore characterization of the humanized anti-PD-1 antibodies

A surface plasmon resonance (SPR) based assay has been used to determine the kinetic parameters of the binding between several murine PD1 binders as well as commercial human PD1 binding references. Therefore, an anti-human IgG was immobilized by amine coupling to the surface of a (Biacore) CM5 sensor chip. The samples were then captured and hu PD1-ECD was bound to them. The sensor chip surface was regenerated after each analysis cycle. The equilibrium constant and kinetic rate constants were finally gained by fitting the data to a 1:1 langmuir interaction model.

About 2000 response units (RU) of 20 µg/ml anti-human IgG (GE Healthcare #BR-1008-39) were coupled onto the flow cells 1 and 2 (alternatively: 3 and 4) of a CM5 sensor chip in a Biacore T200 at pH 5.0 by using an amine coupling kit supplied by GE Healthcare.

The sample and running buffer was HBS-EP+ (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05 % v/v Surfactant P20, pH 7.4). Flow cell temperature was set to 25 °C and sample compartment temperature to 12 °C. The system was primed with running buffer.

The samples were injected for 20 seconds with a concentration of 10 nM and bound to the second flow cell. Then a complete set of human PD1-ECD concentrations (144 nM, 48 nM, 16 nM, 5.33 nM, 1.78 nM, 0.59 nM, 0.20 nM and 0 nM) was injected over each sample for 120s followed by a dissociation time of 30/300s and two 20s regeneration steps with 3 M MgCl₂, of which the last one contained an “extra wash after injection” with running buffer.

Finally the double referenced data was fitted to a 1:1 Langmuir interaction model with the Biacore T200 Evaluation Software. Resulting K_D , k_a and k_d values are shown in Table 3.

Table 3: Kinetic rate constants and equilibrium constants for chimeric PD1-0103 and humanized PD1-Abs determined by Biacore

Ligand	$k_a [M^{-1} s^{-1}]$	$k_d [s^{-1}]$	$K_D [nM]$
chimeric PD1-0103	3.86E+05	3.07E-04	0.8
PD1-0103-0312	1.95E+05	3.45E-04	1.8
PD1-0103-0313	1.60E+05	3.67E-04	2.3
PD1-0103-0314	1.87E+05	2.79E-04	1.5
PD1-0103-0315	1.89E+05	2.91E-04	1.5

As shown in Table 3, all the humanized versions of chimeric PD1-0103 (generation see Example 6) display kinetic properties similar to the parental antibody (chimeric PD1-0103).

5 Kinetics

A CM5 sensor series S was mounted into the Biacore 4000 System and the detection spots were hydrodynamically addressed according to the manufacturer's instructions.

The polyclonal rabbit IgG antibody <IgGFC γ M>R (Jackson ImmunoResearch Laboratories Inc.) was immobilized at 10 000 RU on the detection spots 1 and 5 in the flow cells 1,2,3 and 4. Coupling was done via EDC/NHS chemistry according to the manufacturer's instructions. The remaining spots in the flow cells served as a reference. The sample buffer was the system buffer supplemented with 1 mg/ml carboxymethyl dextrane.

In one embodiment the assay was driven at 25 °C. In another embodiment the assay was driven at 37 °C. 50 nM of each murine monoclonal antibody was captured on the sensor surface by a 1 min injection at 10 μ l/min. Subsequently the respective antigens were injected in a concentration series of 100 nM, 2x 33 nM, 11 nM, 4 nM, 1 nM and system buffer 0 nM at 30 μ l/min for 4 min association phase time. The dissociation was monitored for another 4 min. The capture system was regenerated using a 3 min injection of 10 mM glycine pH 1.5 at 30 μ l/min. The relevant kinetic data was calculated using the Biacore evaluation software according to the manufacturer's instructions.

Epitope Mapping

A Biacore 4000 instrument was mounted with a Biacore CAP sensor and was prepared like recommended by the manufacturer. The instrument buffer was HBS-ET (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% w/v Tween 20). The instrument was running at 25 °C.

All samples were diluted in system buffer. A 35kDa biotinylated antigen PD1-ECD-AviHis was captured at 200 RU on the CAP sensor surface by a 1 min injection at 30 μ l/min in the flow cells 1, 2, 3 and 4 in the spots 1 and 5. Spots 2, 3 and 4 served as a reference. In another

embodiment, a 35 kDa biotinylated antigen PD1-ECD-AviHis was captured at 200 RU on the CAP sensor in the same manner.

Subsequently a primary antibody was injected at 100 nM for 3 min at 30 μ l/min followed by the injection of a secondary antibody at 100 nM for 3 min at 30 μ l/min. The primary antibody was injected until full saturation of the surface presented antigen. At the end of the primary and secondary antibody injection phases report points "Binding Late" (BL) were set to monitor the binding response of the respective antibodies. The Molar Ratio, a quotient between the secondary antibody binding response "BL2" and the primary antibody response "BL1" was calculated. The Molar Ratio was used as an indicator of the antigen accessibility of the secondary antibody, when the antigen was already complexed by the primary antibody.

The complexes were completely removed from the sensor surface by an injection for 2 min at 30 μ l/min 2M guanidine-HCL 250 mM NaOH regeneration buffer as recommended by the manufacturer, followed by a 1 min injection at 30 μ l/min of system buffer.

Example 3

15 **Effect of different anti-PD-1 Antibodies on Cytokine Production in a Mixed Lymphocyte Reaction (MLR)**

3A) The Mixed Lymphocyte Reaction (MLR) is a immune cell assay which measures the activation of lymphocytes from one individual (donor X) to lymphocytes from another individual (donor Y). A mixed lymphocyte reaction was used to demonstrate the effect of blocking the PD1 pathway to lymphocyte effector cells. T cells in the assay were tested for activation and their IFN γ secretion in the presence or absence of an anti-PD1 mAbs.

To perform an allogeneic MLR, peripheral blood mononuclear cells (PBMCs) from at least four healthy donors of unknown HLA type were isolated by density gradient centrifugation using Leukosep (Greiner Bio One, 227 288). Briefly, heparinized blood samples were diluted with the three fold volume of PBS and 25 ml aliquots of the diluted blood were layered in 50 ml Leukosep tubes. After centrifugation at 800 x g for 15 min at room temperature (w/o break) the lymphocyte containing fractions were harvested, washed in PBS and used directly in functional assay or resuspended in freezing medium (10% DMSO, 90 %FCS) at 1.0E+07 cells/ml and stored in liquid nitrogen. Individual 2-way MLR reactions were set up by mixing PBMCs from two different donors at a 1:1 stimulator/responder cell ratio and co-cultures were done at least in duplicate in flat-bottomed 96-well plates for 6 days at 37°C, 5% CO₂, in the presence or w/o of a different concentration range of purified anti-PD1 monoclonal antibodies PD1-0050, PD1-0069, PD1-0073, PD1-0078, PD1-0098, PD1-0102, PD1-0103. As reference anti-PD1 antibodies, antibodies comprising the VH and VL domains of either nivolumab (also known as MDX-5C4

or MDX-1106) or pembrolizumab (also known as MK-3475 or Org 1.09A) were synthesized and cloned with backbones of human IgG1 (with mutations L234A, L235A and P329G (EU index of Kabat)). Either no antibody or an isotype control antibody was used as a negative control and rec hu IL-2 (20 EU/ml) was used as positive control. After day 6 100 µl of medium was taken from each culture for cytokine measurement. The levels of IFN-gamma were measured using OptEIA ELISA kit (BD Biosciences).

The results are shown in Table 4 (IFNγ secretion/release). The anti-PD1 monoclonal antibodies promoted T cell activation and IFNγ secretion in concentration dependent manner. The value of % increase of IFNγ secretion was calculated in relation to IFNγ production of MLR w/o adding of any blocking mAbs (basal allogeneic stimulation induced IFNγ value as E-c) and MLR with adding of 20 EU/ml rec hu IL-2 (positive control = 100% IFNγ value as E+c) and was calculated according to formula: Rel.Stimulation [%] = ((Example - E-c)/(E+c - E-c)*100

Table 4: Percentage of of IFN gamma secretion after allogenic stimulation and treatment with anti-PD-1 antibody in comparison to effect of recombinant human IL-2 treatment (20 EU/ml) (= 100% increase) as positive control

	Concentration (µg/ml)	1:12	1:120	1:1200	Effect in MLR
PD1-0050	44	136	96	33	+++
PD1-0069	60	76	71	55	+++
PD1-0073	43	103	63	38	++
PD1-0078	64	99	72	21	++

Several PD1 blocking antibodies PD1-0050, PD1-0069, PD1-0073, PD1-0078, PD1-0098, PD1-0102, PD1-0103 demonstrated strong immune modulating activity by enhancing secretion of interferon gamma (IFNγ) (data not shown for all antibodies).

3B) In a further experiment chimeric PD1-0103 (human IgG1 isotype with mutations L234A, L235A and P329G (EU index of Kabat)) was evaluated. Blockade of PD1 with chimeric PD1-0103 strongly enhances IFN-gamma secretion by allogenic stimulated primary human T cells. Chimeric PD1-0103 was more potent than reference anti-PD1 antibodies. For comparison the reference anti-PD1 antibodies comprising the VH and VL domains of either nivolumab (also known as MDX5C4 or MDX-1106) and pembrolizumab (also known as MK-3475 or Org 1.09A) were synthesized and cloned with backbones of human IgG1 (with mutations L234A, L235A and P329G (EU index of Kabat)) were used.

3C) In additional experiments the immune modulating activity of the humanized variants of anti-PD-1 antibody PD1-0103 (humanized antibodies PD1-0103-0312, PD1-0103-0314, in

figures 2 and 3, see also Example 9 below) the a) IFN γ release (secretion) b) TNF-alpha release (secretion) was evaluated in MLR as described above. The effect of the chimeric PD1-0103 antibody and its humanized versions were compared to the reference anti-PD1 antibodies comprising the VH and VL domains of either nivolumab (also known as MDX5C4 or MDX-1106) and pembrolizumab (also known as MK-3475 or Org 1.09A) with backbones of human IgG1 (with mutations L234A, L235A and P329G (EU index of Kabat)). After 6 days of MLR culture 50 μ l of supernatant was taken and multiple cytokines were measured in a single culture using Bio-Plex Pro™ Human Cytokine Th1/Th2 Assay (Bio-Rad Laboratories Inc.). (data not shown for all cytokines). The chimeric PD1-0103 antibody and its humanized versions (PD1-0103_0312 and PD1-0103_0314) were more potent compared to the reference anti-PD1 antibodies in enhancing the T cell activation and IFN-gamma secretion. Furthermore, the chimeric PD1-0103 antibody and its humanization variants increased tumor necrosis factor alpha (TNF alpha) and IL-12 secretion by antigen presenting cells and enhance capacity of monocytes/macrophages or antigen presenting cells to stimulate a T cell.

Example 4

Effect of anti-PD-1 blockade on cytotoxic Granzyme B release and IFN- γ secretion by human CD4 T cells cocultured with allogeneic mature dendritic cells

To further investigate the effect of anti-PD-1 treatment in an allogeneic setting we developed an assay in which freshly purified CD4 T cells are cocultured for 5 days in presence of monocyte-derived allogeneic mature dendritic cells (mDCs). Monocytes were isolated from fresh PBMCs one week before through plastic adherence followed by the removal of the non-adherent cells. We then generated immature DCs from the monocytes by culturing them for 5 days in media containing GM-CSF (50 ng/ml) and IL-4 (100 ng/ml). To induce iDCs maturation, we added TNF- α , IL-1 β and IL-6 (50 ng/ml each) to the culturing media for 2 additional days. We then assessed DCs maturation by measuring their surface expression of Major Histocompatibility Complex Class II (MHCII), CD80, CD83 and CD86 thorough flow cytometry (LSRFortessa, BD Biosciences).

On the day of the minimal mixed lymphocyte reaction (mMLR), CD4 T cells were enriched via a microbead kit (Miltenyi Biotec) from 10^8 PBMCs obtained from an unrelated donor. Prior culture, CD4 T cells were labeled with 5 μ M of Carboxy-Fluorescein-Succinimidyl Esther (CFSE). 10^5 CD4 T cells were then plated in a 96 well plate together with mature allo-DCs (5:1) in presence or absence of blocking anti-PD1 antibody (either PD1-0103, chimeric PD1-0103, or humanized antibodies PD1-0103-0312, PD1-0103-0313, PD1-0103-0314, PD1-0103-0315, abbreviated as 0312, 0313, 0314, 0315), at the concentration of 10 μ g/ml if not differently indicated in the figures.

-137-

Five days later the cell-culture supernatants were collected and used to measure the IFN- γ levels by ELISA (R&D systems). The cells were left at 37 °C for additional 5 hours in presence of Golgi Plug (Brefeldin A) and Golgi Stop (Monensin). The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). Intracellular staining was performed for Granzyme B (BD Bioscience), IFN- γ and IL-2 (both from eBioscience).

All humanized variants PD1-0103 (humanized antibodies PD1-0103-0312, PD1-0103-0313, PD1-0103-0314, PD1-0103-0315, abbreviated as 0312, 0313, 0314, 0315) were found to be equally good in enhancing granzyme B and interferon gamma (data not shown).

Example 5

Chimeric PD1 antibody derivatives

Chimeric PD1 antibodies were generated by amplifying the variable heavy and light chain regions of the anti-PD1 mouse antibodies PD1-0098, PD1-0103 via PCR and cloning them into heavy chain expression vectors as fusion proteins with human IgG1 backbones / human CH1-Hinge-CH2-CH3 with mutations L234A, L235A and P329G (EU index of Kabat)) (Leucine 234 to Alanine, Leucine 235 to Alanine, Proline 329 to Glycine) abrogating effector functions and light chain expression vectors as fusion proteins to human C-kappa. LC and HC Plasmids were then cotransfected into HEK293 and purified after 7 days from supernatants by standard methods for antibody purification. The chimeric PD1-antibodies were renamed chimeric chiPD1-0098 (chiPD1-0098) and chimeric PD1-0103 (chiPD1-0103). For comparison the reference anti-PD1 antibodies comprising the VH and VL domains of either nivolumab (also known as MDX-5C4 or MDX-1106) and pembrolizumab (also known as MK-3475 or Org 1.09A) were synthesized and cloned with backbones of human IgG1 (with mutations L234A, L235A and P329G (EU index of Kabat)) were used.

Example 6

Generation, Expression and Purification of humanized variants of anti-PD1 antibody PD-0103 (huMab PD-0103) and characterization

Humanization of the VH and VL domains of murine anti-PD1 antibody 0103

Based upon the amino acid sequence of the murine VH and VL domains of murine anti-PD1 antibody PD1-0103 (SEQ ID NO: 7 and 8), humanized anti-anti-PD1 antibody variants were generated.

The humanized VH-variant is based on the human germline IMGT_hVH_3_23 in combination with the human J-element germline IGHJ5-01 with several mutations. (resulting in SEQ ID NO: 9).

The humanized variants of VL are based on the human germlines IMGT_hVK_4_1, IMGT_hVK_2_30, IMGT_hVK_3_11 and IMGT_hVK_1_39 in combination with the human J-element germline IGKJ1-01. Different mutations resulted in humanized variants of SEQ ID NO: 10 to SEQ ID NO: 13.

The humanized amino acid sequences for heavy and light chain variable regions of PD1-0103 were backtranslated into DNA and the resulting cDNA were synthesized (GenArt) and then cloned into heavy chain expression vectors as fusion proteins with human IgG1 backbones /human CH1-Hinge-CH2-CH3 with LALA and PG mutations (Leucine 234 to Alanine, Leucine 235 to Alanine, Proline 329 to Glycine) abrogating effector functions or into light chain expression vectors as fusion proteins to human C-kappa. LC and HC Plasmids were then cotransfected into HEK293 and purified after 7 days from supernatants by standard methods for antibody purification. The resulting humanized PD1-antibodies named as follows:

Table 5: VH and VL sequences of humanized variant antibodies of PD1-0103

Humanized antibodies of PD1-0103	humanized variant of VH/SEQ ID NO:	humanized variant of VL/SEQ ID NO:
PD1-0103-0312	SEQ ID NO: 9	SEQ ID NO: 10
PD1-0103-0313	SEQ ID NO: 9	SEQ ID NO: 11
PD1-0103-0314	SEQ ID NO: 9	SEQ ID NO: 12
PD1-0103-0315	SEQ ID NO: 9	SEQ ID NO: 13

Humanized PD1-0103 antibody variants and parental chimeric PD1-0103 were characterized as described above. Results are shown in Table 6.

Table 6: Summary of results for humanized PD1-0103 antibody variants and parental chimeric PD1-0103

Assay	chimeric PD1-0103	PD-0103-0312	PD-0103-0313	PD-0103-0314	PD-0103-0315
Affinity $K_{D\ 37^{\circ}\text{C}}$ [nM]	2.0 / 0.8	1.5 / 1.8	1.9 / 2.3	1.6 / 1.5	1.7 / 1.5
ELISA EC_{50} [nM]	0,2	0,1	0,07	0,07	0,06

CHO-PD1 EC ₅₀	+	+	+	+	+
IC ₅₀ PD-L1, 2 [nM]	1.35	tbd	tbd	tbd	tbd
Mixed Lymphocyte Reaction assay	+++	+++	+++	++++	++
cynomolgus crossreactivity (EC ₅₀ [nm])	+	0,08	0,06	0,05	0,04

The humanized variant PD-0103-0312 is termed aPD1 antibody clone PD1-0376 in the following.

Example 7

5 Generation of anti-LAG3 antibodies

Immunization of rabbits

Roche proprietary transgenic rabbits expressing a humanized antibody repertoire were immunized with LAG3 expressing plasmid DNA.

A set of 3 rabbits was immunized genetically, using a plasmid expression vector coding for full-length human LAG3 (*15352_pIntronA_fl-hLag3_DNA-IMS*), by intradermal application of 400 ug vector DNA, followed by Electroporation (5 square pulses of 750 V/cm, duration 10 ms, interval 1 s). Rabbits received 7 consecutive immunizations at days 0, 14, 28, 49, 70, 98 and 126. Blood (10% of estimated total blood volume) was taken at days 35, 77, 105 and 133. Serum was prepared, which was used for titer determination by ELISA (see below), and peripheral mononuclear cells were isolated, which were used as a source of antigen-specific B cells in the B cell cloning process below.

Determination of serum titers (ELISA)

Human recombinant LAG3 protein was immobilized on a 96-well NUNC Maxisorp plate at 2 ug/ml, 100 ul/well, in PBS, followed by: blocking of the plate with 2% Crotein C in PBS, 200 ul/well; application of serial dilutions of antisera, in duplicates, in 0.5% Crotein C in PBS, 100 ul/well; detection with either (1) HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch/Dianova 711-036-152; 1/16 000), or (2) HRP-conjugated rabbit anti-human IgG antibody (Pierce/Thermo Scientific 31423; 1/5000), or (3) biotinylated goat anti-human kappa antibody (Southern Biotech/Biozol 2063-08, 1/5 000) and streptavidin-HRP; each diluted 25 in 0.5% Crotein C in PBS, 100 ul/well. For all steps, plates were incubated for 1 h at 37⁰ C.

Between all steps plates were washed 3 times with 0.05% Tween 20 in PBS. Signal was developed by addition of BM Blue POD Substrate soluble (Roche), 100 ul/well; and stopped by addition of 1 M HCl, 100 ul/well. Absorbance was read out at 450 nm, against 690 nm as reference. Titer was defined as dilution of antisera resulting in half-maximal signal.

5 Isolation of rabbit peripheral blood mononuclear cells (PBMC)

Blood samples were taken of immunized transgenic rabbits. EDTA containing whole blood was diluted twofold with 1x PBS (PAA, Pasching, Austria) before density centrifugation using lympholyte mammal (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the specifications of the manufacturer. The PBMCs were washed twice with 1x PBS.

10 EL-4 B5 medium

RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2 mM Glutamin, 1% penicillin/streptomycin solution (PAA, Pasching, Austria), 2 mM sodium pyruvate, 10 mM HEPES (PAN Biotech, Aidenbach, Germany) and 0,05 mM b-mercaptoethanole (Gibco, Paisley, Scotland) was used.

15 Coating of plates with protein antigen

Sterile cell culture 6-well plates were coated with human LAG3 ECD conjugated to a human Fc part (2 µg/ml) in carbonate buffer (0,1 M sodium bicarbonate, 34 mM Disodiumhydrogencarbonate, pH 9,55) over night at 4°C. Plates were washed in sterile PBS three times before use.

20 Depletion of cells

(a) Sterile 6-well plates (cell culture grade) covered with a confluent monolayer of CHO cells were used to deplete macrophages/monocytes through unspecific adhesion as well as unspecifically binding lymphocytes.

(b) Blank sterile 6-well plates (cell culture grade) were used to deplete macrophages and monocytes and other cells through unspecific adhesion.

Half of the PBMC sample was used for (a) and half for (b).

Each well was filled at maximum with 4 ml medium and up to 6x10⁶ PBMCs from the immunized rabbit and allowed to bind for 1 h at 37 °C in the incubator. The cells in the supernatant (peripheral blood lymphocytes (PBLs)) were used for the antigen panning step.

Enrichment of B cells on LAG3 antigen

Protein Antigen: 6-well tissue culture plates coated with LAG3-ECD-huFc protein were seeded with up to 6×10^6 PBLs per 4 ml medium from the depletion steps using the blank 6-well plate and allowed to bind for 1 h at 37 °C in the incubator. Non-adherent cells were removed by
5 carefully washing the wells 1-2 times with 1x PBS. The remaining sticky cells were detached by trypsin for 10 min at 37 °C in the incubator. Trypsination was stopped with EL-4 B5 medium. The cells were kept on ice until the immune fluorescence staining.

Cell surface antigen: 6-well tissue culture plates covered with a monolayer of human LAG3-positive CHO cells were seeded with up to 6×10^6 PBLs per 4 ml medium from the
10 depletion steps using the CHO-covered 6-well plate and allowed to bind for 1 h at 37 °C in the incubator. Non-adherent cells were removed by carefully washing the wells 1-2 times with 1x PBS. The remaining sticky cells were detached by trypsin for 10 min at 37 °C in the incubator. Trypsination was stopped with EL-4 B5 medium. The cells were kept on ice until the immune fluorescence staining.

15 Immune fluorescence staining and Flow Cytometry

The anti-IgG FITC (AbD Serotec, Düsseldorf, Germany) and the anti-huCk PE (Dianova, , Hamburg, Germany) antibody was used for single cell sorting. For surface staining, cells from the depletion and enrichment step were incubated with the anti-IgG FITC and the anti-huCk PE antibody in PBS and incubated for 45 min in the dark at 4°C. After staining the PBMCs were
20 washed two fold with ice cold PBS. Finally the PBMCs were resuspended in ice cold PBS and immediately subjected to the FACS analyses. Propidium iodide in a concentration of 5 µg/ml (BD Pharmingen, San Diego, CA, USA) was added prior to the FACS analyses to discriminate between dead and live cells. A Becton Dickinson FACSaria equipped with a computer and the FACSDiva software (BD Biosciences, USA) were used for single cell sort.

25 B-cell cultivation

The cultivation of the rabbit B cells was performed by a method described by Seeber et al. (S Seeber et al. PLoS One 9 (2), e86184. 2014 Feb 04). Briefly, single sorted rabbit B cells were incubated in 96-well plates with 200 µl/well EL-4 B5 medium containing Pansorbin Cells (1:100000) (Calbiochem (Merck), Darmstadt, Deutschland), 5% rabbit thymocyte supernatant
30 (MicroCoat, Bernried, Germany) and gamma-irradiated murine EL-4 B5 thymoma cells (5×10^5 cells/well) for 7 days at 37 °C in the incubator. The supernatants of the B-cell cultivation were removed for screening and the remaining cells were harvested immediately and were frozen at – 80 °C in 100 µl RLT buffer (Qiagen, Hilden, Germany).

Isolation of V-Domains of LAG3 antibodies

PCR amplification of V-domains

Total RNA was prepared from B cells lysate (resuspended in RLT buffer - Qiagen - Cat. N° 79216) using the NucleoSpin 8/96 RNA kit (Macherey&Nagel; 740709.4, 740698) according to manufacturer's protocol. RNA was eluted with 60 µl RNase free water. 6µl of RNA was used to generate cDNA by reverse transcriptase reaction using the Superscript III First-Strand Synthesis SuperMix (Invitrogen 18080-400) and an oligo dT-primer according to the manufactures's instructions. All steps were performed on a Hamilton ML Star System. 4µl of cDNA were used to amplify the immunoglobulin heavy and light chain variable regions (VH and VL) with the AccuPrime Supermix (Invitrogen 12344-040) in a final volume of 50µl using the primers rbHC.up and rbHC.do for the heavy chain and BcPCR_FHLC_leader.fw and BcPCR_huCkappa.rev for the light chain (Table 7). All forward primers were specific for the signal peptide (of respectively VH and VL) whereas the reverse primers were specific for the constant regions (of respectively VH and VL). The PCR conditions for the RbVH were as follows: Hot start at 94°C for 5 min; 35 cycles of 20s at 94°C, 20s at 70°C, 45s at 68 °C, and a final extension at 68°C for 7 min. The PCR conditions for the HuVL were as follows: Hot start at 94°C for 5 min; 40 cycles of 20s at 94°C, 20s at 52°C, 45s at 68 °C, and a final extension at 68°C for 7 min.

Table 7

SEQ ID NO: 76 rbHC.up	AAGCTTGCCACCATGGAGACTGGGCTGCGCTGGCTTC
SEQ ID NO: 77 rbHCf.do	CCATTGGTGAGGGTGCCCGAG
SEQ ID NO: 78 BcPCR_FHLC_leader.fw	ATGGACATGAGGGTCCCCGC
SEQ ID NO: 79 BcPCR_huCkappa.rev	GATTTCAACTGCTCATCAGATGGC

8µl of 50µl PCR solution were loaded on a 48 E-Gel 2% (Invitrogen G8008-02). Positive PCR reactions were cleaned using the NucleoSpin Extract II kit (Macherey&Nagel; 740609250) according to manufacturer's protocol and eluted in 50µl elution buffer. All cleaning steps were performed on a Hamilton ML Starlet System.

Recombinant expression of rabbit monoclonal bivalent antibodies

For recombinant expression of rabbit monoclonal bivalent antibodies, PCR-products coding for VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (RS Haun et al., Biotechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007)

4, 251-256). The expression vectors contained an expression cassette consisting of a 5' CMV promoter including intron A, and a 3' BGH poly adenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication and a beta-lactamase gene conferring ampicillin resistance for plasmid amplification in *E.coli*. Three
 5 variants of the basic plasmid were used: one plasmid containing the rabbit IgG constant region designed to accept the VH regions while containing human kappa LC constant region to accept the VL regions. Linearized expression plasmids coding for the kappa or gamma constant region and VL /VH inserts were amplified by PCR using overlapping primers. Purified PCR products were incubated with T4 DNA-polymerase which generated single-strand overhangs. The reaction
 10 was stopped by dCTP addition.

In the next step, plasmid and insert were combined and incubated with recA which induced site specific recombination. The recombined plasmids were transformed into *E.coli*. The next day the grown colonies were picked and tested for correct recombined plasmid by plasmid preparation, restriction analysis and DNA-sequencing.

15 For antibody expression, the isolated HC and LC plasmids were transiently co-transfected into HEK293 cells and the supernatants were harvested after 1 week.

Example 8

Characterization of anti-LAG3 antibodies

Table 8: Summary of Characterization of different anti-LAG3 Antibodies

anti-Lag3 antibodies	aLAG3 (0403)	aLAG3 (411)	aLAG3 (414)	aLAG3 (416)	aLAG3 (417)	MDX-25F7(25F7)	BMS-986016	MDX-26H10 (26H10)	Humanized BAP 050 (LAG525)
K _D [M] monovalent	tbd	tbd	4.63 E-10	2.82 E-11	tbd	tbd	tbd	tbd	tbd
bivalent	tbd	tbd	tbd	tbd	tbd	tbd	tbd	tbd	tbd
kd [1/s]	5,00 E-06	3,87 E-05	1,95 E-04	2,21 E-04	9,48 E-05	3,86 E-04		3,99 E-04	

anti-Lag3 antibodies	aLAG3 (0403)	aLAG3 (411)	aLAG3 (414)	aLAG3 (416)	aLAG3 (417)	MDX-25F7(25F7)	BMS-986016	MDX-26H10 (26H10)	Humanized BAP 050 (LAG525)
Epitope Bin	E3	E3	E3	E2b	E3	E5 (D1-loop)	E5	E4	E2c
MHCII/ ELISA IC ₅₀ [nM]	0.9	0.8	0.9	0.9	0.9	0.8/ 0.6	/0.4	0.9 / 0.6	/1.0
CHO-cell ELISA inflexion point [ng/ml]	30.9	41.3	48.1	37.2	27.8	75			

ELISA for human Lag3

Nunc maxisorp plates (Nunc 464718) were coated with 25 µl/well recombinant Human LAG-3 Fc Chimera Protein (R&D Systems, 2319-L3) at a protein concentration of 800 ng/ml and incubated at 4°C overnight or for 1h at room temperature. After washing (3x90 µl/well with PBST-buffer) each well was incubated with 90 µl blocking buffer (PBS + 2% BSA + 0.05% Tween 20) for 1 h at room temperature. After washing (3x90 µl/well with PBST-buffer) 25 µl anti-Lag3 samples at a concentration of 1-9µg/ml (1:3 dilutions in OSEP buffer) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat anti-Human Ig κ chain antibody-HRP conjugate (Milipore, AP502P) was added in a 1:2000 dilution and incubated at RT for 1 h. After washing (3x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated for 2-10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Cell-surface Lag3 binding ELISA

25 µl/well of Lag3 cells (recombinant CHO cells expressing Lag3, 10000 cells/well) were seeded into tissue culture treated 384-well plates (Corning, 3701) and incubated at 37°C for one or two days. The next day after removal of medium, 25 µl anti-Lag3 samples (1:3 dilutions in OSEP buffer, starting at a concentration of 6-40 nM) were added and incubated for 2h at 4°C. After washing (1 x 90µl in PBST) cells were fixed by addition of 30 µl/well glutaraldehyde to a final concentration of 0,05% (Sigma Cat.No: G5882), 10 min at room temperature. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat anti-Human Ig κ chain antibody-HRP

conjugate (Milipore, AP502P) was added in a 1:1000 dilution and incubated at RT for 1 h. After washing (3x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated for 6- 10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

5 SPR (Biacore) characterization of anti-LAG3 antibodies

A surface plasmon resonance (SPR) based assay has been used to determine the kinetic parameters of the binding between anti-Lag3 antibodies in bivalent format or as monovalent Fab fragments and human Fc tagged human Lag3 extra cellular domains (ECDs) at 25°C.

Therefore two flow cells of a C1 biosensor chip were prepared in a Biacore T200 by immobilizing neutravidin, diluted to 25 µg/ml in acetate buffer pH 4.5, onto it using the 'immobilization wizard'. This yielded in immobilization levels of around 1900 RU. Then, CaptureSelect™ Biotin Anti-IgG-Fc (Human) Conjugate was bound to the neutravidin, using a 20 µg/ml dilution in running buffer (HBS-EP+, GE Healthcare).

The method itself consisted of four commands per cycle. First command: capturing of ~46 RU of huLag3-Fc (20s, 10 µl/min). Second command: sample injection for 120s followed by a 1200s long dissociation at a flow speed of 30 µl/min. Third and fourth command: regeneration by injecting Glycine-HCl pH 1.5 for 30 seconds. A dilution series (3.13 nM - 200 nM, two-fold dilutions in running buffer) of each antibody Fab fragment and additional blank cycles were then measured using the previously described method. The Biacore T200 Evaluation Software was then utilized to gain kinetic values by applying a 1:1 Langmuir fit with the Rmax fit parameter set to 'local' since the capture levels were not perfectly reproducible. Results (K_D values and k_d values) are shown in Table 8.

Epitope Mapping

Epitope binning was performed using a surface plasmon resonance (SPR) based assay. Therefore aLag3 binders were bound to huLag3 on a Biacore T200 instrument. Then the accessibility of other binders to the previously formed aLag3 binder – huLag3 complex was assessed.

A SA CAP Kit (GE Healthcare) was used to carry out this assay. If not described otherwise, the assay was done according to the SA CAP Kit manual. The run included only one cycle type. After hybridization, a 10 nM dilution of biotinylated, huFc-tagged huLag3 was allowed to bind to the streptavidin on the sensor chip for 20s at a flow rate of 10 µl/min. Then a first 200 nM sample diluted in running buffer was injected for 180s at a flow rate of 30 µl/min and

immediately followed by a second sample under the same conditions. The surface was then regenerated.

The samples were then assigned to different epitope groups with similar competition patterns. A first rough categorization was done, based on the relative response of the second injection using a threshold of 6.1 RU, which was just above the highest value observed when a binder was injected as first and second sample. All values and decisions were finally validated by visual inspection of the sensorgrams.

Results are shown in Table 8. Three major epitope patterns (E1, E2 and E3) were identified. Since aLag3-0416 and humanized BAP 050 share the same group but do not completely inhibit each other, they were assigned to subgroups E2b and E2c.

Binding of anti-Lag3 antibodies from tg rabbits to recombinant cyno Lag3 positive HEK cells

In addition to the binding analysis using HEK cells recombinantly expressing human Lag3 on the surface, binding to cynomolgus Lag3-positive HEK cells was also evaluated. For this experiment, frozen HEK293F cells, previously transiently transfected with cyno-LAG-3, were thawed, centrifuged and resupplemented in PBS/2%FBS. 1.5×10^5 cells/well were seeded into 96-well plates. Anti-Lag3 antibodies were added to a final normalized concentration of 10 µg/ml. For referencing and as controls, autofluorescence and positive control (Medarex 25F7) as well as isotype control (huIgG1 from Sigma, cat.no. # I5154, *data not shown*) antibodies were prepared and measured in the experiment. HEK cells were incubated with indicated antibodies for 45 min on ice, washed twice with 200 µl ice-cold PBS buffer containing 2% FBS, before secondary antibody (APC-labelled goat anti-human IgG-kappa, Invitrogen, cat.no.#MH10515) was added (1:50 diluted in FACS-Puffer/well) and further incubated for 30 min on ice. Cells were again washed twice with 200 µl ice-cold PBS/2% FBS buffer before samples were finally resuspended in 150 µl FACS buffer and binding was measured on FACS CANTO-II HTS Module.

Results: Shown in the below table is the binding and cross-reactivity of different anti-Lag3 antibodies to HEK293 cells expressing cynoLAG3, binding either given in % positive cells or the GeoMean of the signal intensity.

Table 9: Binding of different anti-LAG3 Antibodies to recombinant cyno Lag3 positive HEK cells

LAG3 antibody	% pos.	GeoMean
Reference LAG3 antibody MDX25F7	41.2	3062
aLAG3(0411)	88.6	11007
aLAG3(0414)	81.6	9169

aLAG3(0416)	67.9	4221
aLAG3(0417)	75.9	7115
aLAG3(0403)	82.0	7457

Binding of anti-Lag3 antibodies from tg rabbits to (activated) cynomolgus PBMC/T cells expressing Lag3

After binding to recombinant Lag3 protein and Lag3 expressed recombinantly on mammalian cells, binding to Lag3 expressed on activated cynomolgus T cells was also assessed.

The binding characteristics of the newly generated anti-Lag3 antibodies (derived from Roche's transgenic rabbits) to Lag3 expressed on the cell surface of cynomolgus T cells or PBMC was confirmed by FACS analysis. While Lag3 is not expressed on naïve T cells it is upregulated upon activation and/or on exhausted T cells. Thus, cynomolgus peripheral blood mononuclear cells (PBMC) were prepared from fresh cynomolgus blood and were then activated by CD3/CD28 pre-treatment (1µg/ml) for 2-3 days. Activated cells were subsequently analyzed for Lag3 expression: Briefly, $1-3 \times 10^5$ activated cells were stained for 30-60 min on ice with indicated anti-Lag3 antibodies and respective control antibodies at 10µg/ml final concentration. The bound anti-Lag3 antibodies were detected via fluorochrome-conjugated anti-human IgG or an anti-rabbit IgG secondary antibodies. After staining, cells were washed two times with PBS/2% FCS and analyzed on a FACS Fortessa (BD).

Results: The following table summarizes the percentage of Lag3 positive cells within activated cynomolgus PBMC.

Table 10: Binding of different anti-LAG3 Antibodies to (activated) cynomolgus PBMCs/ T cells expressing Lag3

Anti-Lag3/ctrl Antibodies	% positive cyno cells (PBLs) after CD3/CD28 activation
only 2nd Ab (hu)	7.62
DP47 (human isotype)	9.19
Reference LAG3 antibody (MDX25F7)	22.1
Reference LAG3 antibody BMS-986016	18.6
Reference LAG3 antibody (humanized BAP050(LAG525))	50.7
only 2nd Ab (rb)	5.26
aLAG3(0403)	44.2
aLAG3(0411)	46.6
aLAG3(0414)	43.0

Anti-Lag3/ctrl Antibodies	% positive cyno cells (PBLs) after CD3/CD28 activation
aLAG3(0416)	38.9
aLAG3(0417)	35.3

On activated cynomolgus T cells all of the rabbit anti-Lag3 antibodies demonstrated a significant binding to Lag3⁺ cells. Hereby, all newly generated antibodies showed an increased percentage of positive cells compared to human anti-Lag3 reference antibodies (e.g. such as MDX25F7, BMS-986016).

Inhibition of LAG-3 binding to MHC-II expressed on human A375 tumor cells (by ELISA)

25 µl/well of A375 cells (10000 cells/well) were seeded into tissue culture treated 384-well plates (Corning, 3701) and incubated at 37°C overnight. Anti-Lag3 antibodies were pre-incubated for 1h with biotinylated-Lag3 (250 ng/ml) in cell culture medium in 1:3 dilutions starting at 3 µg/ml antibody-concentration. After removal of medium from the wells with the seeded cells, 25 µl of the antibody-Lag3 pre-incubated mixtures were transferred to the wells and incubated for 2 h at 4°C. After washing (1 x 90µl in PBST) cells were fixed by addition of 30 µl/well glutaraldehyde to a final concentration of 0,05% (Sigma Cat.No: G5882), 10 min at room temperature. After washing (3x90 µl/well with PBST-buffer) 25µl/well Poly-HRP40-Streptavidin (Fitzgerald, 65R-S104PHRPx) was added in a 1:2000 or 1:8000 dilution and incubated at RT for 1 h. After washing (3x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, #11835033001) was added and incubated for 2 to 10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Inhibition of LAG-3 binding to MHC-II expressed on human A375 tumor cells (by FACS analysis)

Assay principle: To study the antagonistic function of the anti-Lag3 antibodies, an MHCII:Lag3 competition assay was conducted. MHCII⁺ human A375 cells were stained with inhouse generated biotinylated Lag3:Fc fusion protein with or without pre-incubation with anti-Lag3 antibodies. This analysis was studied in a FACS competition experiment: A375 cells (ATCC, #CRL-1619) were cultured for 2-3 passages in EM Eagle's medium supplemented with EBSS (PAN, cat.no. #P04-00509), 10% FBS, 2mM L-Glutamin, 1x NEAA and 1x Sodium Pyruvate. All antibodies, were diluted in FACS buffer to a final concentration of 20µg/ml in 25µl (in 96well U-bottom plates). 25µl of inhouse generated, biotinylated recombinant LAG-3:Fc fusion protein was added to a final concentration of 10µg/ml either to medium or to anti-Lag3 antibodies or controls and were pre-incubated for 30 min at room temperature. A375 cells were washed with PBS and adjusted to 3x10⁶ cells/ml in PBS. 100µl were seeded per well in a 96well V-bottom plate. Plates were centrifuged and supernatant was removed. Then the pre-

incubated LAG-3:Fc fusion protein/ antibody mix (50µl/well) was added to the cells and incubated for 1h at room temperature. After this, cells were washed with 200µl FACS buffer. For detection of biotinylated Lag3:Fc protein bound to cellular MHCII, an APC-conjugated goat anti-Biotin antibody was used at 3µl/sample (Miltenyi Biotec, cat.no. #130-090-856) and

5 incubated for additional 10-15 mins. After staining, cells were again washed and then transferred in 150µl FACS buffer (PBS/2% FBS) to a U-bottom plate and analyzed on a FACS Canto-II using an HTS module.

Two anti-Lag3 antibodies (clones 25F7 and 26H10; Medarex) served as positive controls and a human IgG1 (Sigma, cat.no. #I5154) as appropriate isotype control. All antibodies were

10 used at 10µg/ml final concentration.

Results: Shown in the below table is the result of the FACS analysis demonstrating the percent inhibition of the Lag3 protein binding to MHC-II on cells (calculated as the reduced binding signal in reference to the maximal value in the absence of a blocking antibody).

Table 11: Binding of different anti-LAG3 Antibodies to (activated) cynomolgus PBMC/T cells expressing Lag3

aLAG3 antibody	% Inhibition
aLAG3(0403)	34.9
aLAG3(0414)	67.3
aLAG3(0411)	45.6
aLAG3(0416)	68.6
aLAG3(0417)	59.1
Reference MDX25F7	70.0
Reference MDX26H10	71.7
Isotype control	-2.9
No mAb	0.0

These data support a functional interplay with Lag3 and blockade of the cellular interaction of all tested antibodies.

Neutralizing potency of the novel anti-Lag3 antibodies in a standard LAG3 Blockade Bio/Reporterassay

To test the neutralizing potency of the novel anti-Lag3 antibodies in restoring a suppressed T cell response *in vitro*, a commercially available reporter system was used. This system consists of Lag3⁺ NFAT Jurkat effector cells (Promega, cat. no. #CS194801), MHC-II⁺ Raji cells

(ATCC, #CLL-86), and a super-antigen. In brief, the reporter system is based on three steps: (1) superantigen-induced NFAT cell activation, (2) inhibition of the activating signal mediated by the inhibiting interaction between MHCII (Raji cells) and Lag3⁺ NFAT Jurkat effector cells, and (3) recovery of the NFAT activation signal by Lag3-antagonistic/neutralizing aVH-Fc fusion constructs.

For this experiment, Raji and Lag-3⁺ Jurkat/NFAT-luc2 effector T cells were cultured as described by the provider. Serial dilutions (40pg/ml-50µg/ml) of several anti-Lag3 and reference antibodies were prepared in assay medium (RPMI 1640 (PAN Biotech, cat.no. #P04-18047), 1%FCS) in flat, white bottom 96-well culture plates (Costar, cat.no.#3917). 1x10⁵ Lag3⁺ NFAT-Jurkat cells/well) were added to the antibody solution. After this step, 2.5x10⁴ Raji cells/well were added to the Jurkat cell/antibody mix as well as 50ng/ml final concentration of the SED super- antigen (Toxin technology, cat.no. DT303). After an incubation of six hrs at 37°C and 5% CO₂, Bio-Glo substrate (Promega, #G7940) was warmed up to room temperature and 75 µl were added per well, incubated for 5-10 min before the overall luminescence was measured at a Tecan Infinite reader according to the kit's manufacturer's recommendation.

Shown in the table is the restoration of a MHCII/Lag3-mediated suppression of the NFAT luciferase signal by different anti-Lag3 antibodies upon SED stimulation (given as EC₅₀ values):

Table 12: Results with different anti-LAG3 Antibodies in the standard LAG3 Blockade Bio/Reporter assay

Anti-LAG3	EC ₅₀ [nM] in Jurkat LAG3 + SED + Raji		
	1st assay	2nd assay	3rd assay
Reference MDX25F7	7.8/5.9	8.6	n.t.
Reference BMS-986016	n.t.	9.6	n.t.
Reference humanized BAP050(LAG525)	n.t.	22.6	n.t.
Lag3 IgG-Fc	n.t.	no effect	n.t.
aLAG3(0411)	1.1	1.0	n.t.
aLAG3(0414)	1.1	1.0	1.8
aLAG3(0416)	3.1	2.5	3.5
aLAG3(0417)	1.0	n.t.	n.t.

n.t. molecules not tested in this experiment

Example 9**Functional Characterization of anti-LAG3 antibodies**

Table 13 summarizes the biological activity and effects of different anti-LAG3 antibodies (alone or in combination with anti-PD1 antibodies) in different assays as described herein.

5 Table 13: Summary of biological activity of different anti-LAG3 Antibodies (alone or in combination with anti-PD1 antibodies)

Assay type	Anti-Lag3 aLAG3 (0403)	Anti-Lag3 aLAG3 (0411)	Anti-Lag3 aLAG3 (0414)	Anti-Lag3 aLAG3 (0416)	Anti-Lag3 aLAG3 (0417)	Ref. 1 BMS 986016	Ref. 2 humanized BAP050 (LAG525)
mMLR (GrzB)	+	-	+++	++	+	-	++
mMLR (IL-2)	-	-	+	+	++	+	++
CD4+AR H77			+++	+++		+	+
Treg-suppression (GrzB)			+++	+		-	+
Treg-suppression (IFN- γ)			+++	++		+	+
Melanoma patient PBMCs			+++				

Effect of PD-1 and LAG-3 blockade on cytotoxic Granzyme B release and IL-2 secretion by human CD4 T cells cocultured with allogeneic mature dendritic cells

- 10 To screen anti-LAG-3 blocking antibodies in combination with anti-PD-1 in an allogeneic setting an assay was developed in which freshly purified CD4 T cells are cocultured for 5 days in presence of monocyte-derived allogeneic mature dendritic cells (mDCs). Monocytes were isolated from fresh PBMCs one week before through plastic adherence followed by the removal of the non-adherent cells. Immature DCs were then generated from the monocytes by culturing
- 15 them for 5 days in media containing GM-CSF (50 ng/ml) and IL-4 (100 ng/ml). To induce iDCs maturation, TNF-alpha, IL-1beta and IL-6 (50 ng/ml each) were added to the culturing media for

2 additional days. DCs maturation was then assessed by measuring their surface expression of Major Histocompatibility Complex Class II (MHCII), CD80, CD83 and CD86 thorough flow cytometry (LSRFortessa, BD Biosciences).

On the day of the minimal mixed lymphocyte reaction (mMLR), CD4 T cells were enriched via a microbead kit (Miltenyi Biotec) from 10^8 PBMCs obtained from an unrelated donor. Prior culture, CD4 T cells were labeled with $5\mu\text{M}$ of Carboxy-Fluorescein-Succinimidyl Esther (CFSE). 10^5 CD4 T cells were then plated in a 96 well plate together with mature allo-DCs (5:1) in presence or absence of blocking anti-PD-1 antibody aPD1(0376) (= PD1-0103-0312, as described herein before or in PCT Application PCT/EP2016/073248) alone or in combination with chimeric anti-LAG-3 antibodies (aLAG3(0403) to aLAG(0418)) or reference antibodies (humanized BAP050 (LAG525) and BMS 986016) at the concentration of $10\mu\text{g/ml}$. DP47 is a non-binding human IgG with a LALA mutation in the Fc portion to avoid recognition by Fc γ R and was used as negative control.

Five days later the cell-culture supernatants were collected and used to measure the IL-2 levels by ELISA (R&D systems), and the cells were left at 37°C for additional 5 hours in presence of Golgi Plug (Brefeldin A) and Golgi Stop (Monensin). The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). We performed intracellular staining for Granzyme B (BD Bioscience) and IFN- γ (eBioscience). Results are shown in **Figures 2A and 2B**.

Effect of PD-1 and LAG-3 blockade on cytotoxic Granzyme B release by human CD4 T cells cocultured with a B cell-lymphoblatoid cell line (ARH77).

In functional studies, CD4 T cells were co-cultured with the tumor cell line ARH77, a B cell lymphoblastoid cell line which expresses lower levels of PDL-1 than mDCs, to better characterize the contribution of LAG-3 antagonism to PD-1 blockade. The rest of the experimental set up and readout remained unchanged from the mMLR. The anti-LAG-3 antibodies (aLAG3(0414) and aLAG3(0416), chosen based on their ability to co-secrete IL-2 and Granzyme B in the mMLR) in combination with anti-PD-1 antibody caused a more significant increase in Granzyme B secretion by CD4 T cells than reference anti-LAG-3 antibodies ((humanized BAP050 (LAG525) and BMS 986016)) ($P<0.05$) and anti-PD-1 alone ($P<0.01$) as shown in **Figure 3**.

Effect of PD-1 and LAG-3 blockade on Treg suppression of Granzyme B and IFN- γ release by human CD4 T cells cocultured with irradiated allogeneic PBMCs.

In functional studies involving regulatory T cells (Treg)-suppression assays, PBMCs from the same donor were divided in two samples: one was enriched in CD4 T cells and the other
5 one in Tregs defined as CD4⁺CD25^{high} CD127^{low} T cells via a microbead kit (Miltenyi Biotec). Once purified the two populations, CD4 T cells were labelled with 5 μ M of Carboxy-Fluorescein-Succinimidyl Esther (CFSE) while Tregs with 5 μ M Cell-Trace-Violet (CTV) to be able to distinguish them at the FACS later on.

Both CD4 T cells (10⁵) and Tregs (10⁵) were then co-cultured in a 96 well plate at 1:1 ratio
10 together with irradiated, CD4-depleted PBMCs (10⁵) from an unrelated donor in presence or absence of anti-LAG-3 antibodies (aLAG3(0414) and aLAG3(0416) or reference anti-LAG-3 antibodies (humanized BAP050 (LAG525) and BMS 986016) in combination with anti-PD-1 antibody aPD1(0376) at the concentration of 10 μ g/ml. As control to estimate the magnitude of the suppression of CD4 T cell effector functions by Tregs, CD4 T cells (10⁵) were also co-
15 cultured with irradiated PBMCs (10⁵) in the absence of Tregs.

Five days later the cell-culture supernatants were collected and used later to measure IFN- γ levels by ELISA (R&D systems), and the cells were left at 37 °C for additional 5 hours in presence of Golgi Plug (Brefeldin A) and Golgi Stop (Monensin). The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua
20 (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). Intracellular staining was performed for Granzyme B (BD Bioscience) and IFN- γ (eBioscience). Results are shown in **Figures 4A and 4B**.

The anti-LAG-3 antibodies (aLAG3(0414) and aLAG3(0416), in combination with anti-PD-1 antibody aPD1(0376) (= PD1-0103-0312, from PCT Application PCT/EP2016/073248)
25 elicited Tconv escape from regulatory T cell tight control as demonstrated by the secretion of significantly higher amount of Granzyme B than Tconv in presence of anti-PD-1 alone ($P<0.05$) or in absence of checkpoint inhibitors ($P<0.001$). Reference anti-LAG-3 antibodies (humanized BAP050 (LAG525) and BMS 986016) in combination with anti-PD-1 did not significantly rescue Tconv effector functions from Treg suppression. Similar results were obtained for IFN- γ
30 even if the difference did not reach statistical significance with only 4 donors.

Effect of PD-1 and LAG-3 blockade on Granzyme B and IFN- γ secretion by CD4 T cells from melanoma patient PBMCs after recall with immunogenic melanoma-antigen peptide pools.

It has been previously described that melanoma patient PBMCs contain detectable frequencies of tumor-antigen specific T cells. Therefore, for POC purposes, we tested anti-LAG-3 antibody (0414) plus anti-PD-1 versus or anti-PD-1 alone on melanoma patient PBMCs re-stimulated overnight with immunogenic melanoma associated antigens peptide pools.

10^5 to 10^6 PBMCs from melanoma patients were incubated at room temperature in presence or absence of saturating concentrations (10 μ g/ml) of anti-PD-1 alone (0376), in combination with anti-LAG-3 (aLAG3(0414) = (0414), 10 μ g/ml) antibody. T cells were then re-stimulated over-night with a pool of immunogenic tumor related antigens like MAGEA1, MAGEA3, MAGEA4, Melan-A/MART-1, NYESO-1, Melanocyte protein Pmel 17 gp100, Tyrosinase, Tyrosinase-related protein 2 in presence of protein transport inhibitors Golgi Plug (Brefeldin A) and Golgi Stop (Monensin).

The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). Intracellular staining was performed for Granzyme B (BD Bioscience) and IFN- γ (eBioscience).

The combination of anti-LAG-3 and anti-PD-1 antibodies ($P < 0.01$ and $P < 0.001$) significantly ($P < 0.01$ and $P < 0.0001$) enhanced tumor-antigen specific T cell effector functions (i.e. Granzyme B and IFN- γ secretion) while PD-1 blockade alone did not show any effect (data not shown).

Example 10

Generation and Production of bispecific anti-PD1/anti-LAG3 antibodies

10.1 Production and expression of bispecific antibodies which bind to PD1 and LAG3 with VH/VL domain exchange/replacement (*CrossMab*^{Vh-VL}) in one binding arm and with single charged amino acid substitutions in the CH1/CL interface

Multispecific antibodies which bind to human PD1 and human LAG3 were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F or Expi293F cells as described above. The multispecific 1+1 *CrossMab*^{Vh-VL} antibodies are described also in WO 2009/080252. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid

sequences depicted in **Table 14**. A schematic structure of the 1+1 *CrossMab*^{Vh-Vl} bispecific antibodies is shown in Fig. 1A.

Table 14: Amino acid sequences of light chains (LC) and heavy chains (HC), with VH/VL domain exchange/replacement (1+1 *CrossMab*^{Vh-Vl})

1+1 Antibody	HC1	HC2	LC1	LC2
PD1/LAG3 0799 PD1(0376)/ aLAG3(0416)	SEQ ID NO:96	SEQ ID NO:97	SEQ ID NO:98	SEQ ID NO:99
PD1/LAG3 0927 PD1(0376)/ aLAG3(0414)	SEQ ID NO:96	SEQ ID NO:100	SEQ ID NO:98	SEQ ID NO:101
PD1/LAG3 0222 PD1(0069)/ aLAG3(25F7)	SEQ ID NO:102	SEQ ID NO:103	SEQ ID NO:104	SEQ ID NO:105
PD1/LAG3 0224 PD1(0098)/ aLAG3(25F7)	SEQ ID NO:106	SEQ ID NO:103	SEQ ID NO:107	SEQ ID NO:105

5

For all constructs knobs into holes heterodimerization technology was used with a typical knob (T366W) substitution in the first CH3 domain and the corresponding hole substitutions (T366S, L368A and Y410V) in the second CH3 domain (as well as two additional introduced cysteine residues S354C/Y349'C) (contained in the respective corresponding heavy chain (HC) sequences depicted above).

10

10.2 Production and expression of multispecific antibodies which bind to PD1 and LAG3 with CH1/Ck domain exchange/replacement (2+2 *CrossMab*^{CH1/Ck}) in two binding arms and with charged amino acid substitutions in the CH1/CL interfaces of the other

In this example multispecific antibodies which bind to human PD1 and human TIM3 were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F of Expi293F cells as described above. The multispecific 2+2 *CrossMab*^{CH1/Ck} antibodies are described also in WO 2010/145792. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 15**. A schematic structure of the 2+2 *CrossMab*^{CH1/Ck} bispecific antibodies is shown in Fig. 1A.

15

20

Table 15: Amino acid sequences of light chains (LC) and heavy chains (HC), with VH/VL domain exchange/replacement (2+2 *CrossMab*^{CH1/Ck})

2+2 Antibody	2x HC	2x LC1	2x LC2
PD1/LAG3 8970 PD1(0376)/ aLAG3(0414)	SEQ ID NO:114	SEQ ID NO:115	SEQ ID NO:101
PD1/LAG3 8984 PD1(0376)/ aLAG3(0416)	SEQ ID NO:116	SEQ ID NO:115	SEQ ID NO:99
PD1/LAG3 9010 PD1(0376)/ aLAG3(25F7)	SEQ ID NO:117	SEQ ID NO:115	SEQ ID NO:105

10.3 Production and expression of multispecific antibodies which bind to PD1 and LAG3

5 with CH1/Ck domain exchange/replacement (2+1 *CrossMab*^{CH1/Ck}) in one binding arm (PD1 crossFab fused to the C-terminus of the Fc knob heavy chain) and with charged amino acid substitutions in the CH1/CL interfaces of the other

10 In this example multispecific antibodies which bind to human PD1 and human TIM3 were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F of Expi293F cells as described above. Multispecific 2+1 *CrossMab*^{CH1/Ck} antibodies are described also in WO2013/026831. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 16**. A schematic structure of the 2+1 *CrossMab*^{CH1/Ck} bispecific antibodies is shown in Fig. 1B.

Table 16: Amino acid sequences of light chains (LC) and heavy chains (HC), with CH1/Ck domain exchange/replacement (2+1 *CrossMab*^{CH1/Ck})

2+1 Antibody	HC1	HC2	LC1	2x LC2
PD1/LAG3 8310 aLAG3(0414)/ PD1(0376)	SEQ ID NO:118	SEQ ID NO:119	SEQ ID NO:115	SEQ ID NO:101
PD1/LAG3 8311 aLAG3(0416)/ PD1(0376)	SEQ ID NO:120	SEQ ID NO:121	SEQ ID NO:115	SEQ ID NO:99
PD1/LAG3 1252 aLAG3(25F7)/ PD1(0376)	SEQ ID NO:122	SEQ ID NO:103	SEQ ID NO:115	SEQ ID NO:105

Alternatively, the PD1 crossFab fused to the C-terminus of the Fc knob heavy chain can be replaced by single chain Fab (scFab). Such multispecific 2+1 antibodies comprising a scFab are described also in WO2010/136172 and can be expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 17**. A schematic structure of the 2+1 bispecific antibodies with a scFab fused at the C-terminus of the Fc knob heavy chain is shown in Fig. 1C.

Table 17: Amino acid sequences of light chains (LC) and heavy chains (HC), with PD1 scFab

2+1 Antibody	HC1	HC2	2x LC
PD1/LAG3 8312 aLAG3(0414)/ PD1(0376)	SEQ ID NO:123	SEQ ID NO:119	SEQ ID NO:101
PD1/LAG3 8313 aLAG3(0416)/ PD1(0376)	SEQ ID NO:124	SEQ ID NO:121	SEQ ID NO:99
PD1/LAG3 1088 aLAG3(25F7)/ PD1(0376)	SEQ ID NO:125	SEQ ID NO:103	SEQ ID NO:105

10.4 Production and expression of multispecific antibodies which bind to PD1 and LAG3 with VH/VL fused each at a C-terminus of the heavy chains (2+1 PRIT format)

In this example multispecific antibodies which bind to human PD1 and human TIM3 were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F of Expi293F cells as described above. This type of multispecific 2+1 antibodies is also described in WO 2010/115589. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 18**. A schematic structure of the 2+1 PRIT-type bispecific antibodies is shown in Fig. 1D.

Table 18: Amino acid sequences of light chains (LC) and heavy chains (HC), with VH and VL domain fused C-terminally to heavy chains

2+1 Antibody	HC1	HC2	2x LC
PD1/LAG3 0918 aLAG3(25F7)/ aPD1(0376)	SEQ ID NO:126	SEQ ID NO:127	SEQ ID NO:109

10.5 Production and expression of multispecific antibodies which bind to PD1 and LAG3 with VH/VL domain exchange/replacement (1+1 *CrossMab*^{VH/VL} trans format) in one binding arm and with charged amino acid substitutions in the CH1/CL interfaces of the LAG3 Fab fused to the C-terminus of the Fc hole heavy chain

Multispecific antibodies which monovalently bind to both human PD1 and to human LAG3 were produced wherein a LAG3 Fab is fused via its variable heavy domain to the C-terminus of one of the heavy chains, preferably the Fc hole heavy chain. The molecules were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F of Expi293F cells as described above. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 19**. A schematic structure of the 1+1 *CrossMab*^{VH/VL} trans-type bispecific antibodies is shown in Fig. 1H.

Table 19: Amino acid sequences of light chains (LC) and heavy chains (HC), with aLAG3 Fab fused C-terminally to heavy chains

1+1 Antibody	HC1	HC2	LC1	LC2
PD1/LAG3 0725 aLAG3(0414)/ aPD1(0376)	SEQ ID NO:96	SEQ ID NO:144	SEQ ID NO:98	SEQ ID NO:101

10.6 Production and expression of multispecific antibodies which bind to PD1 and LAG3 with VH/VL domain exchange/replacement (2+1 *CrossMab*^{VH/VL} trans format) in one binding arm and with charged amino acid substitutions in the CH1/CL interfaces of the two LAG3 Fabs, one of them fused to the C-terminus of the Fc hole heavy chain

Multispecific antibodies which monovalently bind to human PD1 and bivalently bind to human LAG3 were produced wherein a LAG3 Fab is fused via its variable heavy domain to the C-terminus of one of the heavy chains, preferably the Fc hole heavy chain. The molecules were generated as described in the general methods section by classical molecular biology techniques and were expressed transiently in 293F of Expi293F cells as described above. The multispecific antibodies were expressed using expression plasmids containing the nucleic acids encoding the amino acid sequences depicted in **Table 20**. A schematic structure of the 2+1 *CrossMab*^{VH/VL} trans-type bispecific antibodies is shown in Fig. 1I.

Table 20: Amino acid sequences of light chains (LC) and heavy chains (HC), wherein one of the aLAG3 Fabs is fused C-terminally to heavy chains

1+1 Antibody	HC1	HC2	LC1	2 x LC2
PD1/LAG3 0750 aLAG3(0414)/ aPD1(0376)	SEQ ID NO:96	SEQ ID NO:145	SEQ ID NO:98	SEQ ID NO:101

10.7 Purification and characterization of multispecific antibodies which bind to PD1 and TIM3

The multispecific antibodies expressed above were purified from the supernatant by a combination of Protein A affinity chromatography and size exclusion chromatography. All multispecific antibodies can be produced in good yields and are stable. The obtained products were characterized for identity by mass spectrometry and analytical properties such as purity by SDS-PAGE, monomer content and stability

Mass spectrometry

The expected primary structures were analyzed by electrospray ionization mass spectrometry (ESI-MS) of the deglycosylated intact CrossMabs and deglycosylated/plasmin digested or alternatively deglycosylated/limited LysC digested CrossMabs.

- 5 The CH1/Ck CrossMabs were deglycosylated with N-Glycosidase F in a phosphate or Tris buffer at 37°C for up to 17 h at a protein concentration of 1 mg/ml. The plasmin or limited LysC (Roche) digestions were performed with 100 µg deglycosylated CH1/Ck CrossMabs in a Tris buffer pH 8 at room temperature for 120 hours and at 37°C for 40 min, respectively. Prior to mass spectrometry the samples were desalted via HPLC on a Sephadex G25 column (GE
10 Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).

Stability of multispecific antibodies

- In order to assess stability of the antibody constructs, thermal stability as well as aggregation onset temperatures are assessed according to the following procedure. Samples of
15 the indicated antibodies are prepared at a concentration of 1 mg/mL in 20 mM Histidine/Histidine chloride, 140 mM NaCl, pH 6.0, transferred into a 10 µL micro-cuvette array and static light scattering data as well as fluorescence data upon excitation with a 266 nm laser are recorded with an Optim1000 instrument (Avacta Inc.), while the samples are heated at a rate of 0.1 °C/min from 25°C to 90°C.
- 20 The aggregation onset temperature (T_{agg}) is defined as the temperature at which the scattered light intensity starts to increase. The melting temperature (T_m) is defined as the inflection point in a fluorescence intensity vs. wavelength graph.

Example 11

Characterization of bispecific anti-PD1/anti-LAG3 antibodies

25 **11.1 Binding Elisa**

ELISA for hu PD1

- Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 µl/well biotinylated PD1-ECD-AviHis at a concentration of 500 ng/ml and incubated at 4°C over night. After washing (3x90 µl/well with PBST-buffer) 25 µl anti PD1 antibody samples were
30 added in increasing concentrations and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat-anti-human H+L-POD (JIR, JIR109-036-098) was added in 1:5000

dilution and incubated at RT for 1 h on a shaker. After washing (3x90 µl/well with PBST-buffer) 25 µl/well of TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place at 370/492 nm.

Cell ELISA for human PD1

5 Adherent CHO-K1 cell line stably transfected with plasmid 15311_hPD1-fl_pUC_Neo coding for full-length human PD1 and selection with G418 (Neomycin resistance marker on plasmid) were seeded at a concentration of 0.01x10⁶ cells/well in 384-well flat bottom plates and grown over night.

The next day 25 µl/well PD1 sample or human anti PD1 (Roche)/mouse anti
 10 PD1(Biolegend; cat.:329912) reference antibody were added and incubated for 2h at 4°C (to avoid internalization). After washing carefully (1x90µl/well PBST) cells were fixed by adding 30µl/well 0,05% Glutaraldehyde (Sigma, Cat.No: G5882, 25%) diluted in 1xPBS-buffer and incubated for 10min at RT. After washing (3x90µl/well PBST) 25 µl/well secondary antibody was added for detection: goat-anti-human H+L-POD (JIR, JIR109-036-088)/Sheep-anti-mouse-
 15 POD (GE NA9310) followed by 1h incubation at RT on shaker. After washing (3x90µl/well PBST) 25 µl/well TMB substrate solution (Roche 11835033001) was added and incubated until OD 1.0 – 2.0. Plates were measured at 370/492 nm.

Cell ELISA results are listed as “EC₅₀ CHO-PD1”-values [nM] in Table 21 below.

ELISA for human Lag3

20 Nunc maxisorp plates (Nunc 464718) were coated with 25 µl/well recombinant Human LAG-3 Fc Chimera Protein (R&D Systems, 2319-L3) at a protein concentration of 800 ng/ml and incubated at 4°C overnight or for 1h at room temperature. After washing (3x90 µl/well with PBST-buffer) each well was incubated with 90 µl blocking buffer (PBS + 2% BSA + 0.05% Tween 20) for 1 h at room temperature. After washing (3x90 µl/well with PBST-buffer) 25 µl
 25 anti-Lag3 samples at a concentration of 1-9µg/ml (1:3 dilutions in OSEP buffer) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat anti-Human Ig κ chain antibody-HRP conjugate (Milipore, AP502P) was added in a 1:2000 dilution and incubated at RT for 1 h. After washing (3x90 µl/well with PBST-buffer) 25 µl/well TMB
 30 substrate (Roche, 11835033001) was added and incubated for 2-10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Cell-surface Lag3 binding ELISA

25 µl/well of Lag3 cells (recombinant CHO cells expressing Lag3, 10000 cells/well) were seeded into tissue culture treated 384-well plates (Corning, 3701) and incubated at 37°C for one

or two days. The next day after removal of medium, 25 μ l anti-Lag3 samples (1:3 dilutions in OSEP buffer, starting at a concentration of 6-40 nM) were added and incubated for 2h at 4°C. After washing (1 x 90 μ l in PBST) cells were fixed by addition of 30 μ l/well glutaraldehyde to a final concentration of 0,05% (Sigma Cat.No: G5882), 10 min at room temperature. After washing (3x90 μ l/well with PBST-buffer) 25 μ l/well goat anti-Human Ig κ chain antibody-HRP conjugate (Milipore, AP502P) was added in a 1:1000 dilution and incubated at RT for 1 h. After washing (3x90 μ l/well with PBST-buffer) 25 μ l/well TMB substrate (Roche, 11835033001) was added and incubated for 6- 10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm. Cell ELISA results are listed as “EC₅₀ CHO-LAG3”-values [nM] in Table 21 below.

Inhibition of LAG-3 binding to MHC-II expressed on human A375 tumor cells (by ELISA)

25 μ l/well of A375 cells (10000 cells/well) were seeded into tissue culture treated 384-well plates (Corning, 3701) and incubated at 37°C overnight. Anti-Lag3 antibodies were pre-incubated for 1h with biotinylated-Lag3 (250 ng/ml) in cell culture medium in 1:3 dilutions starting at 3 μ g/ml antibody-concentration. After removal of medium from the wells with the seeded cells, 25 μ l of the antibody-Lag3 pre-incubated mixtures were transferred to the wells and incubated for 2 h at 4°C. After washing (1 x 90 μ l in PBST) cells were fixed by addition of 30 μ l/well glutaraldehyde to a final concentration of 0,05% (Sigma Cat.No: G5882), 10 min at room temperature. After washing (3x90 μ l/well with PBST-buffer) 25 μ l/well Poly-HRP40-Streptavidin (Fitzgerald, 65R-S104PHRPx) was added in a 1:2000 or 1:8000 dilution and incubated at RT for 1 h. After washing (3x90 μ l/well with PBST-buffer) 25 μ l/well TMB substrate (Roche, 11835033001) was added and incubated for 2 to 10 min. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm. Inhibition ELISA results are listed as “IC₅₀ MHCII/ELISA”-values [nM] in Table 21 below.

Table 21: Summary of Binding of different bispecific anti-PD1/anti-LAG3 antibodies

Bispecific antibody	ELISA huPD1 rel. EC ₅₀ [nM]	ELISA huLAG3 rel. EC ₅₀ [nM]	EC ₅₀ CHO-PD1 rel. EC ₅₀ [nM]	EC ₅₀ CHO-LAG3 rel. EC ₅₀ [nM]	MHCII/ELISA IC ₅₀ [nM]
PD1/LAG3 0927 (PD1-0376/LAG3-0414) (1+1)	0.07	0.18	0.1	0.23	1.11
PD1/LAG3 0799 (PD1-0376/LAG3-0416) (1+1)	0.06	0.07	0.07	0.20	0.72
PD1/LAG3 0222 (PD1-0069/ LAG3 25F7) (1+1)	0.16	1.14	0.28	0.72	0.77

Bispecific antibody	ELISA huPD1 rel. EC ₅₀ [nM]	ELISA huLAG3 rel. EC ₅₀ [nM]	EC ₅₀ CHO- PD1 rel. EC ₅₀ [nM]	EC ₅₀ CHO- LAG3 rel. EC ₅₀ [nM]	MHCII/ ELISA IC ₅₀ [nM]
PD1/LAG3 0224 (PD1-0098/ LAG3 25F7) (1+1)	0.04	0.86	0.06	0.86	0.79
PD1/LAG3 8310 (PD1-0376/LAG3- 0414) (1+2)	0.06	0.06	0.34	0.20	0.47
PD1/LAG3 8311 (PD1-0376/LAG3- 0416) (1+2)	0.05	0.06	0.32	0.17	0.39
PD1/LAG3 1252 (PD1-0376/LAG3 25F7) (1+2)	0.03	0.02	0.31	0.64	0.47
PD1/LAG3 8970 (PD1-0376/LAG3- 0414) (2+2)	0.05	0.04	0.46	0.20	0.45
PD1/LAG3 8984 (PD1-0376/LAG3- 0416) (2+2)	0.05	0.05	0.54	0.17	0.44
PD1/LAG3 9010 (PD1-0376/LAG3- 25F7) (2+2)	0.04	0.05	0.36	0.48	0.52

11.2 Binding Biacore

Antigen binding properties of multispecific antibodies which bind to PD1 and LAG3

Binding of the multispecific antibodies to their respective target antigens, i.e. PD1 and
5 TIM3, was assessed by Biacore®.

PD1 binding can be assessed according to the following procedure:

Anti-human Fc IgG was immobilized by amine coupling to the surface of a (Biacore) CM5
sensor chip. The samples were then captured and hu PD1-ECD was bound to them. The sensor
chip surface was regenerated after each analysis cycle. The equilibrium constant and kinetic rate
10 constants were finally gained by fitting the data to a 1:1 Langmuir interaction model.

About 10,000 response units (RU) of 20 µg/ml anti-human IgG (GE Healthcare #BR-
1008-39) were coupled onto all flow cells of a CM5 sensor chip in a Biacore T200 using an
amine coupling kit supplied by GE Healthcare. The sample and running buffer was HBS-EP+
(0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05 % v/v Surfactant P20, pH 7.4). Flow cell

temperature was set to 25 °C and sample compartment temperature to 12 °C. The system was primed with running buffer.

Different samples were injected for 15 seconds with a concentration of 10 nM and consecutively bound to the flow cells 2, 3 and 4. Then a complete set of human PD1-ECD concentrations (300 nM, 100 nM, 2×33.3 nM, 11.1 nM, 3.7 nM, 1.2 nM and 2×0 nM) was injected over each sample for 300s followed by a dissociation time of 10/600s and two 30s regeneration steps with 3 M MgCl_2 , of which the last one contained an “extra wash after injection” with running buffer. Finally the double referenced data was fitted to a 1:1 Langmuir interaction model with the Biacore T200 Evaluation Software.

10 LAG3 binding was assessed according to the following procedure:

A Biacore SA CAP Kit provided by GE Healthcare was used to perform this assay. The kinetic values were obtained at 25°C in HBS-EP+ (GE Healthcare) buffer.

The SA CAP Chip was docked to a Biacore T200 as prescribed in the manual of the CAP Kit. The run method contains four commands. Firstly CAP reagent was injected for 300s at a flow rate of 10 $\mu\text{l}/\text{min}$ to hybridize the immobilized single stranded DNAs using a ‘General’ command. The command is followed by a 15 seconds long injection of a 1 $\mu\text{g}/\text{ml}$ dilution of biotinylated Fc-tagged, human Lag3 extra cellular domain in running buffer. This results in a capture level of about 50 RU. A single-cycle command was used to inject five different sample concentrations (100 nM – 6.25 nM, 2-fold dilutions) followed by a 1200 seconds long dissociation phase. The chip was then regenerated as prescribed in the SA CAP Kit manual.

Finally, the obtained curves were evaluated using the Biacore T200 Evaluation software version 3.0.

Results: The interactions did not fit to a 1:1 Langmuir binding model, because all samples aside from 0799 and 0927 have two Lag3 binding moieties and therefore show avidity. Since 0799 and 0927 contained a small miss-paired, bivalent sample population, they also showed some avidity.

Therefore the sensorgrams were only ranked according to their off rates. This was done by visual comparison of the single-cycle kinetic curves. By doing this, it was shown that the 0416-Lag3 ECD complex is more stable than any other in this sample set. The monovalent <Lag3> Crossmab format (0799) still displays a slower offrate than any other sample in this experiment.

Furthermore, it was seen that the affine Lag3-0414/Lag3-0927 – Lag3 ECD complex is the weakest of those, observed in this experiment. The affine binding portions of 0414 and 0416 are

roughly comparable to the affine portions of their monovalent Crossmab counter parts 0927 and 0799. Results are indicated in **Table 22**.

Table 22: Binding Quality of PD1-LAG3 Bispecific Antibodies determined by SPR measurement

Sample	Binding quality
aLAG3(0414)	++
aLAG3(0416)	+++
PD1/LAG3 0927 (1+1)	+
PD1/LAG3 0799 (1+1)	+++
aLAG3(25F7)	++
aLAG3(MDX26H10)	++
aLAG3(BMS986016)	++
aLAG3(BAP050)	+

5

Avidity assessment of the trans formats compared to the 1+1 bispecific antibodies 0927 and 0799:

The dissociation constants of the bispecific molecules (sample) and their individual targets as well as a combination of PD1 and LAG3 (analyte) were determined to assess the avidity gain provided by binding with all valences at the same time.

10

Previous to the measurement on a Biacore 8K, a CM5 sensor chip was prepared using the standard amine coupling kit provided by GE Healthcare. An in-house produced antibody directed against a specific mutation in the Fc part of the sample (i.e. an Fc part carrying the PGLALA mutations), herein called anti-PGLALA antibody (such antibodies are described in WO 2017/072210), was therefore diluted to a concentration of 50 µg/ml in acetate buffer pH 5.0. It was coupled to all flow cells and channels at a 8 µl/min flow speed over 1200s, yielding in a bound response of about 19000 RU.

15

HBS-EP⁺ buffer (GE HC) was used as running buffer for the sensor chip preparation as well as the main run itself. The analysis started after a startup consisting of three 17s long sample injections followed by a regeneration step utilizing a 10 mM NaOH solution. In a first step, the different samples were captured by the anti-PGLALA antibody onto the individual channels' flow-cell two on the sensor chip surface by injecting it for 17s at a flow rate of 10 µl/min. Secondly, one of the three analytes (PD1, LAG3-Fc, 2+2 PD1/LAG3-Fc Fusion) was injected into both flow-cells for 200s at a flow rate of 50 µl/min followed by a 1000s long (600s in case of the LAG3-Fc) dissociation phase. Finally, the anti-PGLALA antibody / sample complex was dissolved by two consecutive injections (30s long) of 10 mM NaOH. Each individual kinetic

20

25

determination consisted of four cycles with different analyte concentrations (0 nM, 5 nM, 25 nM and 100 nM).

The resulting data was evaluated using the Biacore 8K Evaluation Software. A 1:1 dissociation fit was applied and resulting k_d values were converted into complex half-life in minutes. The difference between the avidity binding of the PD1/Lag3-Fc fusion antigen binding molecule and its main individual contributor (either PD1 or Lag3) was calculated and sorted into one of three categories describing the stability gain by multivalent and bispecific binding (Table 23).

Table 23: Increase of Complex Stability provided by the avidity of PD1-LAG3 Bispecific Antibodies determined by SPR measurement

Sample	Binding quality
PD1/LAG3 0927 (1+1)	++
PD1/LAG3 0799 (1+1)	+++
PD1/LAG3 0725 (1+1 trans)	+
PD1/LAG3 0750 (1+2 trans)	++

11.3 Dimerization of cellular PD1 and LAG3 after simultaneous engagement via bispecific anti-PD1 / anti-LAG3 bispecific antibodies

Bispecific anti-PD1 / anti-LAG3 antibodies were generated in various formats as described in Example 10. This cellular assay was used to demonstrate the dimerization or at last binding/interaction of two different receptors, which are cytosolically fused with two fragments of an enzyme, upon ligation or cross-linking with a bispecific antibody against both targets. Hereby only one receptor alone shows no enzymatic activity. For this specific interaction, the cytosolic C-terminal ends of both receptors were individually fused to heterologous subunits of a reporter enzyme. A single enzyme subunit alone showed no reporter activity. However, simultaneous binding of an anti-PD1 / anti-LAG3 bispecific antibody construct to both receptors was expected to lead to local cytosolic accumulation of both receptors, complementation of the two heterologous enzyme subunits, and finally to result in the formation of a specific and functional enzyme that hydrolyzes a substrate thereby generating a chemiluminescent signal.

In order to analyze the cross-linking effect of the bispecific anti-PD1 / anti-LAG3 antibodies, 10,000 PD1⁺ LAG3⁺ human U2OS cells/well were seeded into white flat bottom 96-well plates (costar, cat.no. #3917) and cultured overnight in assay medium. On the next day cell medium was discarded and replaced by fresh medium. Antibody or ligand dilutions were prepared and titrated amounts of indicated (bispecific) antibodies were added and incubated at 37

°C for 2 hours. Next, a substrate/buffer mix (e.g. PathHunterFlash detection reagent) was added and again incubated for 1h. For measuring chemoluminescence induced upon simultaneous binding and dimerization a Tecan infinite reader was used.

The results are shown in **Figures 5A and 5B**. Plotted is the chemoluminescence (measured in RU) against the antibody concentration. Monospecific (bivalent) anti-LAG3 antibodies were not able to provoke a chemoluminescence signal whereas all bispecific anti-PD1 / anti-LAG3 antibodies induced a chemoluminescence signal in a concentration dependent manner.

To show the specificity of the simultaneous binding (and induction of a luminiscence signal) a competition experiment was performed: As shown before treatment with a bispecific antibody (1252) induced a luminiscence signal in a dose-dependent fashion (**Figure 5C**). If the same bispecific antibody was provided in the presence of either an aLAG3 antibody (0156, MDX25F7) or anti-PD1 antibody (0376), the signal was either almost inhibited (for PD1 competition) or at least significantly reduced (LAG3). Both parental antibodies are the same binders as comprised in the bispecific antibody (1252, 2+1 LAG3/PD1-format). The competing antibodies were given each at a constant concentration of 20 µg/ml.

The results of a further experiment are shown in **Figure 5D**. Similar to the previous competition experiment the incubation with parental aLAG3 (0156) or PD1 antibodies (0376; each constantly at 10µg/ml) had an effect on the binding properties of the bispecific antibody (1252, 2+1 format of the bispecific aLAG3-0156 and PD1-0376) to PD1 Lag3 double-expressing cells, as measured by the luminiscence signal. Competition with anti-PD1 antibody (0376) and also recombinant LAG3:Fc protein (0160) almost abolished the signal, whereas presence of the single aLAG3 binder (0156) only led to partial inhibition. The two further anti-LAG3 antibodies 0414 and 0416, which are binding to a different epitope than 0156, did not compete for binding with the bispecific antibody comprising aLAG3 binder (0156), because they did not modulate the signal significantly.

In a further experiment, the simultaneous binding of bispecific anti-LAG3/anti-PD1 antibodies comprising different aLAG3 binder (0414 vs. 0416) and different formats (1+1 vs. 2+1) was compared (**Figures 6A to 6D**). As described before, several anti-LAG3/anti-PD1 bispecific antibodies were tested, either in an 1+1 CrossMab format (0799 and 0927) or 2+1 format (two Lag3 binding arms and one PD1 crossFab fragment fused C-terminal: 8311 and 8310). In Figures 6A and 6B the curves (absorbance vs. concentration) for the constructs with binder aLAG3-0416 and in Figures 6C and 6D those for the corresponding constructs with aLAG4-0414 are shown. All constructs tested were able to bind to the cells and to induce chemoluminescence. The calculated EC₅₀ values for the binding curves are shown in Table 24 below.

Table 24: EC₅₀ values as measured in the dimerization binding assay

Bispecific Antibody	Format	MW [kD]	EC ₅₀ [pM]
0927 (PD1-0376/LAG3-0414)	1+1	145	41
0799 (PD1-0376/LAG3-0416)	1+1	145	76
8310 (PD1-0376/LAG3-0414)	1+2	193	28
8311 (PD1-0376/LAG3-0416)	1+2	193	119

In another experiment, the simultaneous binding of bispecific anti-LAG3/anti-PD1 antibodies comprising different aLAG3 binder (0414 vs. 0416) and different formats (2+1 vs. 2+2) was compared (**Figures 7A to 7D**). Anti-LAG3/anti-PD1 bispecific antibodies were tested, either in or 2+1 format (two LAG3 binding arms and one PD1 crossFab fragment fused C-terminal: 8311 and 8310) or in 2+2 crossmab format (two LAG3 binding arms and two PD1 crossFab fragments fused C-terminal: 8970 and 8984). In Figures 7A and 7B the curves (absorbance vs. concentration) for the constructs with binder aLAG3-0414 and in Figures 7C and 7D those for the corresponding constructs with aLAG4-0416 are shown. All constructs tested were able to bind to the cells and to induce chemoluminescence. The calculated EC₅₀ values for the binding curves are shown in Table 25 below.

Table 25: EC₅₀ values as measured in the dimerization binding assay

Bispecific Antibody	Format	MW [kD]	EC ₅₀ [pM]
8310 (PD1-0376/LAG3-0414)	2+1	193	114
8311 (PD1-0376/LAG3-0416)	2+1	193	124
8970 (PD1-376/LAG3-0414)	2+2	242	83
8984 (PD1-0376/LAG3-0416)	2+2	242	91

In a further experiment, the simultaneous binding of bispecific anti-LAG3/anti-PD1 antibody PD1/LAG3 0927 in the classical 1+1 *CrossMab*^{V_H-V_L} format was compared with the bispecific anti-LAG3/anti-PD1 antibodies in the 1+1 trans format (PD1/LAG3 0725) and 2+1 trans format (PD1/LAG3 0750) For this experiment, the following changes to the method were

applied. In order to analyze the cross-linking effect of the different anti-LAG3/anti-PD1 antibody formats, 7500 PD1⁺ LAG3⁺ human U2OS cells/well were seeded into white flat bottom 96-well plates together with non-serial dilutions of antibodies (final concentration of 0.29 pM to 5484 pM) and were incubated for 20h at 37 °C in a CO₂ incubator. Next, assay plates were
5 equilibrated to room temperature and a substrate/buffer mix (PathHunterFlash detection reagent, Discoverx) was added and again incubated for 4h. For measuring chemoluminescence induced upon simultaneous binding and dimerization a SpectraMax L plate reader (Molecular Devices) was used.

In **Figure 7E** the dose-response curves (luminescence vs. concentration) of the PD1-LAG3
10 bispecific antibodies 1+1 CrossMab (0927), 1+1 trans CrossMab with N-terminal aPD1 and C-terminal aLAG3 (0725) as well as 2+1 trans CrossMab with N-terminal aPD1 and N-plus C-terminal aLAG3 (0750) are depicted. Compared to PD1/LAG3 0927 the PD1 LAG3 receptor crosslinking effect of PD1/LAG3 0725 is clearly higher whereas it is slightly lower for PD1/LAG3 0750.

15 **11.4 Measurement of bispecific anti-LAG3/anti-PD1 trans CrossMab variants in a PD-1 & LAG-3 combo Reporter Assay**

To test the neutralizing potency of the different anti-PD1-LAG3 antibody formats in restoring a suppressed T cell response *in vitro*, a commercially available reporter system was used. The PD1 & LAG3 combo bioassay consists of PD1-, LAG3- and T cell receptor (TCR)-
20 expressing reporter cells, MHC-II- and PDL1-expressing tumor cells and a TCR-activating-antigen.

The effector cells are Jurkat T cells expressing human PD1, human LAG3, a human TCR and a luciferase reporter driven by an NFAT response element (NFAT-RE). The target cells are A375 cells expressing human PD-L1. In brief, the reporter system is based on three steps: (1)
25 TCR activating-antigen-induced NFAT cell activation, (2) inhibition of the activating signal mediated by the interaction between MHCII (A375 cells) and LAG3⁺ (Jurkat cells) as well as PD-L1 (A375 cells) and PD1 (Jurkat cells), and (3) recovery of the NFAT activation signal by PD1 and LAG3-antagonistic/neutralizing antibodies.

For this experiment, 1 x 10⁴ A375 target cells per well were incubated overnight with TCR
30 activating antigen (Promega) in 96-well flat bottom assay plates in a CO₂ incubator at 37 °C. Next, media from plates was removed and serial dilutions (final assay concentration of 0.01 nM to 857 nM) of anti-LAG3/anti-PD1 antibodies as well as 5 x 10⁴ Jurkat effector cells per well were added. After 6 hours of incubation at 37°C in a CO₂ incubator, assay plates were equilibrated to room temperature and 80 µl ONE-Glo Ex substrate (Promega) was added to each
35 well. After 10 min of incubation luminescence was measured in a SpectraMax L plate reader

(Molecular Devices). Simultaneous binding of an anti-PD1/anti-LAG3 bispecific antibody construct to both receptors was expected to lead to local cytosolic accumulation of both receptors, complementation of the two heterologous enzyme subunits, and finally to result in the formation of a specific and functional enzyme that hydrolyzes a substrate thereby generating a chemiluminescent signal. In **Figure 7F** the dose-response curves (luminescence vs. concentration) of the anti-PD1/anti-LAG3 bispecific antibodies 1+1 CrossMab (0927), 1+1 trans CrossMab with N-terminal aPD1 and C-terminal aLAG3 (0725) as well as 2+1 trans CrossMab with N-terminal aPD1 and N- plus C-terminal aLAG3 (0750) are depicted. The ability of 0927 and 0725 to recover reporter cell activation by blocking PD1 and LAG3 interaction with their respective ligands is comparable whereas it is higher for 0750. This is furthermore indicated by the EC₅₀ values listed in Table 26.

Table 26: EC₅₀ values as measured in the PD-1 & LAG-3 combo reporter assay

Bispecific Antibody	Format	MW [kD]	EC ₅₀ [nM]
PD1/LAG3 0927	1+1 cis	145259	3.1
PD1/LAG3 0725	1+1 trans	145890	2.2
PD1/LAG3 0750	2+1 trans	192888	0.6

Example 12

Functional Characterization of bispecific anti-PD1/anti-LAG3 antibodies

12.1 Reduced Internalization upon binding to T-cell surface

Measurement of receptor internalization by flow cytometry

Receptor internalization represents an important sink for the molecule which can be degraded within few hours while the targeted receptors are rapidly re-expressed on the cell-surface ready to inhibit TCR-signalling. We therefore assessed receptor internalization upon the binding of our constructs by flow cytometry where samples stained with different bispecific formats at 4°C were used as reference for comparison with samples incubated at 37°C for 3 hours after the staining at 4°C.

Three days polyclonally activated CD4 T cells, previously cultured with 1 µg/ml of plate bound anti-CD3 and 1 µg/ml of soluble anti-CD28 antibodies, were incubated in presence of either anti-LAG3 or anti-PD1/anti-LAG3 bispecific antibodies (in duplicates) for 30 minutes at

4°C. The cells were then washed, divided in two groups, one of which incubated for 3 additional hours at 37°C and the other one was immediately stained with a labelled secondary antibody (eBioscience) before being fixed with BD Cell Fix. After the 3 hours incubations also the second group of the cells were stained with the labelled secondary antibody before fixation. After staining, cells were washed two times with PBS/2% FCS before acquisition.

The cells were acquired at LSRFortessa (BD Biosciences) and the expression levels of detectable antibody on the cell surface were compared among the two groups. The results are shown in **Figure 8B**. We observed that after 3 hours all the bispecific formats as well as the monospecific bivalent aLAG-3 antibody have been internalized, however the bispecific anti-PD1/anti-LAG3 antibodies in the 1+1 format (PD1/LAG3 0799 and PD1/LAG3 0927) were the least internalized.

Visualization of antibody localization and internalization by Fluorescence Confocal Microscopy

Activated CD4-positive cells were stained with CMFDA (Invitrogen) and plated on round coverslips treated with Retronectin (Takara Bio). Cells were allowed 4 hours to adhere at 37°C before fluorescently-tagged antibodies (1 µg/mL: a-LAG3 (1256), 1+1 PD1/LAG3 Bispec (0927), PD1-LAG3 1+2 Bispec (8310) and PD1-LAG3 2+2 Bispec (8970) labeled with Alexa 647) were added directly into growth media for different durations (15 min, 1 hour and 3 hours). Cold PBS (Lonza) was used to quench the reaction and to wash off unbounded antibodies. Cells were then fixed with Cytifix (BD) for 20 minutes at 4°C and washed twice with PBS (Lonza). Coverslips were then transferred and mounted on glass slides with Fluoromount G (eBioscience) and kept in the dark at 4°C overnight before imaging. A) The fluorescent images are shown in **Figure 9A**. The white signal represents the localization of the labeled antibody. B) The intensity of the fluorescent signal from the membrane ROI, of highly targeted cells, was divided by the intensity of the fluorescent signal from the cytoplasm ROI of the same cells, resulting in a ratio displayed in the Box Charts. In order to compare samples, One Way ANOVA analysis Uncorrected Fisher's LSD was used (* = $p < 0.05$; ** = $p < 0.01$). The results are shown in **Figure 9B**. The analysis over time shows higher membrane localization in the bispecific antibodies and LAG3 antibodies when compared to intracellular clustering of TIM3 antibodies (used as control). We observed that after 3 hours all the bispecific formats as well as the monospecific bivalent aLAG-3 antibody have been internalized with the only exception of the 1+1 PD1/LAG3 Bispec (0927) (Figure 9A).

Fluorescence confocal microscopy was performed with an inverted LSM 700 from Zeiss with a 60x oil objective. Images were collected using Zen software (Zeiss) coupled to the microscope. The analysis of the images was performed with Imaris Software (Bitplane; Oxford Instrument) and the statistical analysis was performed by GraphPad Prism (Graphpad Software).

12.2 Binding to conventional T cells versus Tregs

A desired property of the lead PD1-LAG3 BsAb is the ability to preferentially bind to conventional T cells rather than to Tregs, because LAG3 on Tregs appears to negatively regulate their suppressive function. Therefore targeting LAG3 on Tregs with blocking antibodies could be detrimental by increasing their suppressive function and eventually mask the positive blocking effect on other T cells. We therefore assessed the competitive binding of the different anti-PD1/anti-LAG3 bispecific antibody formats to activated conventional and regulatory T cells cultured together.

Regulatory T cells (Tregs) and conventional T cells (Tconv) were sorted from healthy donor PBMCs (Miltenyi), labelled with 5mM CellTraceViolet or CFSE membrane dyes respectively and cultured together at 1:1 ratio for 3 days with 1 µg/ml of plate bound anti-CD3 and 1 µg/ml of soluble anti-CD28 antibodies. On day 3 the cells were incubated for 30 min at 4°C with either directly labelled anti-PD1, anti-LAG3 or bispecific antibodies, fixed with BD Cell Fix, and acquired at LSRFortessa (BD Biosciences).

While the monospecific anti-LAG3 parental antibody binds equally well to Tregs and conventional T cells (**Fig. 10A**), the anti-PD1 counterpart binds preferentially to conventional T cells due to higher expression levels of PD1 on effector T cells than on Tregs (**Fig. 10B**). Interestingly, also the 1+1 format of the PD1/LAG3 bispecific antibody (0927) retained the ability to preferentially bind to conventional T cells than Tregs (**Fig. 10C**). This preferential binding to conventional T cells can also be visualized by depicting the difference (delta) of the signal on conventional T cells versus the one on Tregs (**Fig. 10D**). The 2+1 and the 2+2 formats did not show an avidity driven selectivity for effector T cells and are comparable in their binding to monospecific anti-LAG3 antibody.

12.3 Effect of PD-1 and LAG-3 blockade on Treg suppression of Granzyme B and IFN-γ release by human CD4 T cells cocultured with irradiated allogeneic PBMCs

It was further tested whether the differences in binding property of the bispecific antibody formats would provide any functional advantage to Tconv over Tregs. In functional studies involving regulatory T cells (Treg)-suppression assays, PBMCs from the same donor were divided in two samples: one was enriched in CD4 T cells and the other one in Tregs defined as CD4⁺CD25^{high}CD127^{low} T cells via a microbead kit (Miltenyi Biotec). Once the two populations were purified, CD4 T cells were labelled with 5 µM of Carboxy-Fluorescein-Succinimidyl Esther (CFSE) while Tregs were labelled with 5 µM Cell-Trace-Violet (CTV) to be able to distinguish them at the FACS later on.

Both CD4 T cells (10^5) and Tregs (10^5) were then co-cultured in a 96 well plate at 1:1 ratio together with irradiated PBMCs (10^5) from an unrelated donor in presence or absence of our anti-LAG3 antibodies (lead 0414 and backup 0416) or competitor anti-LAG3 antibodies (BMS-986016 and humanized BAP050) in combination with our anti-PD1 antibody at the

5 concentration of 10 μ g/ml. As control to estimate the magnitude of the suppression of CD4 T cell effector functions by Tregs, CD4 T cells (10^5) were also co-cultured with irradiated PBMCs (10^5) in the absence of Tregs.

Five days later we collected the cell-culture supernatants, used later to measure IFN γ levels by ELISA (R&D systems), and left the cells at 37°C for additional 5 hours in presence of Golgi

10 Plug (Brefeldin A) and Golgi Stop (Monensin). The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). We performed intracellular staining for Granzyme B (BD Bioscience) and IFN γ (eBioscience). Results are shown in **Figure 11**.

15 Our PD1/LAG-3 bispecific antibody (0927) elicited Tconv escape from regulatory T cell tight control as demonstrated by the secretion of significantly higher amount of Granzyme B than Tconv in presence of parental anti-PD1 antibody or Pembrolizumab alone ($P < 0.05$) or in absence of checkpoint inhibitors ($P < 0.001$). Competitor anti-LAG3 antibody BMS-986016 in combination with Nivolumab did not significantly rescue Tconv effector functions from Treg

20 suppression.

12.4 Effect of PD-1/LAG-3 Bispecific antibodies on cytotoxic Granzyme B release by human CD4 T cells cocultured with a B cell-lymphoblatoid cell line (ARH77)

We assessed the ability of our different bispecific antibody formats to induce Granzyme B secretion by CD4 T cells, when co-cultured with the tumor cell line ARH77, in comparison to

25 the combination of anti-PD-1 and anti-LAG-3 parental antibodies and to anti-PD1 antibodies used in standard of care.

In total 6 formats were tested, 3 generated from the combination of anti-PD1(0376) and anti-LAG3 (hu 1256, chi 0414) antibodies and 3 additional formats from anti-PD1(0376) and anti-LAG-3 (hu1257, chi 0416) antibodies.

30 As can be seen in **Figure 13**, two bispecific formats, 1+1 (0927) and 2+2 (8970) generated from anti-LAG3 (hu 1256, anti-LAG3 0414 as IgG1 PGLALA) and anti-PD1(0376) and as well as the combination of the parental antibodies significantly enhanced Granzyme B secretion by CD4 T cells when compared to untreated CD4 T cells ($P = 0.0005$, $P = 0.01$ and $P = 0.0001$

respectively). The corresponding 2+1 format (8310) showed a similar trend, however it did not reach statistical significance ($P=0.07$).

Regarding the bispecific antibodies generated by combining anti-LAG-3 (hu 1257, anti-LAG3 0416 as IgG1 PGLALA) with anti-PD1(0376), the 1+1 format (0799) and 2+2 (8984) significantly increased the frequencies of Granzyme B positive CD4 T cells when compared to untreated CD4 cells ($P = 0.0032$ and $P = 0.0064$ respectively).

Neither Nivolumab nor Pembrolizumab did significantly promote a higher Granzyme B secretion by CD4 T cells when compared to cells cultured in the absence of checkpoint inhibitors. (Figure 13).

Table 27: Effect of tested PD1-LAG3 bispecific antibodies on cytotoxic Granzyme B release

Sample	Effect
PD1/LAG3 0927 (1+1)	+++
PD1/LAG3 8970 (2+2)	+
PD1/LAG3 8310 (1+2)	+/-
PD1/LAG3 0799 (1+1)	++
PD1/LAG3 8984 (2+2)	++
PD1/LAG3 8311 (1+2)	+/-
aLAG3(BMS986016)	++

12.5 Effect of PD-1 and LAG-3 blockade on Granzyme B and IFN- γ secretion by CD4 T cells from melanoma patient PBMCs after recall with immunogenic melanoma-antigen peptide pools

It has been previously described that melanoma patient PBMCs contain detectable frequencies of tumor-antigen specific T cells. Therefore, for proof of concept purposes, the combination of anti-LAG-3 antibody (0414) plus anti-PD-1(0376) versus the derived bispecific antibody in 1+1 (0927) format or anti-PD-1 alone were tested on melanoma patient PBMCs re-stimulated overnight with immunogenic melanoma associated antigens peptide pools.

10^5 to 10^6 PBMCs from melanoma patients where incubated at room temperature in presence or absence of saturating concentrations (10 $\mu\text{g/ml}$) of anti-PD-1 alone (0376), in combination with anti-LAG-3 (0414, 10 $\mu\text{g/ml}$) antibody or as bispecific 1+1 format (0927, 20 $\mu\text{g/ml}$) antibody. T cells were then re-stimulated over-night with a pool of immunogenic tumor related antigens like MAGEA1, MAGEA3, MAGEA4, Melan-A/MART-1, NYESO-1, Melanocyte protein Pmel 17 gp100, Tyrosinase, Tyrosinase-related protein 2 in presence of protein transport inhibitors Golgi Plug (Brefeldin A) and Golgi Stop (Monensin).

The cells were then washed, stained on the surface with anti-human CD4 antibody and the Live/Dead fixable dye Aqua (Invitrogen) before being fixed/permeabilized with Fix/Perm Buffer (BD Bioscience). Intracellular staining was performed for Granzyme B (BD Bioscience) and IFN- γ (eBioscience).

- 5 Both the combination of anti-LAG-3 and anti-PD-1 antibodies ($P<0.01$ and $P<0.001$) and the bispecific antibody significantly ($P<0.01$ and $P<0.0001$) enhanced tumor-antigen specific T cell effector functions (i.e. Granzyme B and IFN- γ secretion) while PD-1 blockade alone did not show any effect (**Figure 12**).

10

Example 13

Potent anti-tumor effect by combination therapy of PD1/LAG3 bispecific antibodies and CEACAM5 CD3 TCB *in vivo*

- TCB molecules have been prepared according to the methods described in WO 2014/131712 A1 or WO 2016/079076 A1. The preparation of the anti-CEA/anti-CD3 bispecific
15 antibody (CEA CD3 TCB or CEA TCB) used in the experiments is described in Example 3 of WO 2014/131712 A1. CEA CD3 TCB is a “2+1 IgG CrossFab” antibody and is comprised of two different heavy chains and two different light chains. Point mutations in the CH3 domain (“knobs into holes”) were introduced to promote the assembly of the two different heavy chains. Exchange of the VH and VL domains in the CD3 binding Fab were made in order to promote the
20 correct assembly of the two different light chains. 2 +1 means that the molecule has two antigen binding domains specific for CEA and one antigen binding domain specific for CD3. CEA CD3 TCB comprises the amino acid sequences of SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148 and SEQ ID NO:149. CEACAM5 CD3 TCB has the same format, but comprises another CEA binder and comprises point mutations in the CH and CL domains of the CD3
25 binder in order to support correct pairing of the light chains. CEACAM5 CD TCB comprises the amino acid sequences of SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152 and SEQ ID NO:153.

a) Experimental Material and Methods

- 30 The PD1/LAG3 bispecific antibody 0927 was tested in a concentration of 1.5 mg/kg or 3 mg/kg in combination with the human CEACAM5 CD3 TCB in a human pancreatic BXPC3 cancer model. BXPC3 cells were corafted subcutaneously with a mouse fibroblast cell line (3T3) in NSG humanized mice.

Preparation of BXPC3 cell line: BXPC3 cells (human pancreatic cancer cells) were originally obtained from ECACC (European Collection of Cell Culture) and after expansion deposited in the Glycart internal cell bank. BXPC3 cells were cultured in RPMI containing 10% FCS (PAA Laboratories, Austria), 1% Glutamax. The cells were cultured at 37 °C in a water-saturated atmosphere at 5 % CO₂.

Production of fully humanized mice: Female NSG mice, age 4-5 weeks at start of the experiment (Jackson Laboratory), were maintained under specific-pathogen-free condition with daily cycles of 12 h light / 12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). The experimental study protocol was reviewed and approved by local government (P 2011/128). After arrival, animals were maintained for one week to get accustomed to the new environment and for observation. Continuous health monitoring was carried out on a regular basis. The NSG mice were injected i.p. with 15 mg/kg of Busulfan followed one day later by an i.v. injection of 1x10⁵ human hematopoietic stem cells isolated from cord blood. At week 14-16 after stem cell injection mice were bled sublingual and blood was analyzed by flow cytometry for successful humanization. Efficiently engrafted mice were randomized according to their human T cell frequencies into the different treatment groups.

Efficacy Experiment: Fully humanized HSC-NSG mice were challenged subcutaneously with 1 x 10⁶ BXPC3 cells (human pancreatic carcinoma cell line, expressing CEACAM5) at day 0 in the presence of matrigel at 1:1 ratio. Tumors were measured 2 to 3 times per week during the whole experiment by Caliper. At day 15 mice were randomized for tumor size with an average tumor size of 250 mm³ and a weekly scheduled therapy (vehicle (histidine buffer), anti-PD1(0376), Nivolumab, Pembrolizumab or anti PD1-LAG3 0927) started and was given by intra-peritoneal injection in 400 µl max. Tumor growth was measured 2-3 times weekly using a caliper and tumor volume was calculated as followed:

$$T_v: (W^2/2) \times L \quad (W: \text{Width}, L: \text{Length})$$

The study was terminated at day 47.

b) Results

The measurements of tumor volumes (mm³ +/- SEM), over a period of 47 days, are shown as mean volume within the respective treatment group of mice in **Figure 14**. Treatment with CEACAM5-TCB only shows a disease progression identical to the untreated vehicle group. Conversely, Nivolumab and Pembrolizumab reduced the tumor growth, however, without reaching tumor-growth control. Surprisingly, PD1/LAG3 bispecific antibody 0927, at the concentration of 3 mg/Kg, fully suppressed tumor growth in all treated animals showing synergism of the LAG-3 co-blockade in addition to PD-1.

In **Figures 15A to 15F** the measurements of tumor volumes ($\text{mm}^3 \pm \text{SEM}$), over a period of 47 days, are shown for each individual animal showing the homogeneity of the anti-tumor response in each group.

The statistical significance was calculated by using the Dunnett's Method against the CEACAM5 CD3 TCB single treatment. To test for significant differences in group means for multiple comparisons, the standard analysis of variance (ANOVA) is automatically produced, using the Dunnett's method. Dunnett's method tests whether means are different from the mean of a control group.

The resulting TGI and TCR values are shown in **Table 28** (TGI means tumor growth inhibition, $\text{TGI} > 100$ means tumor regression and $\text{TGI} = 100$ is defined as tumor stasis, TCR means treatment to control ratio, $\text{TCR} = 1$ means no effect and $\text{TCR} = 0$ is defined as complete regression).

Table 28: Tumor growth inhibition (TGI) and Treatment to control ration (TCR) on day 46

Group (Day 46 reference CEACAM5-TCB)	TGI	TCR	p-value
CEACAM5 CD3 TCB 2.5 mg/kg + anti-PD1/LAG3 0927 1.5 mg/kg	93.06119	0.207878	0.0056
CEACAM5 CD3 TCB 2.5 mg/kg + anti-PD1/LAG3 0927 3 mg/kg	79.22326	0.006863	0.005
CEACAM5 CD3 TCB 2.5 mg/kg + Nivolumab 1.5 mg/kg	32.9787	0.668563	0.513
CEACAM5 CD3 TCB 2.5 mg/kg + Pembrolizumab 1.5 mg/kg	55.33328	0.437398	0.07

The comparison with the control is further shown as p-values using Dunnett's method.

The treatment with CEACAM5 CD3 TCB cannot control tumor growth in the context of pancreatic cancer. However, its combination with the bi-specific antibody anti-PD1/LAG3 0927, lead to a strong impact on tumor control in a dose specific manner. The statistical analysis showed that the combination with anti-PD1/LAG3 0927, but not with the anti-PD1 antibodies Nivolumab and Pembrolizumab, at both concentration resulted in statistical significant difference

-178-

in control of tumor growth when compared to single treatment, suggesting the superiority of the bi-specific anti-PD1/LAG3 antibody over inhibition of only PD1, bringing the tumor growth to stasis.

Claims

1. A bispecific antibody comprising a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein the bispecific antibody is bivalent and comprises
 - an Fc domain,
 - a first Fab fragment comprising said first antigen binding domain specifically binding to PD1 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 9 and a VL domain comprising the amino acid sequence of SEQ ID NO: 10, and
 - a second Fab fragment comprising the second antigen binding domain specifically binding to LAG3 comprising a VH domain comprising the amino acid sequence of SEQ ID NO: 20 and a VL domain comprising the amino acid sequence of SEQ ID NO: 21.
2. The bispecific antibody of claim 1, wherein the bispecific antibody comprises a Fc domain that is an IgG, optionally an IgG1 Fc domain or an IgG4 Fc domain, and wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor, optionally an Fcγ receptor.
3. The bispecific antibody of claim 1 or 2, wherein the bispecific antibody comprises an Fc domain of human IgG1 subclass with the amino acid mutations L234A, L235A and P329G (numbering according to Kabat EU index).
4. The bispecific antibody of any one of claims 1 to 3, wherein the bispecific antibody comprises an Fc domain comprising a modification promoting the association of the first and second subunit of the Fc domain.
5. The bispecific antibody of any one of claims 1 to 4, wherein the first subunit of the Fc domain comprises the amino acid substitutions S354C and T366W (numbering according to Kabat EU index) and the second subunit of the Fc domain comprises the amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).
6. The bispecific antibody of any one of claims 1 to 5, wherein in one of the Fab fragments the variable domains VL and VH are replaced by each other so that the VH domain is part of the light chain and the VL domain is part of the heavy chain.

7. The bispecific antibody of claim 5 or 6, wherein in the first Fab fragment comprising the antigen binding domain that specifically binds to PD1 the variable domains VL and VH are replaced by each other.
8. The bispecific antibody of any one of claims 1 to 7, wherein the bispecific antibody comprises a Fab fragment wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).
9. The bispecific antibody of any one of claims 6 to 8, wherein in the second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat EU Index), and in the constant domain CH1 the amino acids at positions 147 and 213 are substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).
10. The bispecific antibody of any one of claims 1 to 9, comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 100, and a second light chain comprising an amino acid sequence of SEQ ID NO:101.
11. The bispecific antibody of any one of claims 1 to 9, wherein the bispecific antibody comprises a second Fab fragment comprising the antigen binding domain that specifically binds to LAG3 which is fused to the C-terminus of the Fc domain.
12. The bispecific antibody of any one of claims 1 to 9 or 11, comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO: 96, a first light chain comprising an amino acid sequence of SEQ ID NO: 98, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 144, and a second light chain comprising an amino acid sequence of SEQ ID NO:101.
13. A polynucleotide encoding the bispecific antibody of any one of claims 1 to 12.
14. A prokaryotic or eukaryotic host cell comprising the polynucleotide of claim 13.

15. A method of producing the bispecific antibody of any one of claims 1 to 12, comprising culturing the host cell of claim 14 under conditions suitable for expression of the bispecific antibody and recovering the bispecific antibody from the culture.
16. A pharmaceutical composition comprising the bispecific antibody of any one of claims 1 to 12 and at least one pharmaceutically acceptable excipient.
17. The bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16 for use as a medicament.
18. Use of the bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16 in the manufacture of a medicament for
 - i) modulating an immune response, optionally restoring T cell activity,
 - ii) stimulating a T cell response,
 - iii) delaying progression of a cancer,
 - iv) prolonging survival of a patient suffering from a cancer
 wherein the immune response, T cell response or cancer is characterised by T cells expressing PD1 and LAG3.
19. Use of the bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16 in the manufacture of a medicament for treating a cancer characterised by T cells expressing PD1 and LAG3.
20. Use of the bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16 in the manufacture of a medicament for preventing or treating a cancer characterised by T cells expressing PD1 and LAG3, wherein the bispecific antibody is administered in combination with a chemotherapeutic agent, radiation and/ or other cancer immunotherapy agent.
21. Use of the bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16 in the manufacture of a medicament for preventing or treating a cancer characterised by T cells expressing PD1 and LAG3, wherein the bispecific antibody is administered in combination with an anti-CEA/anti-CD3 bispecific antibody.
22. A method for:
 - i) modulating an immune response, optionally restoring T cell activity, in an individual
 - ii) stimulating a T cell response in an individual,
 - iii) preventing or treating a cancer in an individual,
 - iv) delaying progression of cancer in an individual,

v) prolonging survival of a patient suffering from a cancer, or comprising administering to the individual or patient the bispecific antibody of any one of claims 1 to 12 or the pharmaceutical composition of claim 16, optionally wherein preventing or treating a cancer comprises administering the bispecific antibody in combination with a chemotherapeutic agent, radiation and/ or other cancer immunotherapy agent, or an anti-CEA/anti-CD3 bispecific antibody, wherein the immune response, T cell response or cancer is characterised by T cells expressing PD1 and LAG3.

Fig. 1





Fig. 1



3/24

Fig. 1





Fig. 1


FIG.1H

FIG.1I




5/24

FIG.2A




6/24

FIG.2B



7/24

Fig. 3



8/24

FIG.4B






FIG.4A




9/24

FIG.5A




10/24

FIG.5B



11/24

FIG.5C



12/24

FIG.5D




FIG.6B




FIG.6D




FIG.6A




FIG.6C




FIG.7B




FIG.7D




FIG.7A




FIG.7C




FIG.7E





FIG.7F



16/24

FIG.8B




FIG.8A





Fig. 9A



18/24

Fig. 9B




Fig. 10A

Fig. 10B

Fig. 10C




Fig. 10D




Fig. 11




Fig. 12

PD-1 and LAG-3 co-blockade enhances
Tumor Ag-specific T cell effector functions
in melanoma patient PBMCs





Fig. 13

CD4 & ARH77 coculture GrzB level

normalized to untreated



23/24

Fig. 14




Fig. 15A




Fig. 15B




Fig. 15C




Fig. 15D




Fig. 15E





Fig. 15F



24/24

SEQUENCE LISTING

<110> F. Hoffmann-La Roche AG
 <120> Bispecific Antibodies specifically binding to PD1 and LAG3
 <130> P34215-W0
 <150> EP17165125.0
 <151> 2017-04-05
 <160> 169
 <170> PatentIn version 3.5
 <210> 1
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> heavy chain HVR-H1, PD1-0103
 <400> 1
 Gly Phe Ser Phe Ser Ser Tyr
 1 5
 <210> 2
 <211> 3
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> heavy chain HVR-H2, PD1-0103
 <400> 2
 Gly Gly Arg
 1
 <210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> heavy chain HVR-H3, PD1-0103
 <400> 3
 Thr Gly Arg Val Tyr Phe Ala Leu Asp
 1 5
 <210> 4
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>

<223> light chain HVR-L1, PD1-0103

<400> 4

Ser Glu Ser Val Asp Thr Ser Asp Asn Ser Phe
1 5 10

<210> 5

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L2, PD1-0103

<400> 5

Arg Ser Ser

1

<210> 6

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L3, PD1-0103

<400> 6

Asn Tyr Asp Val Pro Trp

1

5

<210> 7

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain variable domain VH, PD1-0103

<400> 7

Glu Val Ile Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30

Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Asp Trp Val
35 40 45

Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80

Leu Glu Met Ser Ser Leu Met Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
 85 90 95

Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser Trp Gly Gln
 100 105 110

Gly Thr Ser Val Thr Val Ser Ser
 115 120

<210> 8
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain variable domain VL, PD1-0103

<400> 8

Lys Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Pro Val Ser Leu Gly
 1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Thr Ser
 20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp
 65 70 75 80

Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Asn Tyr
 85 90 95

Asp Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> 9
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized variant -heavy chain variable domain VH of PD1-0103_01
 (PD1 0376)

<400> 9

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1					5					10					15				
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ser	Phe	Ser	Ser	Tyr				
			20				25						30						
Thr	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val				
			35				40						45						
Ala	Thr	Ile	Ser	Gly	Gly	Gly	Arg	Asp	Ile	Tyr	Tyr	Pro	Asp	Ser	Val				
			50				55						60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr				
65				70						75						80			
Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys				
			85						90						95				
Val	Leu	Leu	Thr	Gly	Arg	Val	Tyr	Phe	Ala	Leu	Asp	Ser	Trp	Gly	Gln				
			100						105						110				
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser												
			115			120													

```
<210> 10
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> humanized variant -light chain variable domain VL of PD1-0103_01
(PD1 0376)

<400> 10
```

Asp 1	Ile	Val	Met 5	Thr	Gln	Ser	Pro	Asp 10	Ser	Leu	Ala	Val	Ser	Leu 15	Gly
Glu	Arg	Ala 20	Thr	Ile	Asn	Cys	Lys	Ala 25	Ser	Glu	Ser	Val	Asp 30	Thr	Ser
Asp	Asn 35	Ser	Phe	Ile	His	Trp	Tyr 40	Gln	Gln	Lys	Pro	Gly 45	Gln	Ser	Pro
Lys 50	Leu	Leu	Ile	Tyr	Arg 55	Ser	Ser	Thr	Leu	Glu	Ser 60	Gly	Val	Pro	Asp
Arg 65	Phe	Ser	Gly	Ser 70	Gly	Ser	Gly	Thr	Asp 75	Phe	Thr	Leu	Thr	Ile 80	Ser
Ser	Leu	Gln	Ala 85	Glu	Asp	Val	Ala	Val 90	Tyr	Tyr	Cys	Gln	Gln	Asn 95	Tyr

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 11
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized variant -light chain variable domain VL of PD1-0103_02
 <400> 11

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Thr Ser
 20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Val Pro Asp
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser
 65 70 75 80

Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Asn Tyr
 85 90 95

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 12
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> humanized variant -light chain variable domain VL of PD1-0103_03
 <400> 12

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Ser Val Asp Thr Ser
 20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Ile Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Tyr
85 90 95

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 13

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized variant -light chain variable domain VL of PD1-0103_04

<400> 13

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Ser Val Asp Thr Ser
20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Ile Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Asn Tyr
85 90 95

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 14

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H1, aLAG3(0414)

<400> 14

Asp Tyr Thr Met Asn
1 5

<210> 15

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H2, aLAG3(0414)

<400> 15

Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val Lys
1 5 10 15

Gly

<210> 16

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H3, aLAG3(0414)

<400> 16

Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr
1 5 10

<210> 17

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L1, aLAG3(0414)

<400> 17

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L2, aLAG3(0414)

<400> 18

Ala Ala Ser Thr Leu Gln Ser
1 5

<210> 19
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L3, aLAG3(0414)

<400> 19

Gln Gln Thr Tyr Ser Ser Pro Leu Thr
 1 5

<210> 20
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, aLAG3(0414)

<400> 20

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 21
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>

<223> light chain variable domain VL, aLAG3(0414)

<400> 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Ser Pro Leu
85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H1, aLAG3(0403)

<400> 22

Asp Tyr Thr Met His
1 5

<210> 23

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H2, aLAG3(0403)

<400> 23

Leu Val Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asn Ser Val Lys
1 5 10 15

Gly

<210> 24
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, aLAG3(0403)

<400> 24

Ala Ile Thr Asp Thr Ser Leu Tyr Gly Tyr Asp Tyr
 1 5 10

<210> 25
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L1, aLAG3(0403)

<400> 25

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
 1 5 10

<210> 26
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L2, aLAG3(0403)

<400> 26

Ala Ala Ser Ser Leu Gln Ser
 1 5

<210> 27
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L3, aLAG3(0403)

<400> 27

Gln Gln Thr Tyr Ser Thr Pro Leu Thr
 1 5

<210> 28
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, aLAG3(0403)

<400> 28

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Leu Val Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asn Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95

Ala Lys Ala Ile Thr Asp Thr Ser Leu Tyr Gly Tyr Asp Tyr Trp Gly
 100 105 110

Gln Gly Ile Leu Val Thr Val Ser Ser
 115 120

<210> 29

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable domain VL, aLAG3(0403)

<400> 29

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Thr Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 30
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H1, aLAG3(0411)

<400> 30

Asp Tyr Thr Met Asn
 1 5

<210> 31
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H2, aLAG3(0411)

<400> 31

Val Ile Ser Trp Asp Gly Gly Ala Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> 32
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, aLAG3(0411)

<400> 32

Gly Leu Thr Asp Asp Thr Leu Tyr Gly Ser Asp Tyr
 1 5 10

<210> 33
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L1, aLAG3(0411)

<400> 33

Arg Ala Ser Gln Ser Ile Val Ser Tyr Leu Asn
 1 5 10

<210> 34
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L2, aLAG3(0411)

<400> 34

Ala Ser Ser Ser Leu Gln Ser
 1 5

<210> 35
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L3, aLAG3(0411)

<400> 35

Gln Gln Thr Tyr Ser Thr Pro Leu Thr
 1 5

<210> 36
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, aLAG3(0411)

<400> 36

Glu Val His Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Asp Asp Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Val Ile Ser Trp Asp Gly Gly Ala Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Gly Leu Thr Asp Asp Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 37
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain variable domain VL, aLAG3(0411)

<400> 37

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Val Ser Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ser Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Thr Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 38
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H1, aLAG3(0417)

<400> 38

Asp Tyr Ala Met Ser
 1 5

<210> 39
 <211> 17

<212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H2, aLAG3(0417)

<400> 39

Gly	Ile	Asp	Asn	Ser	Gly	Tyr	Tyr	Thr	Tyr	Tyr	Thr	Asp	Ser	Val	Lys
1				5					10					15	

Gly

<210> 40
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, aLAG3(0417)

<400> 40

Thr	His	Ser	Gly	Leu	Ile	Val	Asn	Asp	Ala	Phe	Asp	Ile
1				5					10			

<210> 41
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L1, aLAG3(0417)

<400> 41

Arg	Ala	Ser	Gln	Ser	Ile	Ser	Ser	Tyr	Leu	Asn
1				5					10	

<210> 42
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L2, aLAG3(0417)

<400> 42

Ala	Ala	Ser	Ser	Leu	Gln	Ser
1				5		

<210> 43
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>

<223> light chain HVR-L3, aLAG3(0417)

<400> 43

Gln Gln Thr Tyr Ser Thr Pro Leu Thr
1 5

<210> 44

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain variable domain VH, aLAG3(0417)

<400> 44

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 45

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable domain VL, aLAG3(0417)

<400> 45

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Thr Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 46
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H1, aLAG3(0416)

<400> 46

Asp Tyr Ala Met Ser
 1 5

<210> 47
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H2, aLAG3(0416)

<400> 47

Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val Lys
 1 5 10 15

Gly

<210> 48
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, aLAG3(0416)

<400> 48

Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile
1 5 10

<210> 49

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L1, aLAG3(0416)

<400> 49

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10

<210> 50

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L2, aLAG3(0416)

<400> 50

Asp Ala Ser Ser Leu Glu Ser
1 5

<210> 51

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L3, aLAG3(0416)

<400> 51

Gln Gln Ser Tyr Ser Thr Pro Leu Thr
1 5

<210> 52

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain variable domain VH, aLAG3(0416)

<400> 52

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
 85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
 100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 53

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable domain VL, aLAG3(0416)

<400> 53

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Ala Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 54
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, BMS-986016

<400> 54

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
 20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn His Arg Gly Ser Thr Asn Ser Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 55
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain variable domain VL BMS-986016

<400> 55

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
 85 90 95

Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys
 100 105

<210> 56
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H1, MDX25F7 (25F7)

<400> 56

Asp Tyr Tyr Trp Asn
 1 5

<210> 57
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H2, MDX25F7 (25F7)

<400> 57

Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 58
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, MDX25F7 (25F7)

<400> 58

Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe
 1 5 10

<210> 59
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>

<223> light chain HVR-L1, MDX25F7 (25F7)

<400> 59

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala
1 5 10

<210> 60

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L2, MDX25F7 (25F7)

<400> 60

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 61

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain HVR-L3, MDX25F7 (25F7)

<400> 61

Gln Gln Arg Ser Asn Trp Pro Leu Thr
1 5

<210> 62

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain variable domain VH, MDX25F7 (25F7)

<400> 62

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 63
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> light chain variable domain VL, MDX25F7 (25F7)

<400> 63

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
85 90 95

Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys
100 105

<210> 64
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain variable domain VH, humanized BAP050 (LAG525)

<400> 64

Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Leu Thr Asn Tyr
 20 25 30

Gly Met Asn Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Lys Trp Met
 35 40 45

Gly Trp Ile Asn Thr Asp Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
 50 55 60

Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Ser
 65 70 75 80

Leu Gln Ile Asn Asn Leu Lys Asn Ala Asp Thr Ala Thr Tyr Phe Cys
 85 90 95

Ala Arg Asn Pro Pro Tyr Tyr Tyr Gly Thr Asn Asn Ala Glu Ala Met
 100 105 110

Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120 125

<210> 65

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable domain VL, humanized BAP050 (LAG525)

<400> 65

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Ser Cys Ser Ser Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

Leu Met Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Val Leu Ile
 35 40 45

Tyr Tyr Thr Ser Thr Leu His Leu Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Leu
 65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asn Leu Pro Trp
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 66
 <211> 122
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, MDX26H10 (26H10)

<400> 66

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Glu Trp Ala Val Ala Ser Trp Asp Tyr Gly Met Asp Val Trp
 100 105 110

Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 67
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain variable domain VL, MDX26H10 (26H10)

<400> 67

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
 85 90 95

Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
 100 105

<210> 68

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> human kappa light chain constant region

<400> 68

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
 20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
 35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
 50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
 65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
 85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 100 105

<210> 69

<211> 105

<212> PRT

<213> Artificial Sequence

<220>

<223> human lambda light chain constant region

<400> 69

Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
1 5 10 15

Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
20 25 30

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
35 40 45

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
50 55 60

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
65 70 75 80

His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
85 90 95

Lys Thr Val Ala Pro Thr Glu Cys Ser
100 105

<210> 70

<211> 329

<212> PRT

<213> Artificial Sequence

<220>

<223> human heavy chain constant region derived from IgG1

<400> 70

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly
 325

<210> 71

<211> 329

<212> PRT

<213> Artificial Sequence

<220>

<223> human heavy chain constant region derived from IgG1 with mutations L234A, L235A and P329G

<400> 71

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly
325

<210> 72

<211> 326

<212> PRT

<213> Artificial Sequence

<220>

<223> human heavy chain constant region derived from IgG4

<400> 72

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro

[illegible]

<400> 73

Val Pro Val Val Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys
1 5 10 15

Ser Pro Thr Ile Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly
20 25 30

Val Thr Trp Gln His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro
35 40 45

Gly His Pro Leu Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp
50 55 60

Gly Pro Arg Pro Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly
65 70 75 80

Leu Arg Ser Gly Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu
85 90 95

Arg Gly Arg Gln Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg
100 105 110

Arg Ala Asp Ala Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg
115 120 125

Ala Leu Ser Cys Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr
130 135 140

Ala Ser Pro Pro Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn
145 150 155 160

Cys Ser Phe Ser Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg
165 170 175

Asn Arg Gly Gln Gly Arg Val Pro Val Arg Glu Ser Pro His His His
180 185 190

Leu Ala Glu Ser Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser
195 200 205

Gly Pro Trp Gly Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser
210 215 220

Ile Met Tyr Asn Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Pro Leu
225 230 235 240

Thr Val Tyr Ala Gly Ala Gly Ser Arg Val Gly Leu Pro Cys Arg Leu
245 250 255

Pro Ala Gly Val Gly Thr Arg Ser Phe Leu Thr Ala Lys Trp Thr Pro
 260 265 270

Pro Gly Gly Gly Pro Asp Leu Leu Val Thr Gly Asp Asn Gly Asp Phe
 275 280 285

Thr Leu Arg Leu Glu Asp Val Ser Gln Ala Gln Ala Gly Thr Tyr Thr
 290 295 300

Cys His Ile His Leu Gln Glu Gln Gln Leu Asn Ala Thr Val Thr Leu
 305 310 315 320

Ala Ile Ile Thr Val Thr Pro Lys Ser Phe Gly Ser Pro Gly Ser Leu
 325 330 335

Gly Lys Leu Leu Cys Glu Val Thr Pro Val Ser Gly Gln Glu Arg Phe
 340 345 350

Val Trp Ser Ser Leu Asp Thr Pro Ser Gln Arg Ser Phe Ser Gly Pro
 355 360 365

Trp Leu Glu Ala Gln Glu Ala Gln Leu Leu Ser Gln Pro Trp Gln Cys
 370 375 380

Gln Leu Tyr Gln Gly Glu Arg Leu Leu Gly Ala Ala Val Tyr Phe Thr
 385 390 395 400

Glu Leu Ser Ser Pro Gly Ala Gln Arg Ser Gly Arg Ala Pro Gly Ala
 405 410 415

Leu Pro Ala Gly His Leu Leu Leu Phe Leu Ile Leu Gly Val Leu Ser
 420 425 430

Leu Leu Leu Leu Val Thr Gly Ala Phe Gly Phe His Leu Trp Arg Arg
 435 440 445

Gln Trp Arg Pro Arg Arg Phe Ser Ala Leu Glu Gln Gly Ile His Pro
 450 455 460

Pro Gln Ala Gln Ser Lys Ile Glu Glu Leu Glu Gln Glu Pro Glu Pro
 465 470 475 480

Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Pro Glu Gln
 485 490 495

Leu

<210> 74
 <211> 422
 <212> PRT
 <213> Homo sapiens

<400> 74

Val Pro Val Val Trp Ala Gln Glu Gly Ala Pro Ala Gln Leu Pro Cys
 1 5 10 15

Ser Pro Thr Ile Pro Leu Gln Asp Leu Ser Leu Leu Arg Arg Ala Gly
 20 25 30

Val Thr Trp Gln His Gln Pro Asp Ser Gly Pro Pro Ala Ala Ala Pro
 35 40 45

Gly His Pro Leu Ala Pro Gly Pro His Pro Ala Ala Pro Ser Ser Trp
 50 55 60

Gly Pro Arg Pro Arg Arg Tyr Thr Val Leu Ser Val Gly Pro Gly Gly
 65 70 75 80

Leu Arg Ser Gly Arg Leu Pro Leu Gln Pro Arg Val Gln Leu Asp Glu
 85 90 95

Arg Gly Arg Gln Arg Gly Asp Phe Ser Leu Trp Leu Arg Pro Ala Arg
 100 105 110

Arg Ala Asp Ala Gly Glu Tyr Arg Ala Ala Val His Leu Arg Asp Arg
 115 120 125

Ala Leu Ser Cys Arg Leu Arg Leu Arg Leu Gly Gln Ala Ser Met Thr
 130 135 140

Ala Ser Pro Pro Gly Ser Leu Arg Ala Ser Asp Trp Val Ile Leu Asn
 145 150 155 160

Cys Ser Phe Ser Arg Pro Asp Arg Pro Ala Ser Val His Trp Phe Arg
 165 170 175

Asn Arg Gly Gln Gly Arg Val Pro Val Arg Glu Ser Pro His His His
 180 185 190

Leu Ala Glu Ser Phe Leu Phe Leu Pro Gln Val Ser Pro Met Asp Ser
 195 200 205

Gly Pro Trp Gly Cys Ile Leu Thr Tyr Arg Asp Gly Phe Asn Val Ser
 210 215 220

Ile Met Tyr Asn Leu Thr Val Leu Gly Leu Glu Pro Pro Thr Pro Leu
225 230 235 240

Thr Val Tyr Ala Gly Ala Gly Ser Arg Val Gly Leu Pro Cys Arg Leu
245 250 255

Pro Ala Gly Val Gly Thr Arg Ser Phe Leu Thr Ala Lys Trp Thr Pro
260 265 270

Pro Gly Gly Gly Pro Asp Leu Leu Val Thr Gly Asp Asn Gly Asp Phe
275 280 285

Thr Leu Arg Leu Glu Asp Val Ser Gln Ala Gln Ala Gly Thr Tyr Thr
290 295 300

Cys His Ile His Leu Gln Glu Gln Gln Leu Asn Ala Thr Val Thr Leu
305 310 315 320

Ala Ile Ile Thr Val Thr Pro Lys Ser Phe Gly Ser Pro Gly Ser Leu
325 330 335

Gly Lys Leu Leu Cys Glu Val Thr Pro Val Ser Gly Gln Glu Arg Phe
340 345 350

Val Trp Ser Ser Leu Asp Thr Pro Ser Gln Arg Ser Phe Ser Gly Pro
355 360 365

Trp Leu Glu Ala Gln Glu Ala Gln Leu Leu Ser Gln Pro Trp Gln Cys
370 375 380

Gln Leu Tyr Gln Gly Glu Arg Leu Leu Gly Ala Ala Val Tyr Phe Thr
385 390 395 400

Glu Leu Ser Ser Pro Gly Ala Gln Arg Ser Gly Arg Ala Pro Gly Ala
405 410 415

Leu Pro Ala Gly His Leu
420

<210> 75
<211> 6
<212> PRT
<213> Homo sapiens

<400> 75

Lys Ile Glu Glu Leu Glu
1 5

<210> 76
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer rbHC.up

<400> 76
 aagcttgcca ccatggagac tgggctgcgc tggcttc 37

<210> 77
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer rbHCf.do

<400> 77
 ccattggtga gggtgcccgga g 21

<210> 78
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer BcPCR_FHLC_leader.fw

<400> 78
 atggacatga ggggtccccgc 20

<210> 79
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer BcPCR_huCkappa.rev

<400> 79
 gatttcaact gctcatcaga tggc 24

<210> 80
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H1, PD1-0098

<400> 80

Gly Tyr Ser Ile Thr Ser Asp Tyr
 1 5

<210> 81
 <211> 3

<212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H2, PD1-0098

<400> 81

Tyr Ser Gly
 1

<210> 82
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain HVR-H3, PD1-0098

<400> 82

His Gly Ser Ala Pro Trp Tyr Phe Asp
 1 5

<210> 83
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L1, PD1-0098

<400> 83

Ser Gln Asn Ile Val His Ser Asp Gly Asn Thr Tyr
 1 5 10

<210> 84
 <211> 3
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L2, PD1-0098

<400> 84

Lys Val Ser
 1

<210> 85
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L3, PD1-0098

<400> 85

Gly Ser His Phe Pro Leu
1 5

<210> 86
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain variable domain VH, PD1-0098

<400> 86

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
20 25 30

Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu Trp
35 40 45

Leu Gly Tyr Ile Thr Tyr Ser Gly Phe Thr Asn Tyr Asn Pro Ser Leu
50 55 60

Lys Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Phe
65 70 75 80

Leu Gln Leu Asn Ser Val Ala Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Trp His Gly Ser Ala Pro Trp Tyr Phe Asp Tyr Trp Gly Arg
100 105 110

Gly Thr Thr Leu Thr Val Ser Ser
115 120

<210> 87
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> light chain variable domain VL, PD1-0098

<400> 87

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser
20 25 30

Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Asn Leu Leu Ile Tyr Lys Val Ser Arg Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95

Ser His Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105 110

<210> 88

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H1, PD1-0069

<400> 88

Gly Tyr Thr Phe Thr Asp Tyr
 1 5

<210> 89

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H2, PD1-0069

<400> 89

Tyr Ser Gly
 1

<210> 90

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain HVR-H3, PD1-0069

<400> 90

Gly Ile Thr Thr Gly Phe Ala
 1 5

<210> 91

<211> 11

<212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L1, PD1-0069

<400> 91

Ser Lys Gly Val Ser Thr Ser Ser Tyr Ser Phe
 1 5 10

<210> 92
 <211> 3
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L2, PD1-0069

<400> 92

Tyr Ala Ser
 1

<210> 93
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain HVR-L3, PD1-0069

<400> 93

Ser Arg Glu Phe Pro Trp
 1 5

<210> 94
 <211> 118
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain variable domain VH, PD1-0069

<400> 94

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Val
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Ala Met His Trp Val Lys Gln Ser His Ala Arg Thr Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Ser Gly Asp Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Leu Glu Leu Ala Arg Met Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Leu Gly Ile Thr Thr Gly Phe Ala Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ala
115

<210> 95

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain variable domain VL, PD1-0069

<400> 95

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser
20 25 30

Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Arg Gln Pro Pro
35 40 45

Lys Leu Leu Ile Lys Tyr Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys His His Ser Arg
85 90 95

Glu Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 96

<211> 443

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 1 of 1+1 PD1/LAG3 0799

<400> 96

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Glu Ser Val Asp Thr Ser
 20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
 35 40 45

Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Val Pro Asp
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Asn Tyr
 85 90 95

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser
 100 105 110

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
 115 120 125

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
 130 135 140

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
 145 150 155 160

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
 165 170 175

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 180 185 190

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
 195 200 205

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
 210 215 220

Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro
 225 230 235 240

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 245 250 255

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
260 265 270

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
275 280 285

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
290 295 300

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
305 310 315 320

Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
325 330 335

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp
340 345 350

Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe
355 360 365

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
370 375 380

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
385 390 395 400

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
405 410 415

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
420 425 430

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

<210> 97

<211> 452

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 1+1 PD1/LAG3 0799

<400> 97

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
 85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
 100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 130 135 140

Ala Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr
 145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser
 210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
 225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro
 325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 340 345 350

Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 355 360 365

Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr
 405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 435 440 445

Ser Pro Gly Lys
 450

<210> 98
 <211> 227
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain 1 of 1+1 PD1/LAG3 0799

<400> 98

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
 20 25 30

Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val
 115 120 125

Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
 130 135 140

Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
 145 150 155 160

Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val
 165 170 175

Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu
 180 185 190

Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu
 195 200 205

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg
 210 215 220

Gly Glu Cys
 225

<210> 99

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain 2 of 1+1 PD1/LAG3 0799

<400> 99

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Ala Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Arg Lys Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 100

<211> 451

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 1+1 PD1/LAG3 0927

<400> 100

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys
450

<210> 101

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain 2 of 1+1 PD1/LAG3 0927

<400> 101

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Ser Pro Leu
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Arg Lys Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 102

<211> 443

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 1 of 1+1 PD1/LAG3 0222

<400> 102

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser
 20 25 30

Ser Tyr Ser Phe Met His Trp Tyr Gln Gln Lys Pro Arg Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Lys Tyr Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
 65 70 75 80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys His His Ser Arg
 85 90 95

Glu Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Ser
 100 105 110

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
 115 120 125

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
 130 135 140

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
 145 150 155 160

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
 165 170 175

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 180 185 190

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
 195 200 205

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
 210 215 220

Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro
 225 230 235 240

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 245 250 255

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
260 265 270

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
275 280 285

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
290 295 300

Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
305 310 315 320

Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
325 330 335

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp
340 345 350

Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe
355 360 365

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
370 375 380

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
385 390 395 400

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
405 410 415

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
420 425 430

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

<210> 103

<211> 450

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 1+1 PD1/LAG3 0222

<400> 103

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
 20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140

Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205

Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys
 340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Lys
 450

<210> 104
 <211> 225
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain 1 of 1+1 PD1/LAG3 0222

<400> 104

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Arg Pro Gly Val
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Ala Met His Trp Val Lys Gln Ser His Ala Arg Thr Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Ser Gly Asp Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Leu Glu Leu Ala Arg Met Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys
 85 90 95

Ala Arg Leu Gly Ile Thr Thr Gly Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala Ala Ser Val Ala Ala Pro Ser Val Phe Ile
 115 120 125

Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
 130 135 140

Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys
 145 150 155 160

Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu
 165 170 175

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
 180 185 190

Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
 195 200 205

His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
 210 215 220

Cys
 225

<210> 105
 <211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> light chain 2 of 1+1 PD1/LAG3 0222

<400> 105

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30
 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45
 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
 85 90 95
 Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Arg Lys Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> 106

<211> 444

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 1 of 1+1 PD1/LAG3 0224

<400> 106

Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser
20 25 30

Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Asn Leu Leu Ile Tyr Lys Val Ser Arg Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95

Ser His Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110

Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
115 120 125

Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
165 170 175

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190

Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
195 200 205

Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220

Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
260 265 270

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320

Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg
340 345 350

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly
355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
405 410 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

<210> 107

<211> 227

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain 1 of 1+1 PD1/LAG3 0224

<400> 107

Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 25 30

Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asp Lys Leu Glu Trp
 35 40 45

Leu Gly Tyr Ile Thr Tyr Ser Gly Phe Thr Asn Tyr Asn Pro Ser Leu
 50 55 60

Lys Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80

Leu Gln Leu Asn Ser Val Ala Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95

Ala Arg Trp His Gly Ser Ala Pro Trp Tyr Phe Asp Tyr Trp Gly Arg
 100 105 110

Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val
 115 120 125

Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser
 130 135 140

Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln
 145 150 155 160

Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val
 165 170 175

Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu
 180 185 190

Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu
 195 200 205

Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg
 210 215 220

Gly Glu Cys
 225

<210> 108

<211> 443

<212> PRT

<213> Artificial Sequence

<220>

<223> aLAG3(0156) heavy chain (MDX25F7)

<400> 108

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Gln Pro Lys Ala Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Cys Cys Gly Asp Thr Pro Ser Ser Thr Val Thr
130 135 140

Leu Gly Cys Leu Val Lys Gly Tyr Leu Pro Glu Pro Val Thr Val Thr
145 150 155 160

Trp Asn Ser Gly Thr Leu Thr Asn Gly Val Arg Thr Phe Pro Ser Val
165 170 175

Arg Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Ser Val Thr
180 185 190

Ser Ser Ser Gln Pro Val Thr Cys Asn Val Ala His Pro Ala Thr Asn
195 200 205

Thr Lys Val Asp Lys Thr Val Ala Pro Ser Thr Cys Ser Lys Pro Thr
210 215 220

Cys Pro Pro Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro
225 230 235 240

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
245 250 255

Cys Val Val Val Asp Val Ser Gln Asp Asp Pro Glu Val Gln Phe Thr
260 265 270

Trp Tyr Ile Asn Asn Glu Gln Val Arg Thr Ala Arg Pro Pro Leu Arg
275 280 285

Glu Gln Gln Phe Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile
290 295 300

Ala His Gln Asp Trp Leu Arg Gly Lys Glu Phe Lys Cys Lys Val His
305 310 315 320

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Arg
325 330 335

Gly Gln Pro Leu Glu Pro Lys Val Tyr Thr Met Gly Pro Pro Arg Glu
340 345 350

Glu Leu Ser Ser Arg Ser Val Ser Leu Thr Cys Met Ile Asn Gly Phe
355 360 365

Tyr Pro Ser Asp Ile Ser Val Glu Trp Glu Lys Asn Gly Lys Ala Glu
370 375 380

Asp Asn Tyr Lys Thr Thr Pro Ala Val Leu Asp Ser Asp Gly Ser Tyr
385 390 395 400

Phe Leu Tyr Asn Lys Leu Ser Val Pro Thr Ser Glu Trp Gln Arg Gly
405 410 415

Asp Val Phe Thr Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
420 425 430

Thr Gln Lys Ser Ile Ser Arg Ser Pro Gly Lys
435 440

<210> 109

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> aLAG3(0156) light chain (MDX25F7)

<400> 109

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
 35 40 45

Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu
 85 90 95

Thr Phe Gly Gln Gly Thr Asn Leu Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Cys
 210

<210> 110
 <211> 444
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> aLAG3(0414) heavy chain

<400> 110

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
 20 25 30
 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gln Pro Lys Ala Pro Ser
 115 120 125
 Val Phe Pro Leu Ala Pro Cys Cys Gly Asp Thr Pro Ser Ser Thr Val
 130 135 140
 Thr Leu Gly Cys Leu Val Lys Gly Tyr Leu Pro Glu Pro Val Thr Val
 145 150 155 160
 Thr Trp Asn Ser Gly Thr Leu Thr Asn Gly Val Arg Thr Phe Pro Ser
 165 170 175
 Val Arg Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Ser Val
 180 185 190
 Thr Ser Ser Ser Gln Pro Val Thr Cys Asn Val Ala His Pro Ala Thr
 195 200 205
 Asn Thr Lys Val Asp Lys Thr Val Ala Pro Ser Thr Cys Ser Lys Pro
 210 215 220
 Thr Cys Pro Pro Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Ile Phe
 225 230 235 240
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 245 250 255
 Thr Cys Val Val Val Asp Val Ser Gln Asp Asp Pro Glu Val Gln Phe
 260 265 270

Thr Trp Tyr Ile Asn Asn Glu Gln Val Arg Thr Ala Arg Pro Pro Leu
275 280 285

Arg Glu Gln Gln Phe Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro
290 295 300

Ile Ala His Gln Asp Trp Leu Arg Gly Lys Glu Phe Lys Cys Lys Val
305 310 315 320

His Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335

Arg Gly Gln Pro Leu Glu Pro Lys Val Tyr Thr Met Gly Pro Pro Arg
340 345 350

Glu Glu Leu Ser Ser Arg Ser Val Ser Leu Thr Cys Met Ile Asn Gly
355 360 365

Phe Tyr Pro Ser Asp Ile Ser Val Glu Trp Glu Lys Asn Gly Lys Ala
370 375 380

Glu Asp Asn Tyr Lys Thr Thr Pro Ala Val Leu Asp Ser Asp Gly Ser
385 390 395 400

Tyr Phe Leu Tyr Asn Lys Leu Ser Val Pro Thr Ser Glu Trp Gln Arg
405 410 415

Gly Asp Val Phe Thr Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430

Tyr Thr Gln Lys Ser Ile Ser Arg Ser Pro Gly Lys
435 440

<210> 111

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> aLAG3(0414) light chain

<400> 111

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Ser Ser Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Thr Val Ala Ala
 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Cys
 210

<210> 112
 <211> 445
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> aLAG3(0416) heavy chain

<400> 112

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
 85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
 100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gln Pro Lys Ala Pro
 115 120 125

Ser Val Phe Pro Leu Ala Pro Cys Cys Gly Asp Thr Pro Ser Ser Thr
 130 135 140

Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Leu Pro Glu Pro Val Thr
 145 150 155 160

Val Thr Trp Asn Ser Gly Thr Leu Thr Asn Gly Val Arg Thr Phe Pro
 165 170 175

Ser Val Arg Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Ser
 180 185 190

Val Thr Ser Ser Ser Gln Pro Val Thr Cys Asn Val Ala His Pro Ala
 195 200 205

Thr Asn Thr Lys Val Asp Lys Thr Val Ala Pro Ser Thr Cys Ser Lys
 210 215 220

Pro Thr Cys Pro Pro Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Ile
 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 245 250 255

Val Thr Cys Val Val Val Asp Val Ser Gln Asp Asp Pro Glu Val Gln
 260 265 270

Phe Thr Trp Tyr Ile Asn Asn Glu Gln Val Arg Thr Ala Arg Pro Pro
 275 280 285

Leu Arg Glu Gln Gln Phe Asn Ser Thr Ile Arg Val Val Ser Thr Leu
290 295 300

Pro Ile Ala His Gln Asp Trp Leu Arg Gly Lys Glu Phe Lys Cys Lys
305 310 315 320

Val His Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
325 330 335

Ala Arg Gly Gln Pro Leu Glu Pro Lys Val Tyr Thr Met Gly Pro Pro
340 345 350

Arg Glu Glu Leu Ser Ser Arg Ser Val Ser Leu Thr Cys Met Ile Asn
355 360 365

Gly Phe Tyr Pro Ser Asp Ile Ser Val Glu Trp Glu Lys Asn Gly Lys
370 375 380

Ala Glu Asp Asn Tyr Lys Thr Thr Pro Ala Val Leu Asp Ser Asp Gly
385 390 395 400

Ser Tyr Phe Leu Tyr Asn Lys Leu Ser Val Pro Thr Ser Glu Trp Gln
405 410 415

Arg Gly Asp Val Phe Thr Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430

His Tyr Thr Gln Lys Ser Ile Ser Arg Ser Pro Gly Lys
435 440 445

<210> 113

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> aLAG3(0416) light chain

<400> 113

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Ala Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Thr Val Ala Ala
 100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Cys
 210

<210> 114
 <211> 695
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain of 2+2 PD1/LAG3 8970

<400> 114

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
450 455 460

Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
465 470 475 480

Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser
485 490 495

Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
500 505 510

Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr
515 520 525

Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
530 535 540

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
545 550 555 560

Val Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp
565 570 575

Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala
580 585 590

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
595 600 605

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
610 615 620

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
625 630 635 640

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
645 650 655

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
660 665 670

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
675 680 685

Ser Phe Asn Arg Gly Glu Cys
690 695

<210> 115

<211> 216

<212> PRT

<213> Artificial Sequence

<220>

<223> light chain 1 of 2+2 PD1/LAG3 8970

<400> 115

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Glu Ser Val Asp Thr Ser
20 25 30

Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro
35 40 45

Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu Ser Gly Val Pro Asp
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Asn Tyr
 85 90 95

Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser
 100 105 110

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
 115 120 125

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
 130 135 140

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
 145 150 155 160

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
 165 170 175

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
 180 185 190

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
 195 200 205

Lys Lys Val Glu Pro Lys Ser Cys
 210 215

<210> 116
 <211> 696
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain of 2+2 PD1/LAG3 8984

<400> 116

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140

Ala Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser
210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro
 325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 340 345 350

Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 355 360 365

Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 435 440 445

Ser Pro Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 450 455 460

Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
 465 470 475 480

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
 485 490 495

Ser Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
 500 505 510

Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr
 515 520 525

Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 530 535 540

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 545 550 555 560

Ala Val Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu
 565 570 575

Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val
580 585 590

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
595 600 605

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
610 615 620

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
625 630 635 640

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
645 650 655

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
660 665 670

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
675 680 685

Lys Ser Phe Asn Arg Gly Glu Cys
690 695

<210> 117

<211> 694

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain of 2+2 PD1/LAG3 9010

<400> 117

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140

Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205

Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 450 455 460

Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
 465 470 475 480

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe
 485 490 495

Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 500 505 510

Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro
 515 520 525

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
 530 535 540

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 545 550 555 560

Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser
 565 570 575

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala
 580 585 590

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 595 600 605

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 610 615 620

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 625 630 635 640

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 645 650 655

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 660 665 670

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 675 680 685

Phe Asn Arg Gly Glu Cys
 690

<210> 118
 <211> 695
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain 1of 2+1 PD1/LAG3 8310

<400> 118

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
450 455 460

Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val
465 470 475 480

Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser
485 490 495

Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
500 505 510

Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr
515 520 525

Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
530 535 540

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
545 550 555 560

Val Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp
565 570 575

Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala
580 585 590

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
595 600 605

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
610 615 620

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
625 630 635 640

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
645 650 655

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
660 665 670

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
675 680 685

Ser Phe Asn Arg Gly Glu Cys
690 695

<210> 119

<211> 451

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 2+1 PD1/LAG3 8310

<400> 119

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 120
 <211> 696
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain 1of 2+1 PD1/LAG3 8311

<400> 120

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
 85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
 100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 130 135 140

Ala Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser
210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro
325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
340 345 350

Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val
355 360 365

Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
 405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 435 440 445

Ser Pro Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 450 455 460

Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
 465 470 475 480

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
 485 490 495

Ser Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
 500 505 510

Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr
 515 520 525

Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
 530 535 540

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
 545 550 555 560

Ala Val Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu
 565 570 575

Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val
 580 585 590

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 595 600 605

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 610 615 620

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 625 630 635 640

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 645 650 655

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
660 665 670

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
675 680 685

Lys Ser Phe Asn Arg Gly Glu Cys
690 695

<210> 121
<211> 452
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain 2of 2+1 PD1/LAG3 8311

<400> 121

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
130 135 140

Ala Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr
145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser
 210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
 225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
 260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
 275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
 290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
 305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro
 325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
 340 345 350

Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
 355 360 365

Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
 370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
 385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr
 405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
 420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
 435 440 445

Ser Pro Gly Lys
 450

<210> 122
 <211> 694
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain 1of 2+1 PD1/LAG3 1252

<400> 122

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
 20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140

Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205

Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys Asp
210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350

Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365

Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 450 455 460

Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
 465 470 475 480

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe
 485 490 495

Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 500 505 510

Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro
 515 520 525

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
 530 535 540

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 545 550 555 560

Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser
 565 570 575

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala
 580 585 590

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 595 600 605

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 610 615 620

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 625 630 635 640

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 645 650 655

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 660 665 670

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 675 680 685

Phe Asn Arg Gly Glu Cys
690

<210> 123
<211> 941
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain 1of 2+1 PD1/LAG3 8312

<400> 123

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 450 455 460

Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Asp Ser
 465 470 475 480

Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser
 485 490 495

Glu Ser Val Asp Thr Ser Asp Asn Ser Phe Ile His Trp Tyr Gln Gln
 500 505 510

Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu
 515 520 525

Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
 530 535 540

Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
 545 550 555 560

Tyr Cys Gln Gln Asn Tyr Asp Val Pro Trp Thr Phe Gly Gln Gly Thr
 565 570 575

Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
 580 585 590

Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
 595 600 605

Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
 610 615 620

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
 625 630 635 640

Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
 645 650 655

Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
 660 665 670

Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 675 680 685

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
 690 695 700

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val
 705 710 715 720
 Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 725 730 735
 Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Thr Met
 740 745 750
 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Thr
 755 760 765
 Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro Asp Ser Val Lys Gly
 770 775 780
 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 785 790 795 800
 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Leu
 805 810 815
 Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser Trp Gly Gln Gly Thr
 820 825 830
 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 835 840 845
 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
 850 855 860
 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
 865 870 875 880
 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
 885 890 895
 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
 900 905 910
 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
 915 920 925
 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
 930 935 940

<210> 124

<211> 942

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 1of 2+1 PD1/LAG3 8313

<400> 124

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Asp Asn Ser Gly Tyr Tyr Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Val Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Leu Cys
 85 90 95

Thr Lys Thr His Ser Gly Leu Ile Val Asn Asp Ala Phe Asp Ile Trp
 100 105 110

Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
 115 120 125

Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 130 135 140

Ala Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr
 145 150 155 160

Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 165 170 175

Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 180 185 190

Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 195 200 205

His Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser
 210 215 220

Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
 225 230 235 240

Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
245 250 255

Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
260 265 270

His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
275 280 285

Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr
290 295 300

Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn
305 310 315 320

Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro
325 330 335

Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
340 345 350

Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val
355 360 365

Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
370 375 380

Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
385 390 395 400

Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
405 410 415

Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
420 425 430

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
435 440 445

Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
450 455 460

Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Asp
465 470 475 480

Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala
485 490 495

Ser Glu Ser Val Asp Thr Ser Asp Asn Ser Phe Ile His Trp Tyr Gln
500 505 510

Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Arg Ser Ser Thr
515 520 525

Leu Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr
530 535 540

Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val
545 550 555 560

Tyr Tyr Cys Gln Gln Asn Tyr Asp Val Pro Trp Thr Phe Gly Gln Gly
565 570 575

Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile
580 585 590

Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
595 600 605

Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys
610 615 620

Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu
625 630 635 640

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
645 650 655

Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
660 665 670

His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
675 680 685

Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
690 695 700

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
705 710 715 720

Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
725 730 735

Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Thr
740 745 750

Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
755 760 765

Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro Asp Ser Val Lys
770 775 780

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
785 790 795 800

Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val
805 810 815

Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser Trp Gly Gln Gly
820 825 830

Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
835 840 845

Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
850 855 860

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
865 870 875 880

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
885 890 895

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
900 905 910

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
915 920 925

Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
930 935 940

<210> 125

<211> 940

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 1of 2+1 PD1/LAG3 1088

<400> 125

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
 20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140

Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205

Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350

Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 450 455 460

Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
 465 470 475 480

Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Glu
 485 490 495

Ser Val Asp Thr Ser Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys
 500 505 510

Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu
 515 520 525

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 530 535 540

Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr
 545 550 555 560

Cys Gln Gln Asn Tyr Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys
 565 570 575

Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro
 580 585 590

Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu
 595 600 605

Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp
 610 615 620

Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
 625 630 635 640

Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
 645 650 655

Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln
 660 665 670

Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly
 675 680 685

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
 690 695 700

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln
 705 710 715 720

Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
 725 730 735

Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr Thr Met Ser
 740 745 750

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Thr Ile
 755 760 765

Ser Gly Gly Gly Arg Asp Ile Tyr Tyr Pro Asp Ser Val Lys Gly Arg
 770 775 780

Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met
 785 790 795 800

Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Leu Leu
 805 810 815

Thr Gly Arg Val Tyr Phe Ala Leu Asp Ser Trp Gly Gln Gly Thr Leu
 820 825 830

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
 835 840 845

Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
 850 855 860

Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
 865 870 875 880

Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
 885 890 895

Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
 900 905 910

Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
 915 920 925

Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
 930 935 940

<210> 126
 <211> 589
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> heavy chain 1of 2+1 PD1/LAG3 0918

<400> 126

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
 20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
 50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys
340 345 350

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365

Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp
405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
450 455 460

Gly Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
465 470 475 480

Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
485 490 495

Ser Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Ala Pro Gly Lys
500 505 510

Gly Leu Glu Trp Val Ala Thr Ile Ser Gly Gly Gly Arg Asp Ile Tyr
515 520 525

Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
530 535 540

Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
545 550 555 560

Ala Val Tyr Tyr Cys Val Leu Leu Thr Gly Arg Val Tyr Phe Ala Leu
565 570 575

Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
580 585

<210> 127
<211> 580
<212> PRT
<213> Artificial Sequence

<220>
<223> heavy chain 2 of 2+1 PD1/LAG3 0918

<400> 127

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr
20 25 30

Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Glu Ile Asn His Asn Gly Asn Thr Asn Ser Asn Pro Ser Leu Lys
50 55 60

Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu
65 70 75 80

Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95

Phe Gly Tyr Ser Asp Tyr Glu Tyr Asn Trp Phe Asp Pro Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125

Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140

Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160

Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175

Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190

Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205

Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly
 225 230 235 240

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
 245 250 255

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
 260 265 270

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
 275 280 285

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
 290 295 300

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
 305 310 315 320

Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu
 325 330 335

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
 340 345 350

Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
 355 360 365

Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
 370 375 380

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
 385 390 395 400

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
 405 410 415

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
 420 425 430

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
 435 440 445

Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 450 455 460

Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu
 465 470 475 480

Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Glu
 485 490 495

Ser Val Asp Thr Ser Asp Asn Ser Phe Ile His Trp Tyr Gln Gln Lys
 500 505 510

Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Arg Ser Ser Thr Leu Glu
 515 520 525

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
 530 535 540

Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr
 545 550 555 560

Cys Gln Gln Asn Tyr Asp Val Pro Trp Thr Phe Gly Gln Gly Thr Lys
 565 570 575

Val Glu Ile Lys
 580

<210> 128
 <211> 288
 <212> PRT
 <213> Homo sapiens

<400> 128

Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln
 1 5 10 15

Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp
 20 25 30

Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp
 35 40 45

Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val
 50 55 60

Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
 65 70 75 80

Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg

				85					90					95			
Val	Thr	Gln	Leu	Pro	Asn	Gly	Arg	Asp	Phe	His	Met	Ser	Val	Val	Arg		
			100					105					110				
Ala	Arg	Arg	Asn	Asp	Ser	Gly	Thr	Tyr	Leu	Cys	Gly	Ala	Ile	Ser	Leu		
			115				120					125					
Ala	Pro	Lys	Ala	Gln	Ile	Lys	Glu	Ser	Leu	Arg	Ala	Glu	Leu	Arg	Val		
			130			135					140						
Thr	Glu	Arg	Arg	Ala	Glu	Val	Pro	Thr	Ala	His	Pro	Ser	Pro	Ser	Pro		
145					150					155					160		
Arg	Pro	Ala	Gly	Gln	Phe	Gln	Thr	Leu	Val	Val	Gly	Val	Val	Gly	Gly		
				165					170					175			
Leu	Leu	Gly	Ser	Leu	Val	Leu	Leu	Val	Trp	Val	Leu	Ala	Val	Ile	Cys		
			180					185					190				
Ser	Arg	Ala	Ala	Arg	Gly	Thr	Ile	Gly	Ala	Arg	Arg	Thr	Gly	Gln	Pro		
			195				200					205					
Leu	Lys	Glu	Asp	Pro	Ser	Ala	Val	Pro	Val	Phe	Ser	Val	Asp	Tyr	Gly		
	210					215					220						
Glu	Leu	Asp	Phe	Gln	Trp	Arg	Glu	Lys	Thr	Pro	Glu	Pro	Pro	Val	Pro		
225					230					235					240		
Cys	Val	Pro	Glu	Gln	Thr	Glu	Tyr	Ala	Thr	Ile	Val	Phe	Pro	Ser	Gly		
				245					250					255			
Met	Gly	Thr	Ser	Ser	Pro	Ala	Arg	Arg	Gly	Ser	Ala	Asp	Gly	Pro	Arg		
			260					265					270				
Ser	Ala	Gln	Pro	Leu	Arg	Pro	Glu	Asp	Gly	His	Cys	Ser	Trp	Pro	Leu		
			275				280					285					

<210> 129
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker G4S

<400> 129

Gly	Gly	Gly	Gly	Ser
1				5

<210> 130
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker (G4S)2

<400> 130

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10

<210> 131
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker (SG4)2

<400> 131

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 1 5 10

<210> 132
 <211> 14
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker G4(SG4)2

<400> 132

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 1 5 10

<210> 133
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker

<400> 133

Gly Ser Pro Gly Ser Ser Ser Ser Gly Ser
 1 5 10

<210> 134
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker (G4S)3

<400> 134

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 135

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker (G4S)₄

<400> 135

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Gly Gly Ser
20

<210> 136

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker

<400> 136

Gly Ser Gly Ser Gly Ser Gly Ser
1 5

<210> 137

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker

<400> 137

Gly Ser Gly Ser Gly Asn Gly Ser
1 5

<210> 138

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker

<400> 138

Gly Gly Ser Gly Ser Gly Ser Gly

1

5

<210> 139
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker

<400> 139

Gly Gly Ser Gly Ser Gly
 1 5

<210> 140
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker

<400> 140

Gly Gly Ser Gly
 1

<210> 141
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker

<400> 141

Gly Gly Ser Gly Asn Gly Ser Gly
 1 5

<210> 142
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Peptide linker

<400> 142

Gly Gly Asn Gly Ser Gly Ser Gly
 1 5

<210> 143
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Peptide linker

<400> 143

Gly Gly Asn Gly Ser Gly
1 5

<210> 144

<211> 461

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 1+1 PD1/LAG3 0725 (1+1 trans)

<400> 144

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180	185	190																			
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met						
		195					200					205									
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser						
	210					215					220										
Pro	Gly	Lys	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Glu	Val	Gln						
225					230					235					240						
Leu	Leu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg						
				245					250					255							
Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ile	Phe	Asp	Asp	Tyr	Thr	Met	Asn						
			260					265					270								
Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ala	Val	Ile						
		275					280					285									
Ser	Trp	Asp	Gly	Gly	Gly	Thr	Tyr	Tyr	Thr	Asp	Ser	Val	Lys	Gly	Arg						
	290					295					300										
Phe	Thr	Ile	Ser	Arg	Asp	Asp	Phe	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met						
305					310					315					320						
Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Lys	Gly						
				325					330					335							
Leu	Thr	Asp	Thr	Thr	Leu	Tyr	Gly	Ser	Asp	Tyr	Trp	Gly	Gln	Gly	Thr						
			340					345					350								
Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro						
		355					360					365									
Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly						
	370					375					380										
Cys	Leu	Val	Glu	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn						
385					390					395					400						
Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln						
				405					410					415							
Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser						
			420					425					430								
Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser						

435

440

445

Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
 450 455 460

<210> 145

<211> 685

<212> PRT

<213> Artificial Sequence

<220>

<223> heavy chain 2 of 2+1 PD1/LAG3 0750 (2+1 trans)

<400> 145

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ala Val Ile Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Lys Gly Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln
 450 455 460

Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg
 465 470 475 480

Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Thr Met Asn
 485 490 495

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile
 500 505 510

Ser Trp Asp Gly Gly Gly Thr Tyr Tyr Thr Asp Ser Val Lys Gly Arg
 515 520 525

Phe Thr Ile Ser Arg Asp Asp Phe Lys Asn Thr Leu Tyr Leu Gln Met
 530 535 540

Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly
 545 550 555 560

Leu Thr Asp Thr Thr Leu Tyr Gly Ser Asp Tyr Trp Gly Gln Gly Thr
 565 570 575

Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 580 585 590

Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly
 595 600 605

Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn
 610 615 620

Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
 625 630 635 640

Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
 645 650 655

Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
 660 665 670

Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
 675 680 685

<210> 146
 <211> 215
 <212> PRT

<213> Artificial Sequence

<220>

<223> Light chain CEA (CEA TCB)

<400> 146

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Ala Ala Val Gly Thr Tyr
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Tyr Arg Lys Arg Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Tyr Thr Tyr Pro Leu
85 90 95

Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala
100 105 110

Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser
115 120 125

Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu
130 135 140

Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser
145 150 155 160

Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu
165 170 175

Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val
180 185 190

Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys
195 200 205

Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 147

<211> 214
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Light chain CD3 (CEA TCB)

<400> 147

Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly
 1 5 10 15

Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser
 20 25 30

Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Gly Gln Ala Phe Arg Gly
 35 40 45

Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg Phe
 50 55 60

Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala
 65 70 75 80

Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn
 85 90 95

Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Ser Ala
 100 105 110

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
 115 120 125

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
 130 135 140

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
 145 150 155 160

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
 165 170 175

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
 180 185 190

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
 195 200 205

Val Glu Pro Lys Ser Cys
 210

<210> 148
 <211> 694
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA CD3 crossfab VHck fc knob P329GLALA (CEA TCB)

<400> 148

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Phe
 20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe
 50 55 60

Lys Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys

210		215		220													
Asp	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Glu	Val	Gln	Leu	Leu		
225					230					235					240		
Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	Arg	Leu	Ser		
				245					250					255			
Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	Ala	Met	Asn	Trp	Val		
			260					265					270				
Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ser	Arg	Ile	Arg	Ser		
		275					280					285					
Lys	Tyr	Asn	Asn	Tyr	Ala	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly	Arg		
	290					295					300						
Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met		
305					310					315					320		
Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Val	Arg	His		
				325					330					335			
Gly	Asn	Phe	Gly	Asn	Ser	Tyr	Val	Ser	Trp	Phe	Ala	Tyr	Trp	Gly	Gln		
			340					345					350				
Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Val	Ala	Ala	Pro	Ser	Val		
		355					360					365					
Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser		
	370					375					380						
Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln		
385					390				395						400		
Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val		
				405					410					415			
Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu		
			420					425					430				
Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu		
		435					440					445					
Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg		
	450					455					460						
Gly	Glu	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu		

465		470		475		480									
Ala	Ala	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp
				485					490					495	
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp
			500					505					510		
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly
		515					520					525			
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn
	530					535					540				
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp
545					550					555					560
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Gly
				565					570					575	
Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu
			580					585					590		
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Cys	Arg	Asp	Glu	Leu	Thr	Lys	Asn
		595					600					605			
Gln	Val	Ser	Leu	Trp	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile
	610					615					620				
Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr
625					630					635					640
Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys
				645					650					655	
Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys
			660					665					670		
Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu
		675					680					685			
Ser	Leu	Ser	Pro	Gly	Lys										
	690														

<210> 149

<211> 451

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA VHCH1 Fc hole P329GLALA (CEA TCB)

<400> 149

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Phe
 20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe
 50 55 60

Lys Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
 225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 150

<211> 232

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VH-CL (CEACAM5 TCB)

<400> 150

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
20 25 30

Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Val Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe
100 105 110

Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Val
115 120 125

Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
130 135 140

Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
145 150 155 160

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
165 170 175

Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
180 185 190

Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
195 200 205

Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
210 215 220

Lys Ser Phe Asn Arg Gly Glu Cys
225 230

<210> 151

<211> 449
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEACAM5 VH-CH1(EE)-Fc (hole, P329G LALA)

<400> 151

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr
 20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys Tyr Val Pro Lys Phe
 50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Pro Phe Gly Tyr Tyr Val Ser Asp Tyr Ala Met Ala Tyr Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro

<210> 152
<211> 674
<212> PRT

<213> Artificial Sequence

<220>

<223> CEACAM5 VH-CH1(EE)-CD3 VL-CH1-Fc (knob, P329G LALA)

<400> 152

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr
20 25 30

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys Tyr Val Pro Lys Phe
50 55 60

Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Pro Phe Gly Tyr Tyr Val Ser Asp Tyr Ala Met Ala Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Glu Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Glu Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ala Val Val Thr

225 230 235 240
 Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr
 245 250 255
 Cys Gly Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp
 260 265 270
 Val Gln Glu Lys Pro Gly Gln Ala Phe Arg Gly Leu Ile Gly Gly Thr
 275 280 285
 Asn Lys Arg Ala Pro Gly Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu
 290 295 300
 Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu
 305 310 315 320
 Ala Glu Tyr Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly
 325 330 335
 Gly Gly Thr Lys Leu Thr Val Leu Ser Ser Ala Ser Thr Lys Gly Pro
 340 345 350
 Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
 355 360 365
 Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
 370 375 380
 Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
 385 390 395 400
 Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
 405 410 415
 Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn
 420 425 430
 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
 435 440 445
 Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala
 450 455 460
 Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
 465 470 475 480
 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser

				485						490										495
His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu					
			500					505					510							
Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr					
		515					520					525								
Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn					
	530					535					540									
Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Gly	Ala	Pro					
545					550					555					560					
Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln					
				565					570					575						
Val	Tyr	Thr	Leu	Pro	Pro	Cys	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val					
			580					585					590							
Ser	Leu	Trp	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val					
		595					600					605								
Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro					
	610					615					620									
Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr					
625					630					635					640					
Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val					
				645					650					655						
Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu					
			660					665					670							

Ser Pro

<210> 153
 <211> 218
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEACAM5 VL-CL(RK)

<400> 153

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1				5					10					15	

Glu Arg Ala Thr Leu Ser Cys Arg Ala Gly Glu Ser Val Asp Ile Phe
 20 25 30

Gly Val Gly Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
 35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
 65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Asn
 85 90 95

Glu Asp Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
 100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Arg Lys
 115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
 130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
 145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
 165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
 180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
 195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215

<210> 154

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA-HCDR1

<400> 154

Glu Phe Gly Met Asn

1 5

<210> 155
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-HCDR2

<400> 155

Trp Ile Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe Lys
 1 5 10 15

Gly

<210> 156
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-HCDR3

<400> 156

Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met Asp Tyr
 1 5 10

<210> 157
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-LCDR1

<400> 157

Lys Ala Ser Ala Ala Val Gly Thr Tyr Val Ala
 1 5 10

<210> 158
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-LCDR2

<400> 158

Ser Ala Ser Tyr Arg Lys Arg
 1 5

<210> 159

<211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-LCDR3

<400> 159

His Gln Tyr Tyr Thr Tyr Pro Leu Phe Thr
 1 5 10

<210> 160
 <211> 121
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA VH

<400> 160

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Phe
 20 25 30

Gly Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45

Gly Trp Ile Asn Thr Lys Thr Gly Glu Ala Thr Tyr Val Glu Glu Phe
 50 55 60

Lys Gly Arg Val Thr Phe Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Trp Asp Phe Ala Tyr Tyr Val Glu Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 161
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA VL

<400> 161

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Ala Ala Val Gly Thr Tyr
 20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Ser Ala Ser Tyr Arg Lys Arg Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys His Gln Tyr Tyr Thr Tyr Pro Leu
 85 90 95

Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 162
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-HCDR1 (CEACAM5)

<400> 162

Asp Thr Tyr Met His
 1 5

<210> 163
 <211> 17
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> CEA-HCDR2 (CEACAM5)

<400> 163

Arg Ile Asp Pro Ala Asn Gly Asn Ser Lys Tyr Val Pro Lys Phe Gln
 1 5 10 15

Gly

<210> 164
 <211> 12
 <212> PRT

<213> Artificial Sequence

<220>

<223> CEA-HCDR3 (CEACAM5)

<400> 164

Phe Gly Tyr Tyr Val Ser Asp Tyr Ala Met Ala Tyr
1 5 10

<210> 165

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA-LCDR1 (CEACAM5)

<400> 165

Arg Ala Gly Glu Ser Val Asp Ile Phe Gly Val Gly Phe Leu His
1 5 10 15

<210> 166

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA-LCDR2 (CEACAM5)

<400> 166

Arg Ala Ser Asn Arg Ala Thr
1 5

<210> 167

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA-LCDR3 (CEACAM5)

<400> 167

Gln Gln Thr Asn Glu Asp Pro Tyr Thr
1 5

<210> 168

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> CEA VH (CEACAM5)

<400> 168

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser

1					5					10					15				
Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Phe	Asn	Ile	Lys	Asp	Thr				
			20				25						30						
Tyr	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Met				
			35				40						45						
Gly	Arg	Ile	Asp	Pro	Ala	Asn	Gly	Asn	Ser	Lys	Tyr	Val	Pro	Lys	Phe				
		50				55						60							
Gln	Gly	Arg	Val	Thr	Ile	Thr	Ala	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr				
65				70						75						80			
Met	Glu	Leu	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys				
			85						90						95				
Ala	Pro	Phe	Gly	Tyr	Tyr	Val	Ser	Asp	Tyr	Ala	Met	Ala	Tyr	Trp	Gly				
			100				105						110						
Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser											
		115				120													

<210>	169
<211>	111
<212>	PRT
<213>	Artificial Sequence

<220>
<223> CEA VL (CEACAM5)

<400> 169

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Gly Glu Ser Val Asp Ile Phe
20 25 30

Gly Val Gly Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
35 40 45

Arg Leu Leu Ile Tyr Arg Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80

Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Asn
85 90 95

Glu	Asp	Pro	Tyr	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys
			100					105					110	